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CHAPTER 1 NICOTINE USE DISORDER 
1.1 Public Health Significance 
Tobacco use, especially cigarette smoking, is a significant public health problem. 
Tobacco use is the leading cause of preventable death in the United States (US; 
480,000+ deaths per year) (U.S. Department of Health and Human Services, 2014). 
Approximately one of every five deaths in the US each year are associated with 
tobacco use (U.S. Department of Health and Human Services, 2014). In addition to 
severe health consequences, cigarette smoking costs the US economy $300+ billion 
per year in lost productivity and medical expenses (U.S. Department of Health and 
Human Services, 2014). Approximately 57 million people (aged 12+ yrs) in the US 
currently smoke cigarettes (SAMHSA, 2011). However, encouragingly, ~70% of current 
smokers report a desire to quit (SAMHSA, 2011). 
1.2 Pharmacotherapy  
The most efficacious Food and Drug Administration (FDA)-indicated 
pharmacotherapies for smoking cessation are:  nicotine replacement products (e.g. 
nicotine gum, lozenges, and transdermal patches), varenicline (α4β2 nicotinic 
acetylcholine receptor partial agonist), and bupropion (aminoketone antidepressant) 
(Eisenberg et al., 2008; Etter & Stapleton, 2006; Gonzales et al., 2006; Jorenby et al., 
1999; Lancaster, Stead, Silagy, & Sowden, 2000; Mills et al., 2012; Silagy, Lancaster, 
Stead, Mant, & Fowler, 2005; Ucar et al., 2014). These medications attenuated 
cigarette craving and nicotine withdrawal symptoms, and improved short-term 
abstinence rates, relative to placebo (Eisenberg et al., 2008; Etter & Stapleton, 2006; 
Gonzales et al., 2006; Jorenby et al., 1999; Lancaster et al., 2000; Mills et al., 2012; 
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Silagy et al., 2005; Ucar et al., 2014). However, meta-analyses of treatment studies 
indicated smoking abstinence rates at 6- and 12-month follow-ups were unacceptably 
low (14-36% and 13-28%, respectively) (Eisenberg et al., 2008; Etter & Stapleton, 
2006; Gonzales et al., 2006; Jorenby et al., 1999; Nides et al., 2008; Silagy et al., 2005; 
Ucar et al., 2014). Despite effective attenuation of nicotine craving and withdrawal 
symptoms, the majority of smokers relapsed within the first year of treatment on these 
medications. This begs the question: what other factors precipitate smoking relapse, 
and are not attenuated by these medications? One such factor is stress. Historically, 
stress has been defined as physiological responses to demands placed upon the body 
(Selye, 1936, 1973). In this study, stress is defined by the acute physiological 
responses (e.g. elevated heart rate, blood pressure, breathing rate etc.) that are 
typically associated with stressful events (for a more complete description see below).  
1.3 Stress and Smoking Relapse  
Treatment research studies indicated stress was among the most commonly 
cited precipitants to smoking relapse (M. al'Absi, 2006; Heishman, 1999; Hymowitz, 
Sexton, Ockene, & Grandits, 1991; Matheny & Weatherman, 1998). One study found 
that more than 60% of cigarette smokers attributed their relapse to stress (Hughes, 
2009). Moreover, individuals who reported high stress levels during abstinence were 
more likely to relapse (Brewer, Catalano, Haggerty, Gainey, & Fleming, 1998; S. Cohen 
& Lichtenstein, 1990).  
Stressful events activate the Autonomic Nervous System (ANS) and 
Hypothalamus-Pituitary-Adrenal (HPA) axis which can increase heart rate, blood 
pressure, breathing rate, and levels of circulating noradrenaline and cortisol (among 
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other physiological effects) (Mustafa al'Absi, 2006; G. F. Koob, 2008; Pocock, Richards, 
& Richards, 2013; Sinha, Garcia, Paliwal, Kreek, & Rounsaville, 2006). Activation of the 
sympathetic branch of the ANS (associated with noradrenaline release) prepares an 
individual for immediate action (so-called ‘fight or flight’ response) (Pocock et al., 2013). 
The HPA axis response (associated with cortisol release) is slower and less predictable, 
but has important biological effects (Dickerson & Kemeny, 2004). Acute nicotine 
administration can activate, and chronic nicotine administration can dysregulate, ANS 
and HPA axis responses (Picciotto, Brunzell, & Caldarone, 2002). Nicotine is a central 
nervous system stimulant; acute administration is associated with increased blood 
pressure, heart rate, and plasma noradrenaline and corticosteroid levels (Brazell, 
Mitchell, & Gray, 1991; Cryer, Haymond, Santiago, & Shah, 1976; Picciotto et al., 
2002). Chronic nicotine exposure was associated with elevated levels of noradrenaline 
and cortisol during active use and acute abstinence, and dysregulated physiological 
reactivity to experimental stress-induction (Andersson, Eneroth, Fuxe, Mascagni, & 
Agnati, 1985; Childs & De Wit, 2009; C Kirschbaum, Wüst, & Strasburger, 1992; G. F. 
Koob, 2008; George F. Koob & Moal, 1997; Kreek & Koob, 1998; Picciotto et al., 2002; 
Tsuda, Steptoe, West, Fieldman, & Kirschbaum, 1996; Wilkins et al., 1982). Thus, long-
term cigarette smoking may dysregulate the stress system, which in turn, may increase 
the likelihood of relapse.  
FDA-indicated pharmacotherapies were not designed to, and do not, attenuate 
stress-induced biobehavioral reactions. Ray et al. (2013) demonstrated that varenicline 
decreased basal cigarette craving and blocked cigarette cue-induced craving, but not 
cue- plus stress-induced cigarette craving (Ray et al., 2013). During acute smoking 
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abstinence, bupropion was associated with increased physiological indices of stress 
reactivity at rest and following an experimental stress-induction task (Kotlyar et al., 
2006). Acute nicotine administration (e.g. nicotine replacement products) among 
chronic smokers can attenuate HPA axis response to experimental stress-induction 
(Childs & De Wit, 2009; Rohleder & Kirschbaum, 2006), but may increase 
cardiovascular output (heart rate and blood pressure) (Perkins, Epstein, Jennings, & 
Stiller, 1986). Moreover, chronic nicotine use is associated with overactive HPA axis 
and ANS systems (Andersson et al., 1985; G. F. Koob, 2008; George F Koob & Le 
Moal, 1997).  
1.4 Adjunctive Medications 
The effectiveness of existing pharmacotherapies may be enhanced by adjunctive 
medications that attenuate an individual’s physiological response to stress. In a 
preclinical study, prazosin (α1-adrenoreceptor antagonist) attenuated the effects of 
pharmacological stress-induction on alcohol seeking behavior (A. Le et al., 2011). In 
humans, prazosin blunted the effects of psychosocial stress-induction on blood 
pressure, alcohol craving, anxiety, and negative emotion among alcohol dependent 
individuals during outpatient treatment (Helen C Fox et al., 2012). Similarly, guanfacine 
(α2-adrenoreceptor agonist) attenuated stress- and drug cue-induced craving and 
anxiety among cocaine-dependent individuals (H. C. Fox et al., 2012). These 
preliminary studies suggest that supplementing existing FDA-indicating 
pharmacotherapies with stress-blunting medications may improve smoking cessation 
rates. Indeed, an ongoing clinical trial is investigating the efficacy of combined 
varenicline + prazosin on smoking cessation (results not yet available).  
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1.5 Summary 
The goal of this section was to briefly introduce the public health problem and 
research focus of this study. A review of all smoking cessation treatments (e.g. 
cognitive and behavioral interventions) was beyond the scope of this section and would 
not further clarify the concepts presented herein.  
In summary, nicotine use, especially chronic cigarette smoking, is a significant 
public health problem. FDA-indicated pharmacotherapies for smoking cessation are 
associated with dismal long-term abstinence rates. One plausible explanation is that 
existing pharmacotherapies do not attenuate the deleterious effects of acute stress. 
There is ample non-experimental evidence linking stress to smoking relapse. In the next 
chapter, I will review the evidence that acute experimental stress potentiated substance 
use and reinstatement (model of relapse). In addition, I will review the literature on brain 
regions associated with substance use disorders and the impact of acute experimental 
stress on brain function. Finally, I will describe the dissertation study design, aims, and 
hypotheses. 
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CHAPTER 2 EXPERIMENTAL STRESS EFFECTS 
2.1 Preclinical Models of Substance Use Relapse 
The reinstatement model of preclinical substance use relapse is widely used and 
has good criterion and construct validity (Epstein, Preston, Stewart, & Shaham, 2006). 
The specific parameters of the reinstatement model vary across studies, but generally 
include the following:  acquisition (initial drug self-administration), maintenance (regular 
drug self-administration), extinction (protracted abstinence), experimental challenge, 
and reinstatement (relapse) (Shaham, Shalev, Lu, de Wit, & Stewart, 2003). During the 
acquisition phase, the animal is able to earn units of drug via behavioral responding. 
Drug-seeking behavior is operationalized as behavioral responding (e.g. nose poke, 
pressing a lever) that resulted in drug administration. Drug-seeking behavior is a direct 
behavioral measure of appetitive drug motivation with translational validity in human 
experimental research. During the maintenance phase, the animal is able to earn units 
of drug via behavioral responding during predefined time periods until drug taking 
reaches a plateau and has stabilized. This phase is a proxy of chronic substance use. 
During the extinction phase, behavioral responding no longer results in receipt of drug 
(e.g. saline is substituted). Behavioral responding will gradually decrease until cessation 
(i.e. drug-seeking behavior was extinguished). Finally, the animal is challenged with an 
experimental manipulation (e.g. stress, drug-paired cue, or drug priming dose). If the 
animal exhibits behavioral responding on the drug-associated option, drug-seeking 
behavior has been reinstated (i.e. the animal is said to have relapsed).  
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2.2 Preclinical Experimental Stress Manipulation  
A variety of preclinical experimental stress manipulations exist, including:  
predator scent, foot shock, restraint, and pharmacological agents. Pharmacological 
agents have methodological advantages over other approaches: neurochemical 
specificity, methodological control, and translational potential. Preclinical models of 
relapse demonstrated that pharmacological stress agents (that mimic ANS and HPA 
axis responses) reinstated drug-seeking and self-administration across drugs of abuse 
(Epstein et al., 2006; Feltenstein, Ghee, & See, 2012; Le, Harding, Juzytsch, Funk, & 
Shaham, 2005; Mantsch & Katz, 2007; Mantsch et al., 2014; Mantsch et al., 2010; 
Shaham, Erb, & Stewart, 2000; Shaham et al., 2003; Shaham & Stewart, 1995). 
Yohimbine (YOH) is an α2-adrenoreceptor antagonist that increases noradrenergic 
levels (i.e. sympathetic ANS response to stressful events) by blocking the presynaptic 
autoreceptor (Doxey, Lane, Roach, & Virdce, 1984; Goldberg & Robertson, 1983). 
Acute YOH administration reinstated behavioral responding (i.e. YOH precipitated 
relapse) for cocaine, methamphetamine, alcohol, and nicotine in rodents (Ahmed & 
Koob, 1997; Buczek, Le, Wang, Stewart, & Shaham, 1999; Erb et al., 2000; Erb, 
Shaham, & Stewart, 1996; Gass & Olive, 2007; Le et al., 2005; Mantsch & Katz, 2007; 
Mantsch et al., 2014; Mantsch et al., 2010; Shepard, Bossert, Liu, & Shaham, 2004). 
YOH reliably produced anxiogenic effects in rodents and humans (Charney, Heninger, 
& Redmond Jr, 1983; A. D. Le et al., 2011; Pellow, Johnston, & File, 1987; Stine et al., 
2002). YOH increased biomarkers of a physiological stress response: systolic and 
diastolic blood pressure and saliva α-amylase (Ehlert, Erni, Hebisch, & Nater, 2006; 
Greenwald, Lundahl, & Steinmiller, 2013; Murburg, Villacres, Ko, & Veith, 1991; Stine et 
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al., 2002). Glucocorticoid and mineralocorticoid receptor agonists (corticosterone 
[rodents] and cortisol [humans]) modulated the effect of YOH on drug-seeking behavior 
(de Jong, Steenbergen, & de Kloet, 2009; Deroche, Marinelli, Le Moal, & Piazza, 1997; 
Graf et al., 2013; Mantsch & Katz, 2007; Mantsch et al., 2014). In combination, they 
simulate a robust physiological stress response (both ANS and HPA axis) and reliably 
reinstate drug-seeking behavior in preclinical models of substance use relapse. 
2.3 Human Experimental Stress Manipulation 
Human experimental studies often use psychosocial stress-induction techniques, 
including:  guided imagery, mental arithmetic, or public speaking (Dedovic, D'Aguiar, & 
Pruessner, 2009; Dickerson & Kemeny, 2004). Psychosocial stress-induction 
manipulations have non-trivial limitations, including: lack of placebo-control (possible 
expectancy effects); no dose manipulation (inability to control stressor intensity); and 
unreliable and brief physiological stress response (<30min) (Dickerson & Kemeny, 
2004; Greenwald et al., 2013).  
 Pharmacological stress-induction has methodological advantages over 
psychosocial approaches and reverse-translational validity with preclinical studies. 
Pharmacological agents that mimic the endogenous HPA axis and ANS stress 
response (e.g. YOH in combination with a glucocorticoid and mineralocorticoid receptor 
agonist) provide a powerful model of acute experimental stress-induction. 
Hydrocortisone (HYD) is a glucocorticoid and mineralocorticoid receptor agonist with 
good bioavailability that reliably increases plasma and saliva cortisol levels in humans 
(Meikle & Tyler, 1977). Together, YOH+HYD: a) mimic ANS- and HPA axis-mediated 
stress responses (increase the primary stress hormones:  noradrenaline and cortisol); 
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b) produce reliable, sustained, and dose-dependent physiological stress responses; 
and c) enable double-blind, placebo-controlled administration (de Jong et al., 2009; 
Deroche et al., 1997; Graf et al., 2013; Mantsch & Katz, 2007; Mantsch et al., 2014).  
Our laboratory recently investigated the effects of oral pretreatment of YOH 
alone and YOH+HYD in non-treatment-seeking, opioid-dependent volunteers. The 
primary outcome variable was opioid-seeking behavior. Human experimental stress 
studies often measure proxies of substance use (e.g. craving) or infer statistical 
relationships to future substance use. In contrast to those approaches, drug-seeking 
behavior is a direct measure of appetitive drug motivation that results in drug 
administration. Participants in our recent lab study were able to earn (via computer 
‘mouse’ clicking) units of hydromorphone (μ opioid receptor agonist) or money on a 
choice progressive ratio task. Response requirements (number of mouse clicks) 
increased with each successive unit earned (independently for both drug and money). 
Immediately after the task, earned units of hydromorphone were administered 
(intramuscular injection). Thus, appetitive opioid motivation (number of opioid units 
earned) was measured in the absence of acute drug effects (e.g. disinhibition or 
satiation). Findings indicated YOH alone (Greenwald et al., 2013) and YOH+HYD 
(Greenwald et al., in preparation) increased opioid (hydromorphone) seeking behavior 
in sublingual buprenorphine-maintained (8mg/day) heroin-dependent individuals. In 
addition, oral pretreatment with YOH 54mg + HYD 20mg (similar to doses proposed in 
this study) produced statistically-significant, but clinically-safe, increases in blood 
pressure (both systolic and diastolic) and saliva cortisol that lasted for approximately 
three hours. These findings demonstrated that oral pretreatment with YOH+HYD is a 
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robust pharmacological stress-induction technique that potentiated drug-seeking 
behavior among opioid-dependent individuals. Together with the preclinical literature, 
there is substantial evidence that experimental stress-induction reliably increases drug-
seeking behavior. However, the neurobiological pathways through which stress 
potentiates drug-seeking behavior remain unclear.  
2.4 Substance Use and Brain Function 
2.4.1 Top-down vs. Bottom-up 
Neuroimaging studies provide insight into brain regions and networks associated 
with substance use. Broadly speaking, brain regions associated with drug cue 
appraisal, appetitive motivation, and decision making can be divided into two networks:  
top-down and bottom-up (Bechara, 2005; Nestor, McCabe, Jones, Clancy, & Garavan, 
2011). The top-down network is often conceptualized as the ‘brake pedal’ to the 
bottom-up ‘gas pedal’. Bottom-up signals are associated with appetitive drug 
motivation, craving, and withdrawal/negative affect. Top-down network structures 
modulate bottom-up signals, and are associated with executive function, planning, and 
goal-directed behaviors. Substance use-related decision making (e.g. whether or not to 
use a drug at a particular moment) is thought to arise from these competing signals 
(Rangel, Camerer, & Montague, 2008).  
2.4.2 Bottom-up Network 
Dopaminergic signaling in the ventral striatum (including the nucleus accumbens 
[NAcc]) mediates acute drug reinforcement (Di Chiara & Imperato, 1988). Following 
repeated substance use, drug-paired visual cues become conditioned stimuli and elicit 
dopamine release in the NAcc (in the absence of substance administration), consistent 
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with appetitive craving (N. Volkow, Fowler, Wang, Baler, & Telang, 2009; N. D. Volkow 
et al., 2006, 2008). Substance use disorders are associated with enhanced salience 
attribution to drug-related visual cues (Rita Z Goldstein & Volkow, 2002; R. Z. Goldstein 
& Volkow, 2011). Visual drug cue evoked blood oxygen level-dependent (BOLD) 
activation measured via functional magnetic resonance imaging (fMRI) is often robust, 
but patterns vary across studies and are influenced by several methodological factors 
(Jasinska, Stein, Kaiser, Naumer, & Yalachkov, 2014), such as treatment status (out-of-
treatment individuals show more robust activation), time since last cigarette (acute 
abstinence enhanced cue reactivity), and temporal delay until next smoking opportunity 
(immediate smoking opportunities are associated with more robust activation) (Jasinska 
et al., 2014; Wilson, Sayette, Delgado, & Fiez, 2005). Meta-analyses of fMRI studies 
indicated that consistently activated regions included: the medial orbitofrontal cortex 
(mOFC), medial prefrontal cortex (mPFC), ventral striatum (including NAcc), and dorsal 
striatum (Chase, Eickhoff, Laird, & Hogarth, 2011; Engelmann et al., 2012; Kühn & 
Gallinat, 2011; Wilson, Sayette, & Fiez, 2004)). BOLD activation in the mPFC and 
mOFC is thought to reflect drug cue appraisal and/or salience (Chase et al., 2011; 
Hayashi, Ko, Strafella, & Dagher, 2013; Wilson et al., 2004). The two most consistently 
activated regions are the amygdala and the ventral striatum (e.g. NAcc) (Chase et al., 
2011; Engelmann et al., 2012; Kühn & Gallinat, 2011; Wilson et al., 2004). Activation in 
the amygdala may reflect the emotional salience of the visual drug cue presented 
(Chase et al., 2011; Engelmann et al., 2012; Kühn & Gallinat, 2011; Wilson et al., 
2004). The ventral striatum is associated with craving and appetitive motivation, and is 
part of the ‘final common pathway’ of addiction (Rita Z Goldstein & Volkow, 2002; P. W. 
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Kalivas, Volkow, & Seamans, 2005; G. F. Koob & Volkow, 2010; N. Volkow et al., 
2009). Collectively, activation in bottom-up ‘reward’ network structures is associated 
with drug cue salience, craving, and appetitive motivation.  
2.4.3 Top-down Network 
Top-down (frontal-to-striatal) network function is important for many cognitive 
processes, including: attention, decision making, and goal-directed behavior (Rita Z 
Goldstein & Volkow, 2002; R. Z. Goldstein & Volkow, 2011; Rangel et al., 2008). Top-
down network function emanates from the dorsolateral prefrontal cortex (dlPFC) (Rita Z 
Goldstein & Volkow, 2002; R. Z. Goldstein & Volkow, 2011). Substance abuse is 
associated with structural and functional changes. Relative to matched controls, 
cigarette smokers exhibited reduced gray matter volume in dlPFC and ventrolateral 
PFC (vlPFC) (Brody et al., 2004). Chronic substance use is associated with impaired 
dlPFC-dependent non-drug-specific cognitive processes (attentional control, decision 
making, and impulse inhibition) (Banich, 2009; R. Z. Goldstein & Volkow, 2011). In 
addition, the dlPFC is involved in drug use-related cognitive processes:  self-control, 
delayed gratification, drug cue reactivity, and response inhibition (Hare, Camerer, & 
Rangel, 2009; Hare, Hakimi, & Rangel, 2014; Nestor et al., 2011; Wilson et al., 2004). 
Smoking cue appraisal was associated with attenuated dlPFC, and exaggerated 
striatal, activation in current smokers, compared to ex-smokers (Nestor et al., 2011). 
Moreover, response inhibition (associated with PFC activation (Aron & Poldrack, 2006; 
Chikazoe et al., 2009)) was impaired in cigarette smokers, relative to controls (Luijten, 
Littel, & Franken, 2011; Powell, Dawkins, & Davis, 2002). Activation in the dlPFC was 
positively correlated with selection of delayed monetary rewards (delayed gratification) 
(Figner et al., 2010; Hare et al., 2014; Luo, Ainslie, Pollini, Giragosian, & Monterosso, 
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2012; McClure, Ericson, Laibson, Loewenstein, & Cohen, 2007; McClure, Laibson, 
Loewenstein, & Cohen, 2004). Repetitive transcranial magnetic stimulation (rTMS) is a 
non-invasive technique capable of temporally potentiating (pulse frequency ≥ 5Hz) or 
inhibiting (< 1Hz) neural activity (Leo & Latif, 2007). rTMS delivers a series of magnetic 
pulses that pass through the skull and modulate electrical potential in the brain (usually 
not deeper than the cortex) (Leo & Latif, 2007). rTMS-induced temporary ‘functional 
lesions’ indicated that left (and not right) dlPFC function was associated with selection 
of delayed rewards (Figner et al., 2010). Moreover, rTMS-induced ‘functional lesion’ of 
the left dlPFC attenuated the potentiating effect of an immediate (vs. delayed) smoking 
opportunity on cigarette craving (Hayashi et al., 2013). Collectively, these studies 
illustrated the critical role of the dlPFC (and top-down executive control) in cognitive 
processes (e.g. self-control, delayed gratification, and drug cue appraisal) associated 
with substance use. Further, impaired dlPFC function (and associated cognitive 
processes) may be an important factor that (temporally) precedes substance use 
relapse.  
2.5 Stress, Drugs, and Brain Function 
2.5.1 Stress and Brain Function 
The effects of acute experimental stress on brain function have been widely 
studied in the learning and memory literature (more so than the substance use 
literature). Review of this literature was useful for identifying the neural substrates of 
experimental stress-induction. The specific effects of experimental stress on memory 
vary depending on the stress manipulation and the type of memory investigated. 
However, broadly speaking, experimental stress tends to impair prefrontal-dependent, 
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and enhance striatal-dependent, cognitive processes. It should be noted there is a rich 
literature of the effects of chronic stress on brain function, but discussion of those 
findings are beyond the scope of this dissertation study. 
In a series of studies, Schwabe and colleagues examined the effects of 
pretreatment with pharmacological stress-inducing agents (self-administration of oral 
YOH and HYD) on instrumental learning behavior (L. Schwabe, Joels, Roozendaal, 
Wolf, & Oitzl, 2012; L. Schwabe, Tegenthoff, Hoffken, & Wolf, 2010, 2012; L. Schwabe 
& Wolf, 2011; Lars Schwabe & Wolf, 2013)). Results demonstrated that YOH+HYD, but 
not YOH or HYD alone, rendered participant behavior insensitive to outcome 
devaluation (L. Schwabe et al., 2010; L. Schwabe, Tegenthoff, et al., 2012; L. Schwabe 
& Wolf, 2011). The authors interpreted these data to indicate that participants 
responded habitually and YOH+HYD impaired ‘goal-directed’ behavior during the task. 
Preclinical lesion and human neuroimaging studies indicated that goal-directed 
behavior is dlPFC-dependent (Bernard W Balleine & Dickinson, 1998; B. W. Balleine & 
O'Doherty, 2010; Corbit & Balleine, 2003; Valentin, Dickinson, & O'Doherty, 2007) 
whereas habit-directed responding is associated with the dorsal striatum (Tricomi, 
Balleine, & O’Doherty, 2009; Yin & Knowlton, 2006; Yin, Knowlton, & Balleine, 2004; 
Yin, Ostlund, Knowlton, & Balleine, 2005). YOH+HYD reduced the sensitivity of 
mOFC/mPFC to changes in outcome value, whereas the dorsal striatum was 
unaffected (L. Schwabe et al., 2010; L. Schwabe, Tegenthoff, et al., 2012; L. Schwabe 
& Wolf, 2011). Thus, during YOH+HYD, the outcome devaluation signal (encoded by 
mOFC/mPFC) failed to shift behavior (i.e. to goal-directed responding; dlPFC) during 
task performance (L. Schwabe et al., 2010; L. Schwabe, Tegenthoff, et al., 2012; L. 
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Schwabe & Wolf, 2011). In the context of substance use, acute stress may shift an 
individual’s behavior from goal-directed (e.g. maintaining abstinence) to habit-directed 
(stimulus-response; e.g. cue elicited smoking relapse). Acute stress may increase the 
likelihood of substance use relapse via impaired dlPFC function. As described above, 
dlPFC function is associated with cognitive processes essential for maintenance of 
substance use abstinence (e.g. self-control, delayed gratification, and goal-directed 
behavior).  
A widely studied cognitive function associated with the dlPFC function is working 
memory. Working memory is the active maintenance and neural representation of 
information over a brief delay period (typically 2-10 sec) prior to recall. A meta-analysis 
of fMRI studies indicated that working memory task performance (N-back; described in 
Section 3.2.8) was consistently associated with dlPFC and vlPFC activation (Owen, 
McMillan, Laird, & Bullmore, 2005). Importantly, the N-back working memory task is 
versatile and can be administered with or without drug-related stimuli (e.g. smoking 
images). One study found that psychosocial stress-induction attenuated dlPFC 
activation during a neutral N-back task performance and impaired response accuracy in 
healthy control subjects (Qin, Hermans, van Marle, Luo, & Fernández, 2009).  
In non-human primates, spatial working memory has been studied. Primates 
were trained to retain the spatial location of a visual cue and respond via saccade (eye 
movement) following a brief delay period (typically 2-10 sec) (Goldman-Rakic, 1995). 
Electrodes implanted in the primate dlPFC indicated that spiking frequency increased 
during the delay period (time period between stimulus presentation and recall). 
Researchers concluded that feedforward microcircuits in the dlPFC (cortical layer III) 
16 
 
 
 
maintained a neural representation of the cue during the delay period, such that the 
primate was able to respond accurately (A. F. Arnsten, Wang, & Paspalas, 2012; 
Goldman-Rakic, 1995; Wang et al., 2013). Follow-up studies indicated that local, and 
systemic, administration of NMDA receptor antagonists attenuated neural spiking 
activity in the dlPFC and impaired response accuracy (Honey et al., 2004; Krystal et al., 
2005; Wang et al., 2013). These well-controlled studies provided compelling evidence 
that working memory performance was mediated via neural spiking activity – 
specifically, glutamatergic neurotransmission binding post-synaptic NMDA receptors – 
in the dlPFC.  
Non-human primate working memory performance (using the same experimental 
paradigm) exhibited an inverted “U” relationship with noradrenaline levels (A. F. 
Arnsten, 2009). Abnormally low (e.g. fatigue) (A. Arnsten & Goldman-Rakic, 1985) and 
high levels of noradrenaline (e.g. stress or YOH dose) (A. F. Arnsten, Mathew, Ubriani, 
Taylor, & Li, 1999; S. Birnbaum, Gobeske, Auerbach, Taylor, & Arnsten, 1999; S. G. 
Birnbaum et al., 2004; Doxey et al., 1984; Ramos et al., 2005) impaired working 
memory task performance (A. F. Arnsten, 2009). Optimal working memory performance 
(during alert and non-stressed conditions) was associated with moderate noradrenaline 
levels, and predominantly, α2A-adrenoreceptor stimulation (A. Arnsten & Goldman-
Rakic, 1985; Li & Mei, 1994). High levels of noradrenaline stimulated the lower affinity 
α1- and β1-adrenoreceptors (S. Birnbaum et al., 1999; Ramos et al., 2005), suppressed 
dlPFC neuronal spiking activity (Li, Mao, Wang, & Mei, 1999; Wang et al., 2007), and 
impaired response accuracy (A. F. Arnsten et al., 1999; S. G. Birnbaum et al., 2004).  
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In summary, a widely studied dlPFC-dependent cognitive process is working 
memory. Experimental stress (or administration of its neurochemical substrates: i.e. 
noradrenaline) attenuated dlPFC working memory task engagement (BOLD and neural 
spiking frequency) and impaired response accuracy. In addition, pharmacological 
stress-induction was associated with impaired ‘goal-directed’ behavior (dlPFC-
dependent). Collectively, these studies provide support for the hypothesis that acute 
stress may increase the likelihood of substance use relapse via attenuated dlPFC 
engagement and impaired function.  
2.5.2 Stress, Drugs, and Brain Function 
The effects of acute experimental stress on substance use-related cognitive 
processes are not well understood. Research in this area has been limited by the 
experimental approaches used. As described above, with few exceptions, prior 
research studies used psychosocial stress manipulations. Psychosocial stress 
manipulations are associated with unreliable and short-lived (<30min) physiological 
stress responses that hinder their utility in neuroimaging investigations. Perhaps most 
limiting, psychosocial stressors are inherently dependent on cognitive processing to 
induce a physiological stress response. The BOLD response associated with the stress-
inducing task will confound network activation changes associated with the 
physiological stress response (i.e. elevated cortisol and noradrenaline). These 
limitations and varied psychosocial stress-induction methodology have contributed to an 
inconsistent, and sometimes conflicting, neuroimaging literature (Dedovic et al., 2009). 
Despite these limitations, several effects have been reliably observed across studies 
and are described below.  
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Experimental stress-induction (in the absence of drug cues or drug 
administration) reliably increased dopaminergic neurotransmission in the NAcc in 
preclinical and clinical studies (Abercrombie, Keefe, DiFrischia, & Zigmond, 1989; 
Imperato, Angelucci, Casolini, Zocchi, & Puglisi-Allegra, 1992; Pruessner, Champagne, 
Meaney, & Dagher, 2004; Rougé-Pont, Piazza, Kharouby, Le Moal, & Simon, 1993). As 
described above, increased dopaminergic signaling in the NAcc is consistent with the 
reinforcing effects of acute drug administration (G. F. Koob & Volkow, 2010). Thus, 
acute stress may elicit appetitive craving in absence of drug cues or administration (i.e. 
stress may amplify ‘bottom-up’ signals). In addition, fMRI studies indicated that acute 
psychosocial stressors altered neural network activation and increased drug craving in 
the absence of drug cues (Sinha, 2001; Sinha, 2009; Sinha et al., 2006; Sinha & Li, 
2007). Despite similar levels of subjective distress during a guided imagery stress-
inducing technique, cocaine-dependent individuals exhibited greater BOLD activation in 
the caudate and dorsal striatum, and less activation in the parahippocampal gyrus, 
hippocampus, fusiform and anterior cingulate, compared to drug-naive controls (Sinha 
et al., 2005). In a related study (using the same stress-induction technique), increased 
BOLD activation in the mPFC during stress predicted shorter time to relapse during a 
90-day post-treatment follow-up period (Sinha & Li, 2007).  
To date, no clinical neuroimaging studies (to the knowledge of the author) have 
examined the potentially additive effects of concurrent experimental stress-induction 
and drug cue appraisal. Two studies examined the effects of sequential stress-induction 
and visual drug cue exposure during BOLD fMRI (Dagher, Tannenbaum, Hayashi, 
Pruessner, & McBride, 2009; Potenza et al., 2012). However, both studies used 
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psychosocial stress-induction techniques that may have confounded the physiological 
stress effects on visual drug cue appraisal and resultant BOLD activation. Moreover, 
physiological stress response biomarkers were not consistently measured. One study 
did not measure cortisol or noradrenaline levels (Potenza et al., 2012), whereas the 
other reported non-significant stress effects on saliva cortisol (Dagher et al., 2009). 
Moreover, neither study measured blood pressure (Dagher et al., 2009; Potenza et al., 
2012). Thus, it remains unclear whether experimental stress-induction alters neural 
network response to visual drug cues.  
Figure 1.1:  Proposed Mechanisms of Action. The conceptual guiding hypothesis and 
proposed mechanisms of action are illustrated. Acute stress may potentiate drug-seeking 
behavior via impaired top-down executive function (specifically, dlPFC function) and/or 
enhanced bottom-up signals (aversive internal states, cue salience, drug craving, or 
withdrawal symptoms).  
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2.6 Study Aims and Hypotheses 
2.6.1 Conceptual Overview 
Conceptually, the guiding hypothesis of this project is that stress potentiates 
drug-seeking and self-administration by altering frontostriatal network function (with the 
dlPFC acting as a fulcrum) to: 1) disrupt homeostasis; 2) mediate aversive internal 
states; 3) enhance smoking cue salience and appetitive motivation; and 4) attenuate 
dlPFC task engagement and impair dlPFC function (Figure 1.1). Our approach aligns 
with Goldstein & Volkow’s conceptualization of substance use disorders (impaired 
response inhibition and salience attribution; iRISA), and with Koob’s theory that chronic 
substance use causes neural counter-adaptations that dysregulate motivation and 
induce sensitization to stressors (Rita Z Goldstein & Volkow, 2002; R. Z. Goldstein & 
Volkow, 2011; G. F. Koob, 2008, 2009, 2010; George F. Koob & Moal, 1997).  
2.6.2 Neurobiological Mechanism 
The central aim of this study was to investigate a plausible neurobiological 
mechanism for stress-potentiated drug-seeking behavior. This study used a 
pharmacological stress-induction approach (oral pretreatment with YOH 54mg + HYD 
10mg). Combined oral pretreatment with YOH+HYD offers a powerful stress-induction 
approach that activates both HPA and ANS stress systems. We hypothesized that 
acute experimental stress would attenuate dlPFC engagement and impair response 
accuracy on a dlPFC-dependent cognitive task. Impaired dlPFC function is a plausible 
neurobiological mechanism through which acute stress may potentiate nicotine self-
administration. A multimodal neuroimaging approach (in vivo functional proton magnetic 
resonance spectroscopy [
1
H fMRS] and BOLD fMRI) was used to examine dlPFC 
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engagement and function during letter N-back task performance. There is widespread 
support indicating this neurobiological mechanism is plausible (described in detail 
above), but has not been directly tested in any published studies (known to the author).   
2.6.3 Study Aims and Hypotheses 
Brief study overview.  Chronic, regular cigarette smokers were recruited locally 
and screened for participation. Participants completed two identical experimental 
sessions under double-blind, placebo-controlled and within-subject randomized cross-
over oral-dosing conditions:  active (YOH 54mg + HYD 10mg) and placebo (YOH 0mg + 
HYD 0mg) stress. Throughout each session, subjective and physiological stress effects 
were assessed periodically. Participants completed a 60min MRI scan (which included 
1
H fMRS and BOLD fMRI). Finally, nicotine-seeking and self-administration behavior 
was measured via a choice, progressive ratio task. Nicotine-seeking and self-
administration directly measure nicotine motivation. This experimental design isolated 
the effects of pharmacological stress-induction on stress response biomarkers, 
subjective internal states, dlPFC function and task engagement, and nicotine-seeking 
and self-administration among non-treatment-seeking cigarette smokers. 
Aim 1: Assess the effects of YOH+HYD on physiologic stress response 
biomarkers and subjective internal states. Hypotheses: 1a) Relative to placebo (0mg + 
0mg), oral pretreatment with YOH+HYD (54mg + 10mg) will significantly increase blood 
pressure (systolic and diastolic), saliva cortisol and α-amylase. Prior research in our 
laboratory indicated that comparable oral pretreatment doses of YOH+HYD elicited a 
robust physiological stress response among buprenorphine-maintained, opioid-
dependent individuals (Greenwald et al., in preparation). 1b) Relative to placebo, 
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YOH+HYD will significantly increase self-reported anxiety, negative affect, nicotine 
withdrawal symptom severity, and relief-motivated nicotine craving, but will not alter 
positive affect or appetitive craving. Prior research indicated that acute stressors can 
induce aversive internal states (M. al'Absi, 2006; al'Absi, Hatsukami, & Davis, 2005; 
Kalman, 2002; Swan, Ward, & Jack, 1996). Exploratory hypothesis: 1c) Relative to 
placebo, YOH+HYD will produce a physiologic stress response (e.g. heart rate, blood 
pressure, and saliva cortisol) comparable in magnitude to robust psychosocial stressors 
(i.e. qualitative comparison of effect sizes from the literature).   
Aim 2: Investigate the effect of YOH+HYD on nicotine-seeking and self-
administration among non-treatment-seeking current cigarette smokers. Hypotheses:  
2a) Relative to placebo, YOH+HYD will potentiate nicotine-seeking and self-
administration behavior (more cigarette puffs earned during the choice progressive ratio 
task and smoked during the self-administration phase). Prior research in our laboratory 
(Section 3.2.10) demonstrated that oral pretreatment with YOH+HYD increased opioid-
seeking among buprenorphine-maintained, opioid-dependent individuals (Greenwald et 
al., in preparation). Exploratory hypothesis: 2b) YOH+HYD will not alter nicotine 
consumption rate (i.e. inter-puff intervals). 
Aim 3: Investigate 
1
H fMRS glutamate (GLU) modulation in the dlPFC during 
working memory task performance.  Hypotheses:  3a) Relative to fixation cross rest, 2-
back task performance will be associated with higher GLU levels during placebo. Prior 
research indicated that 2-back task performance was associated with robust BOLD 
activation bilaterally in the dlPFC (Owen et al., 2005) and fMRI BOLD activation was co-
located with elevated GLU levels (measured via 
1
H fMRS) (Mangia et al., 2006; 
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Schaller, Mekle, Xin, Kunz, & Gruetter, 2013; Schaller, Xin, O'Brien, Magill, & Gruetter, 
2014). GLU modulation is an in vivo biomarker of neural activation (or task-
engagement) that may reflect increased metabolic activity (Mangia et al., 2006; Schaller 
et al., 2013; Schaller et al., 2014). Importantly, GLU modulation is not confounded by 
vasoactive pharmaceutical agents (e.g. YOH). 3b) During YOH+HYD, 2-back GLU 
levels will not differ from fixation cross rest GLU levels. 3c) 2-back response accuracy 
will be higher during placebo, relative to YOH+HYD. Prior research in working memory 
task performance indicated that acute stress (e.g. YOH+HYD) attenuated dlPFC 
engagement (BOLD and neural spiking frequency) and impaired response accuracy (A. 
F. Arnsten, 2009; Qin et al., 2009).  
Aim 4:  Investigate BOLD activation changes associated with YOH+HYD during 
smoking (> neutral) cued N-back fMRI task. Hypotheses: 4a) Relative to placebo, 
YOH+HYD will enhance BOLD activation in the mPFC, mOFC, ventral and dorsal 
striatum during smoking cue (> neutral) images across N-back task levels (0-, 1-, and 2-
back). These hypotheses are consistent with published literature; YOH+HYD will 
increase mOFC/mPFC activation (consistent with (Sinha & Li, 2007)), and decrease 
activation of the Amg (consistent with (Dagher et al., 2009)) and dlPFC (consistent with 
(Qin et al., 2009)). 4b) During 2-back task performance, smoking cued images will be 
associated with higher response accuracy, relative to neutral images, during both 
experimental sessions. Consistent with the iRISA theory (Rita Z Goldstein & Volkow, 
2002; R. Z. Goldstein & Volkow, 2011), attentional bias toward drug-related stimuli will 
facilitate more accurate responding for smoking cued images, relative to neutral 
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images. 4c) Response accuracy will not differ by image type during 0- or 1-back task 
performance during either experimental session (ceiling effect anticipated).  
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CHAPTER 3 MATERIALS AND METHODS 
3.1 
1
H fMRS Pilot Study  
3.1.1 Study Overview 
Prior 
1
H fMRS research has demonstrated significant GLU modulation in the 
occipital cortex (during visual stimulation) (Mangia et al., 2006; Schaller et al., 2013) 
and motor cortex (during a finger tapping task) (Schaller et al., 2014). Our group 
recently extended this approach to cognitive task performance and replicated this effect 
in the hippocampus (during hippocampal-dependent cognitive task performance) 
(Jeffrey A Stanley et al., 2017). However, 
1
H fMRS measurement of in vivo GLU 
modulation in the dlPFC during working memory task performance is novel. Therefore, 
a pilot study was conducted to develop a 
1
H fMRS working memory task paradigm and 
evaluate the effect of task performance on GLU levels in the dlPFC.   
3.1.2 Participant Recruitment 
The Wayne State University Institutional Review Board (WSU IRB) approved all 
study procedures, which were conducted in accordance with the Declaration of Helsinki 
(1964). Healthy right-hand dominant male and female volunteers (aged 18-30 years) 
who reported no MRI contraindications, psychiatric diagnoses, or psychoactive 
medications were recruited from the Detroit metropolitan area. Interested individuals 
completed a brief screening procedure to verify eligibility. Participants deemed eligible 
provided informed consent and were compensated $50 for their time.  
3.1.3 Experimental Protocol 
Participants (N = 16) completed self-report measures (medication history, 
demographic questionnaire, and contact information), a comprehensive MRI safety 
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screen with an MRI technologist (~5 min), and a MRI scan (~60 min) during a single 
experimental session. Each participant received verbal instructions and completed 
several practice runs of the letter 2-back task outside of the magnet (until deemed 
proficient by the experimenter), prior to the MRI scan. Experimental tasks were 
programmed using Presentation software (version 18.1) and displayed on-screen inside 
the MRI scanner via projection system. Participants were able to communicate with the 
MR technologist via speaker/microphone system inside the scanner.  
Each MRI scan consisted of a structural image, left dlPFC B0-field shimming, 
voxel placement, and two 
1
H fMRS experimental tasks (Figure 3.1): continuous fixation-
cross rest and letter 2-back. Participants were verbally instructed to relax, focus their 
gaze on the fixation-cross, and let their thoughts drift during continuous fixation-cross 
rest. On screen, participants were prompted to “Rest” (2s) followed by a static, 
continuous fixation-cross (238s; centered on screen). The letter 2-back working 
memory task consisted of two phases:  flashing grayscale checkerboard (3Hz; 208s) 
and seven blocks of alternating periods of fixation-cross rest (32s) and letter 2-back 
(64s). Prior research in our laboratory demonstrated that the flashing checkerboard 
minimized the variability in the GLU signal prior to investigation of task-related 
modulation (Lynn et al., in preparation). Participants were instructed to relax, focus their 
gaze on screen, and let their thoughts drift during the flashing checkerboard and 
interleaved fixation-cross rest. Every period of interleaved fixation-cross rest was 
prompted on screen with “Rest” (2s) prior to static fixation-cross (30s). Similarly, every 
letter 2-back task block was prompted with “2-back” (4s) followed by serial presentation 
of 20 capitalized letters (3s/letter; 6 target letters; letters displayed for 500ms followed 
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by 2500ms of blank screen). Subjects indicated (via button press) if the letter on screen 
matched the letter presented two previously. Participants were not provided feedback 
about response accuracy. Response accuracy was quantified as a percentage of 
correct responses for each task block.  
3.1.4 Neuroimaging Parameters 
All imaging was conducted on a 3 Tesla Siemens Verio system with 32-channel 
receive-only head coil. All participant scans were completed in the morning between 
9:00-11:30am. High resolution T1-weighted structural scans were collected using the 3D 
Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence with the following 
parameters:  TR = 2.2s, TE = 3ms, TI = 799ms, flip angle = 13°, Field-of-View (FOV) = 
256 x 256 x 160mm, 256 x 1mm thick axial slices, matrix = 176 x 256. Prior to 
1
H fMRS 
acquisition, a region of the left dlPFC (2.5 x 2.5 x 2.5cm) larger than 
1
H fMRS voxel was 
Figure 3.1:  
1
H fMRS Pilot Study Experimental Paradigm. The continuous fixation cross rest 
(left) consisted of instructions (‘Rest,’ 2s) followed by continuous, static fixation cross (238s). 
The letter 2-back task (right) consisted of two phases:  flashing checkerboard (3Hz, 208s) 
and seven repetitions of letter 2-back (64s; instructions ‘2-back’ [4s], 20 letters [3s/letter; 
60s]) with interleaved fixation cross rest (instructions ‘Rest’ [2s] and static fixation cross rest 
[30s]).  
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shimmed to improve B0-field homogeneity (FASTESTMAP). 
1
H fMRS spectra were 
continuously acquired every 16s (PRESS with OVS and VAPOR, TE = 23ms, TR = 
4.0s, 4 averages/spectrum, bandwidth = 2 kHz, 2048 data points, no apodization) 
during the continuous fixation-cross task (15 spectra, 240s) and letter 2-back (55 
spectra, 880s). 
1
H fMRS spectra were acquired without water suppression immediately 
after each task (TE = 23ms, TR = 10s, 2 averages/spectrum, bandwidth = 2 kHz, 2048 
data points, no apodization). Unsuppressed water levels were used to scale metabolite 
levels to absolute concentration values (mmol/kg wet weight). 
3.1.5 Voxel Placement 
1
H fMRS spectra were acquired from the left dlPFC (15 x 20 x 15 mm; 4.5 cm
3
; 
Brodmann Areas 45 and 46; Figure 3.2). The voxel location was selected to encompass 
regions consistently associated with significant BOLD activation in the dlPFC during 
letter 2-back task performance (fMRI meta-analysis) (Owen et al., 2005). The 
automated voxel placement (AVP) method (Woodcock, Arshad, Khatib, & Stanley, 
2017) was used to prescribe 15 of 16 participant’s voxel locations (AVP not used for 
one subject; experimenter error).  
Figure 3.2:  
1
H fMRS Pilot Study Voxel Placement. The 
1
H fMRS Pilot Study voxel (1.5 x 2.0 
1.5 cm; 4.5 cm
3
) was located in the left dlPFC (Brodmann Areas 45 and 46). 
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3.1.6 Automated Voxel Placement (AVP) 
Single voxel MRS research studies often manually prescribe a voxel based on a 
2D image of the current subject’s anatomy. Despite its widespread use, manual voxel 
placement is time-consuming, challenging, and unreliable. This is especially 
problematic for research studies, whose goal is often to investigate neurochemistry as a 
function of psychiatric diagnosis (i.e. between-group research study) or treatment (i.e. 
longitudinal study). Metabolite levels are known to vary across brain regions and by 
voxel tissue composition (gray matter vs white matter vs cerebrospinal fluid). Therefore, 
to avoid Type I or II error, voxel placement must be accurate and reliable across 
research subjects and/or within a research subject across scans. AVP was developed 
in response to the lack of reliable automated approaches for single voxel prescription.  
The AVP suite consisted of three Linux- and Matlab-based scripts (Woodcock et 
al., 2017). The first script, avp_create, facilitated creation of a library of template voxel 
locations that were retained for future subject scans. The second script, avp_coregister, 
facilitated accurate coregistration and prescription of a template voxel to each research 
subject at the scanner (~2 min computer processing time) based on that subject’s T1-
weighted image (i.e. subject head position in the scanner). Figure 3.3 illustrates the 
processing logic used in avp_create and avp_coregister. The third and final script, 
avp_overlap, gathered information stored in the subject’s .rda file (ASCII file created 
during MRS measurements), recreated the prescribed voxel, coregistered the voxel to 
the template brain, and calculated 3D geometric voxel overlap accuracy and reliability 
across subject scans. The AVP suite is available for download free-of-charge 
(Woodcock et al., 2017). 
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Figure 3.3:  AVP Processing Logic. First, the user selects a template brain and enters 
voxel parameters (dimensions, center coordinate, and rotation angles; ‘avp_create’). 
The generated voxel is retained for future coregistration. Second, the user selects a 
template voxel for coregistration to the current subject (‘avp_coregister’). The subject’s 
structural image is coregistered to the template brain and two inversion matrices are 
generated (DOF = 6 and 9). These matrices facilitate calculation of rotation angles and 
voxel center coordinate (respectively) in subject space for voxel prescription.  
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3.1.7 Analysis Strategy 
1
H fMRS Analyses.  
1
H fMRS spectra were analyzed using LCModel version 6.3 
(Provencher, 2008). Post-processing and metabolite quantification steps were 100% 
automated. Eddy current effects were corrected using the unsuppressed water signal 
(Klose, 1990). T1-weighted structural images were B1-field corrected, the brain image 
extracted, and segmented into partial volume maps of CSF, grey and white matter 
using FreeSurfer and FSL tools (e.g. FLIRT, NU_CORRECT, BET and FAST) (Dale, 
Fischl, & Sereno, 1999; Smith et al., 2004). Finally, tissue composition within the MRS 
voxel and appropriate correction factors (e.g. T1 and T2 relaxation) were used to 
calculate absolute GLU concentration (mmol/kg wet weight) (J. A. Stanley, Drost, 
Williamson, & Thompson, 1995). Raw spectra were phase- and shift-corrected prior to 
quantification. Consecutive raw spectra (4 averages, 16s, no apodization or zero-filling) 
were averaged which resulted in 32s temporal resolution (8 averages). GLU levels 
during the first 32s and final 32s of 2-back task performance (2-back A and B, 
respectively) were contrasted with fixation-cross rest GLU levels (continuous and 
interleaved fixation-cross considered separately). 
Shapiro-Wilk test of normality and skewness and kurtosis statistics were used to 
evaluate variable distributions prior to outcome analyses. Whenever necessary, 
extreme values were winsorized (extreme value replaced with nearest value) to 
normalize distributions prior to outcome analyses. Repeated measures analyses of 
variance (rmANOVA) were used to analyze behavioral and neurochemical data. Follow-
up paired t-tests were used to clarify significant main effects. Mean metabolite levels 
during 2-back task were contrasted with rest levels. The metabolite of interest for this 
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study was GLU. However, other metabolites (NAA, Myo-Inositol, GPC+PC, and 
PCr+Cr) were analyzed to determine the neurochemical specificity of working memory 
task modulation. Voxel overlap was quantified using the avp_overlap script (included in 
the AVP suite) (Woodcock et al., 2017). 3D geometric voxel overlap percentage was 
calculated between each subject’s voxel and the template voxel (i.e. accuracy), and 
voxel overlap across all subjects (i.e. reliability). Descriptive statistics are presented as 
mean ± one standard deviation (M ± 1 SD) unless otherwise noted. In all figures, error 
bars represent ± one standard error of the mean (SEM). 
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3.2 Dissertation Study 
3.2.1 Participant Recruitment 
The WSU IRB approved all study procedures, which were conducted in 
accordance with the Declaration of Helsinki (1964). Participants were recruited from the 
Detroit metropolitan area via Craigslist advertisements. Interested individuals (> 500) 
completed a brief (20min) standardized phone screen to rule out obvious study 
contraindications. At the end of the phone screen, eligible individuals were provided an 
overview of experimental procedures, including a description of pharmacological agents 
(and possible side effects), MRI scan, and urine drug screen (UDS) procedure. 
Interested individuals (105) were scheduled for a thorough in-person screen (2hr) at the 
Human Pharmacology Laboratory (Tolan Park Medical Building, Suite 2A).  
Upon arrival to the in-person screening appointment, participant sobriety was 
verified (expired breath alcohol concentration: <.002%). Prior to obtaining participant 
informed consent, a research assistant described the in-person interview procedures in 
detail. Participants who provided written informed consent were eligible to complete the 
remainder of the in-person screen which included: self-report measures (described in 
the Self-Report Measures section below), brief (~20min) computerized psychiatric 
interview, expired breath carbon monoxide measurement (CO; biomarker of recent 
cigarette smoking), UDS (tested for substance use and pregnancy), electrocardiogram 
(ECG), vital signs measurement (resting blood pressure, heart rate, blood oxygen 
saturation), and MRI contraindications screen (self-report). A licensed cardiologist 
evaluated the ECG. A complete description of inclusion and exclusion criteria is listed 
below. Participants were compensated $20 for completion of the in-person screening 
visit (independent of eligibility). 
34 
 
 
 
3.2.2 Inclusion and Exclusion Criteria 
Inclusion criteria:   
1) Current smoker:  expired breath CO ≥ 5ppm, self-reported 10+ cigarettes/day, 
Fagerstrom Test of Nicotine Dependence (FTND) score ≥ 4 
2) Aged 21-35 years:  date of birth verification (driver’s license) 
3) Sober at screening:  negligible expired breath alcohol (<.002%) 
4) Cardiovascular health:  normal resting blood pressure (systolic: 80-160mmHg; 
diastolic: 50-90mmHg), heart rate (50-90bpm), and ECG 
5) Normal or corrected-normal vision 
6) Cognitively Intact:  Shipley Institute of Living Scale (Zachary, 1991) verbal 
intelligence score ≥ 80 
Exclusion criteria: 
1) Urinalysis:  positive for illicit substance use (opioids, methadone, cocaine 
metabolites, benzodiazepines, barbiturates [≥300ng/ml], or amphetamines 
[≥1000ng/ml]) or pregnancy (females only) 
2) Recent substance use:  15+ days of marijuana and/or alcohol use in past month 
3) Psychiatric evaluation:  met criteria for current Axis I disorder (MINI-6) 
4) Medical contraindications:  diabetes, steroid-based contraceptives 
5) MRI contraindications:  pacemaker, ferrous implants, metal fragments 
6) Current motivation to reduce, or seek treatment for, their nicotine use  
7) Lactose intolerance (placebo dose) 
Individuals (N = 27) who satisfied inclusion and exclusion criteria were deemed 
eligible and invited to participate in the research study. Participants provided written 
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informed consent to all experimental study procedures prior to the first experimental 
session. Participants were scheduled for experimental sessions on non-consecutive 
weekdays (M-F). Whenever possible, experimental sessions were scheduled within the 
same week. Eligible female participants were scheduled for both experimental sessions 
during their luteal phase (self-reported final 14 days of the menstrual cycle) to minimize 
stress reactivity variability (Clemens Kirschbaum, Kudielka, Gaab, Schommer, & 
Hellhammer, 1999; Kumsta, Entringer, Hellhammer, & Wüst, 2007). Participants who 
completed both experimental sessions (N = 21) were included in outcome analyses. 
3.2.3 Power Analyses 
Power analyses for this study were based on the effect sizes observed in a related 
study using similar experimental procedures. Prior research in our laboratory 
(Greenwald et al., in preparation) demonstrated that similar pharmacological doses, 
YOH 54mg + [HYD 0mg vs. 20mg], were associated with moderate effects on opioid 
drug-seeking behavior (Cohen’s d = 0.62 and 0.68, respectively) in opioid-dependent, 
buprenorphine-maintained volunteers. The pharmacological doses (YOH 54mg + HYD 
10mg) used in the present study were assumed to be associated with similar effect 
sizes (Cohen’s d = 0.64) on the primary outcome variable:  nicotine-seeking and self-
administration behavior (see Choice Task section below). G*Power version 3.1 
(Dusseldorf, Germany) indicated that a sample of 21 subjects would afford sufficient 
statistical power to reliably detect a main effect for a two-tailed paired t-test, power = 
.80, and α < .05 (J. Cohen, 1992).  
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3.2.4 Experimental Procedures 
Participants completed two experimental sessions (active vs. placebo stress; 
random order) using a double-blind, placebo-controlled, and within-subject crossover 
design. Participants were allowed to smoke cigarettes ad libitum prior to each 
experimental session. Upon arrival at our laboratory (11:00am), participants were tested 
for sobriety (expired breath alcohol < .002%). At 11:20am, a saliva sample was 
collected, vital signs (resting blood pressure and heart rate) and expired breath CO (see 
Physiological Measures section below) were measured, and the periodic battery of self-
report measures (see Periodic Self-Report Battery below) was completed (see Table 
3.1 for complete experimental procedures). The periodic battery of self-report measures 
was collected five times throughout each experimental visit and included:  Minnesota 
Nicotine Withdrawal Scale (MNWS), Brief Questionnaire of Smoking Urges (QSU), 
State-Trait Anxiety Inventory (STAI; state version), and Positive and Negative Affect 
Scale (PANAS). At 11:30am, participants completed the paced puff procedure. 
Participants smoked one puff (1-2sec inhale; video-verified) of their preferred brand of 
cigarette every minute for five minutes (6 total puffs; stopwatch timed; experimental 
control of recent nicotine exposure; experimental room ventilated). At 11:40am, 
participants were moved to a new experimental room that was not used for cigarette 
smoking and was devoid of smoking/cigarette cues. A saliva sample was collected, and 
vital signs and expired breath CO were measured. At 11:45am, participants self-
administered the oral YOH dose (54mg or 0mg). Prior research in our laboratory 
(Greenwald et al., in preparation) indicated that an oral 54mg YOH dose elevated 
resting blood pressure (relative to placebo; consistent with a physiological stress 
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response) approximately 75min after dose and remained elevated for 2+ hours. For this 
study, YOH was self-administered 75min prior to the onset of the MRI scan. 
Participants completed another repetition of the self-report measure battery, as well as 
the Timeline Follow-Back Questionnaire. At 12:15pm, participants self-administered the 
oral HYD dose (10mg or 0mg). Prior research in our laboratory (Greenwald et al., in 
preparation) demonstrated that oral HYD dose elevated saliva cortisol levels (relative to 
placebo; consistent with a physiological stress response) approximately 45min after 
dose and remained elevated for 2+ hours. Participants received detailed instructions 
about the MRI scan procedure and experimental tasks, and completed practice runs of 
the letter 2-back (until proficient). At 12:40am, periodic self-report questionnaires were 
completed, vital signs were measured, and a saliva sample collected. Participants were 
escorted to the MRI center (~8min walk) and upon arrival allowed to rest briefly (~3-
4min), while the 
MRI room was 
prepared. 
Participants 
completed the MRI 
safety screen with 
the MR 
technologist (Dalal 
Khatib) prior to the 
scan (1-2pm; see 
Neuroimaging 
Table 3.1:  Experimental Timeline. Experimental timeline was 
identical for both experimental sessions (active and placebo stress). 
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Experimental Tasks and Neuroimaging Parameters sections below). After being 
escorted back to the Tolan Park Medical building (~8min walk) and following a brief rest 
(~5min), a saliva sample was collected, vital signs were measured, and periodic self-
report measures were completed (2:20pm). At 2:28pm, participants were provided 
verbal instructions that described the cigarette puff vs. money choice progressive ratio 
task. From 2:30-3pm, participants completed the 30min choice task (see Choice Task 
section below). At 3:00pm, vital signs were measured, a saliva sample was collected, 
and the periodic self-report battery was completed. At 3:05pm, participants were 
escorted to the cigarette-smoking experimental room (ventilated) and self-administered 
the cigarette puffs earned on the choice task. Participants were instructed to smoke 
exactly the number of earned puffs (not more and not fewer; 1-2sec inhale; video-
verified) at a comfortable pace of their choosing. Inter-puff interval (s) was measured 
via video monitor unbeknownst to the participant. Participants remained on site until 
4pm for monitoring. Participants were not able to smoke ad libitum until after 4pm. Each 
experimental session lasted 5 hours. Participants were compensated $70 at the end of 
each experimental session and a bonus of $40 for completing both sessions (total 
compensation for study completion:  $200). Any money earned during the choice task 
was added to the participant’s study payment.  
Participant safety. Participant safety was paramount. Previous research in our 
laboratory using comparable and higher YOH and HYD oral dose combinations were 
not associated with adverse events. However, personnel and safety procedures were 
established prior to participant enrollment to ensure participant safety throughout the 
study. Medical staff (licensed physicians and nurses), clinical psychologists, trained 
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masters-level clinical students, and research staff were onsite throughout each 
experimental session. Medications were onsite and available to counteract YOH and 
HYD if necessary [e.g. clonidine and/or diazepam; (Charney et al., 1983; Charney, 
Woods, Krystal, Nagy, & Heninger, 1992; Mattila, Seppala, & Mattila, 1988)]. 
3.2.5 Physiological Measures 
Vital signs:  Resting heart rate and systolic and diastolic blood pressure were 
measured during the in-person screening visit (index of cardiovascular health) and 
periodically throughout each experimental session (biomarker of physiological stress 
response) via Welch-Allyn vital signs monitor. In addition, heart rate and blood pressure 
were monitored to ensure participant cardiovascular safety throughout the study (safety 
thresholds; resting heart rate ≤ 100 beats/min and blood pressure ≤ 160 / 100 mmHg 
[systolic / diastolic]).  
Saliva measures:  Saliva was collected via oral swab (SalivaBio Oral Swab; 
Salimetrics®, State College, PA) which was placed under the participant's tongue for ~2 
minutes. After saliva collection, swabs were returned to the individual storage tube. At 
the end of each experimental session, samples were spun down via centrifuge (3386 
RPMs) for 15 minutes and stored upright at -80ºC until analysis and quantification. 
Saliva α-amylase is a digestive enzyme and indirect biomarker of sympathetic ANS 
activity (Nater & Rohleder, 2009). Saliva α-amylase responds to β-adrenergic receptor 
stimulation, but prior research indicated α-amylase reflected indirect stimulation by YOH 
(Ehlert et al., 2006). Saliva α-amylase was quantified (units: U/mL) via enzymatic 
reaction with 2-chloro-p-nitrophenol and the change in spectrophotometric absorption at 
405nm (sensitivity threshold:  0.4 U/mL). Salivary cortisol is a well-validated correlate of 
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plasma cortisol levels and HPA axis activity (Kahn, Rubinow, Davis, Kling, & Post, 
1988). HYD reliably and dose-dependently increases cortisol levels (van Stegeren, 
Roozendaal, Kindt, Wolf, & Joëls, 2010). Saliva cortisol was quantified (units: ug/dL) via 
ELISA assay and reaction with horseradish peroxidase enzyme, followed by 
measurement of optical density at 450nm (sensitivity threshold:  <0.007 ug/dL). 
3.2.6 Self-Report Measures 
The following self-report measures were administered during the in-person 
screening visit only (unless otherwise noted). Drug History and Use Questionnaire: The 
DHUQ was developed in-house as a comprehensive assessment of substance use 
history (across drugs of abuse), including age at onset, use frequency, and substance 
use consequences. This measure was used to determine participant eligibility (e.g. 
past-month cigarette smoking and alcohol use frequency). Medical History 
Questionnaire: The MHQ was developed in-house as a comprehensive self-report 
assessment of participant medical history, including lifetime and current medical 
diagnoses, reproductive status, current medication and contraceptive use. This 
measure was used to determine participant eligibility (e.g. cardiovascular conditions, 
medication allergies). Distress Tolerance Scale: This 15-item 5-point Likert scale (1 = 
‘strongly agree’ to 5 = ‘strongly disagree’) measured an individual’s ability to tolerate 
distress. This scale demonstrated good construct validity and reliability (Simons & 
Gaher, 2005). Barratt Impulsivity Scale (BIS-11): This widely-used 30-item 4-point Likert 
scale (0 = ‘rarely/never’ to 4 = ‘almost always/always) measured trait impulsivity (e.g. ‘I 
plan tasks carefully’) along three dimensions: motor, attention, and non-planning 
impulsiveness (Patton & Stanford, 1995; Stanford et al., 2009). State-Trait Anxiety 
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Inventory (STAI; trait): The 20-item 4-point Likert scale (1 = ‘not at all’ to 4 = ‘very much 
so’) measured trait anxiety (‘how you generally feel’) via first-person statements (e.g. ‘I 
feel secure’) (Spielberger, 1983). The STAI has excellent psychometric properties 
(Spielberger, 1983, 2010). Stress Mindset Scale (SMS): This 8-item 5-point Likert scale 
(1 = ‘strongly disagree’ to 5 = ‘strongly agree’) measured an individual’s subjective 
assessment (or experience) of how stress affected his/her performance, health, and 
learning ability (e.g. ‘the effects of stress are negative and should be avoided’) (Crum, 
Salovey, & Achor, 2013). Fagerstrom Test for Nicotine Dependence (FTND): The FTND 
is the gold standard self-report questionnaire for assessing nicotine dependence. The 
FTND consists of 6 items (e.g. ‘do you smoke more frequently in the morning?’ [yes=1, 
no=0]) that are summed for a total score (range: 0-10) of nicotine dependence severity 
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991). Timeline Follow-Back 
Questionnaire (TLFB): Participants completed the TLFB questionnaire once during 
each experimental session. The TLFB assessed frequency of past week (7 days) 
nicotine use across products (cigarettes, e-cigarettes, cigars, and smokeless tobacco).  
3.2.7 Periodic Self-Report Battery 
Questionnaires described below were administered periodically throughout each 
experimental session (see Table 3.1). State-Trait Anxiety Inventory (STAI): The 20-item 
4-point Likert scale (1 = ‘not at all’ to 4 = ‘very much so’) measured state anxiety (‘right 
now, at this moment’) via first-person statements (e.g. ‘I feel calm’) (Spielberger, 1983).  
Positive and Negative Affect Schedule (PANAS): The PANAS is a 20-item 5-point Likert 
scale (1 = ’not at all or very slightly’ to 5 = ’extremely’) that is a reliable and well-
validated measure of state positive and negative affect (Watson, Clark, & Tellegen, 
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1988). Participants rated 20 adjectives (e.g. ‘interested’ or ‘excited’) ‘at the present 
moment.’ Items loaded onto one of two affect subscales: ‘positive’ or ‘negative’ 
(analyzed separately). Questionnaire of Smoking Urges (QSU; brief version): This 10-
item 7-point Likert scale (1 = ‘strongly disagree’ to 7 = ‘strongly agree’) measured a 
participant’s desire to smoke a cigarette (e.g. ‘I have a desire for a cigarette right now’) 
‘at this moment’ (Cox, Tiffany, & Christen, 2001). Items loaded onto one of two craving 
subscales: ‘appetitive’ or ‘relief-motivated’ (analyzed separately). Minnesota Nicotine 
Withdrawal Scale (MNWS): The MNWS consisted of 15 adjectives (descriptions of 
possible nicotine withdrawal symptoms; e.g. ‘restless’ and ‘impatient’) rated on a 5-point 
Likert scale (0 = ‘none’ to 4 = ‘severe’) (Hughes & Hatsukami, 1986). The MNWS is a 
well-validated measure of nicotine withdrawal severity (Hughes, 1992; Hughes, Gust, 
Skoog, Keenan, & Fenwick, 1991; Hughes & Hatsukami, 1986; Shiffman, West, & 
Gilbert, 2004). 
3.2.8 Neuroimaging Experimental Tasks 
Participant scans were completed in the afternoon (1-2pm) for both experimental 
sessions. Prior to each scan, participants completed an MRI safety assessment (~3min) 
with the MR technologist (Dalal Khatib). All imaging was conducted on a 3 Tesla 
Siemens Verio system with 32-channel receive-only head coil. Experimental tasks were 
programmed using Presentation software version 18.1 and displayed on-screen inside 
the MRI scanner via projection system. Participants were able to communicate with the 
MR technologist via speaker/microphone system. 
1
H fMRS Letter 2-back Task. The letter 2-back task paradigm (Figure 3.4) was a 
shortened version of the letter 2-back task paradigm used in the pilot study. The pilot 
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study contained seven blocks of alternating letter 2-back and interleaved fixation-cross 
rest, while this version contained only five blocks. All other aspects of the task paradigm 
and instructions were identical. Briefly, the task consisted of two phases: flashing 
grayscale checkerboard (3Hz; 208s) and 5 blocks of alternating letter 2-back (64s; on-
screen ‘2-back’ instructions [4s] followed by 20 capitalized letters [3s/letter; 6 target 
letters; each letter [500ms] followed by blank screen [2500ms]) and interleaved fixation-
cross rest (32s; ‘Rest’ instructions [2s], static fixation-cross [30s]). Participants indicated 
(via button press) if the letter on screen matched the letter presented two previously. 
Participants were not provided feedback about response accuracy. Response accuracy 
was quantified as a percentage of correct responses for each task block.  
fMRI Letter 2-back Task.  The fMRI version of the letter 2-back task consisted of 
two blocks of letter 2-back (64s; same parameters as 
1
H fMRS version) and fixation-
Figure 3.4:  
1
H fMRS Dissertation Study Experimental Paradigm. The letter 2-back task 
(right) consisted of two phases:  flashing checkerboard (3Hz, 208s) and five repetitions of 
letter 2-back (64s; instructions ‘2-back’ [4s], 20 letters [3s/letter; 60s]) with interleaved 
fixation cross rest (instructions ‘Rest’ [2s] and static fixation cross rest [30s]). 
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cross rest (32s). The fMRI letter 2-back task blocks were mixed in among blocks of the 
smoking vs. neutral cued N-back task.  
fMRI Smoking vs. Neutral Cued N-back Task.  This task consisted of blocks of 
letter 0-, 1-, and 2-back overlaid in the center of either cigarette smoking-related images 
or neutral, non-smoking images (Figure 3.5; matched for image characteristics and 
content [e.g. image of a hand with and without a lit cigarette]). Two blocks of each N-
back category (e.g. 0-back smoking cued, 1-back neutral cued, etc.) was displayed in 
pseudo-random order. Each block had an identical structure (32s; instructions [e.g. ‘1-
back’; 2s], 10 letters [3s/letter; 750ms on-screen, 2250ms blank screen; 3 targets]) 
separated by fixation-cross rest (16s; not analyzed; minimize carry-over effects). 
Participants were instructed to focus on the letters in the center of screen (as they 
would during a letter N-back task) and indicate (via button press) when the current letter 
on screen matched the target letter (0-back), when the same letter was depicted 
sequentially (1-back), or when the current letter matched the letter presented two 
Figure 3.5:  fMRI Smoking Cued N-back Paradigm. Participants completed two blocks of 
each task difficulty (0-, 1-, and 2-back) of letter N-back yoked with neutral or smoking-
related images. Each block (32s) consisted of instructions (e.g. ‘1-Back’; 2s) and 10 
letters (3s/letter) interleaved with fixation cross (16s). 
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previous (2-back). Participant performance (% correct and response latency [ms]) was 
analyzed separately for each N-back trial (0-, 1-, and 2-back) and image type (smoking 
vs. neutral).  
Cerebrovascular Reactivity (CVR) Task.  Following the fMRI N-back task, a 
subset of participants completed the CVR task. The task consisted of five blocks of 
unconstrained ‘normal’ breathing (22s), paced breathing (4 repetitions of breathing in 
[3s] and out [3s]), and breath-hold challenges (11s; following exhale). On-screen 
instructions guided participant breathing throughout the task (Figure 3.6). Prior research 
demonstrated that breath-hold challenge tasks were robust and reliable measures of 
CVR (Bright & Murphy, 2013; Lipp, Murphy, Caseras, & Wise, 2015; Magon et al., 
2009; Murphy, Harris, & Wise, 2011; Sousa, Vilela, & Figueiredo, 2014). Carbon 
dioxide is a powerful vasodilator. As carbon dioxide accumulates in blood vessels 
during breath hold, cerebral blood flow will increase substantially. The ratio of 
Figure 3.6:  Cerebrovascular Reactivity Paradigm. Participants were instructed to alter 
their breathing to match the instructions on screen. Three phases were completed 
sequentially across five repetitions:  normal (uncontrolled; 22s), paced breathing (3s in/ 
3s out; four repetitions), and breath hold (11s). 
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oxygenated hemoglobin to deoxygenated hemoglobin will increase which will alter local 
T2* decay, resulting in a robust BOLD signal (relative to periods of paced breathing). 
The source of the CVR BOLD signal is vascular (i.e. non-neuronal). Thus, this task 
facilitated identification of clusters throughout the brain that differed as a function of 
active vs. placebo stress. Clusters identified on this task were subtracted from between-
session contrasts of interest (see Analysis Strategy section below for a detailed 
explanation).  
3.2.9 Neuroimaging Parameters 
All imaging was conducted on a 3 Tesla Siemens Verio system with 32-channel 
receive-only head coil. High-resolution T1-weighted structural scans were collected 
using the 3D MPRAGE sequence with the following parameters:  TR = 2.2s, TE = 3ms, 
TI = 799ms, flip angle = 13°, FOV = 256x256x160mm, 256 x 1mm thick axial slices, 
matrix = 176 x 256. Prior to 
1
H fMRS acquisition, a region of the left dlPFC (2.5 x 2.5 x 
2.5cm) larger than 
1
H fMRS voxel was shimmed to improve B0-field homogeneity 
(FASTESTMAP). 
1
H fMRS spectra were continuously acquired every 16s (PRESS with 
OVS and VAPOR, TE = 23ms, TR = 4.0s, 4 averages/spectrum, bandwidth = 2 kHz, 
2048 data points, no apodization) during the letter 2-back task (42 spectra, 672s). 
1
H 
fMRS spectra were acquired without water suppression immediately after the task (TE = 
23ms, TR = 10s, 2 averages/spectrum, bandwidth = 2 kHz, 2048 data points, no 
apodization). Unsuppressed water levels were used to scale metabolite levels to 
absolute concentration values during each task (mmol/kg wet weight). BOLD fMRI data 
were collected continuously throughout the N-back and CVR tasks using a gradient 
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echo planar imaging sequence with the following acquisition parameters:  TE = 36ms, 
TR = 2.83s, matrix = 80x80, 40 interleaved slices, voxel size = 2.9mm isotropic.    
3.2.10 Choice Task 
The choice progressive ratio task was the only opportunity for participants to 
smoke cigarette puffs (after the 11:30am paced puff procedure) during either 
experimental session (until after the 4pm discharge). During this task, participants were 
seated at a computer and could earn (via computer ‘mouse’ clicking) one puff of their 
preferred brand of cigarette or a money alternative ($0.25 [amount based on prior 
study] (Tidey, Higgins, Bickel, & Steingard, 1999)) on 11 independent choice trials. On 
each trial, the participant was able to earn a cigarette puff, money, or do nothing (not 
punished). Once an option (cigarette puff vs. money) was selected on each trial, the 
participant had to satisfy each trial’s response requirement (escalating number of 
mouse clicks for each subsequent trial [progressive ratio schedule]; i.e., 5, 12, 33, 100, 
180, 340, 540, 835, 1220, 1660 and 2275 clicks) to earn that unit of the option selected. 
Participants could earn any combination of cigarette puffs or money that summed to a 
total of 11 units. After the 30min task, participants were presented with the earned units 
(money was added to their study payment). Participants were instructed to smoke the 
exact number of puffs earned (not more or less) at the pace of their choosing. 
Participants were instructed to inhale 1-2s for each cigarette puff and were video-
monitored to verify compliance. Number of puffs earned and smoked during each 
experimental session is a direct measure of appetitive nicotine motivation and will be 
referred to as ‘nicotine-seeking and self-administration’ hereafter. Unbeknownst the 
participant, the amount of time between cigarette puffs was timed via stopwatch and 
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mean inter-puff interval (s) was calculated for each experimental session. Inter-puff 
interval was a direct measure of nicotine consumption rate. Nicotine-seeking and self-
administration (appetitive phase) was analyzed separately from nicotine consumption 
rate (consumptive phase). 
3.2.11 Analysis Strategy  
1
H fMRS Analyses.  
1
H fMRS spectra were analyzed using LCModel version 6.3 
(Provencher, 2008). Post-processing and metabolite quantification steps were 100% 
automated. Eddy current effects were corrected using the unsuppressed water signal 
(Klose, 1990). T1-weighted structural images were B1 field corrected, the brain image 
extracted, and segmented into partial volume maps of CSF, grey and white matter 
using FreeSurfer and FSL tools (e.g. FLIRT, BET, and FAST) (Dale et al., 1999; Smith 
et al., 2004). Finally, tissue composition within the MRS voxel and appropriate 
correction factors (e.g. T1 and T2 relaxation) were used to calculate the absolute 
glutamate (GLU) concentration (mmol/kg wet weight) (J. A. Stanley et al., 1995). Two 
outcome analysis strategies were employed in this study. First, raw spectra were 
phase- and shift-corrected. Consecutive raw spectra (4 averages, 16s, no apodization 
or zero-filling) were averaged which resulted in 32s (8 averages) temporal resolution. 
LCModel fit characteristics demonstrated that this temporal resolution was at the lower 
limit of reliable GLU quantification. Therefore, a second analysis strategy was used: 64s 
temporal resolution moving average. 32s resolution spectra from the first approach 
were averaged across consecutive task blocks (moving average: 64s resolution) to 
improve signal-to-noise (SNR) and fit reliability. Therefore, spectra collected during first 
32s of letter 2-back task block 1 (2-back A) were averaged with spectra collected during 
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first 32s of letter 2-back task block 2 (2-back A; and so on for 2-back B and rest). Mean 
metabolite levels during 2-back task were contrasted with interleaved fixation-cross rest. 
The metabolite of interest for this study was GLU. However, other metabolites (NAA, 
Myo-Inositol, GPC+PC, and PCr+Cr) were also analyzed to determine the 
neurochemical specificity of working memory task modulation. 
1
H fMRS voxel overlap was quantified using the avp_overlap script (Woodcock et 
al., 2017). 3D Geometric voxel overlap percentage was calculated between each 
subject’s voxel and the template voxel (i.e. accuracy), and across all subjects (i.e. 
reliability). 
fMRI Analyses. Statistical Parametric Mapping (SPM) version 8 software was 
used to process the raw fMRI data. Raw data were slice time-corrected, motion-
corrected, high-pass filtered (128Hz), coregistered to the Montreal Neurologic Institute 
(MNI) template space, spatially-smoothed (6mm Gaussian kernel), and resliced (2mm 
isotropic) prior to outcome analyses. First-level contrast maps (e.g. 1-back smoking 
cued > 1-back neutral cued; within-subject) were submitted to group-level, random-
effects analyses (FTND included as a covariate) and cluster-level corrected (AFNI 
3dClustSim; p < .05). FTND was included as a covariate for three reasons: 1) chronic 
cigarette smoking has known vascular effects and thus could alter the BOLD signal, 2) 
chronic cigarette smoking could alter smoking cue salience and thus BOLD response, 
and 3) to be consistent with the analysis strategy used for other variables. Regions of 
interest included:  ventrolateral [vl] PFC (Brodmann areas 44 and 45), dlPFC 
(Brodmann Area 46), dPFC (Brodmann area 9), dorsal anterior cingulate (dACC), 
mOFC, mPFC, striatum, insula and amygdala. Within an experimental session, clusters 
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that survived cluster-level correction were considered significant and interpreted. For 
comparisons between experimental sessions (active vs. placebo stress), an additional 
analysis step was implemented. First-level CVR contrast maps (breath hold > paced 
breathing) were submitted to group-level, random-effects analyses. Between-session 
CVR contrasts (active > placebo stress and placebo > active stress) were saved as 
thresholded maps (voxel-level; p < .05). Using ImCalc in SPM8, CVR between-session 
difference maps were subtracted from cluster-level corrected between-session 
contrasts of interest (e.g. active > placebo stress:  1-back smoking image > 1-back 
neutral image) to remove regions that exhibited vascular reactivity differences as a 
function of active vs. placebo stress. This approach reduced the likelihood of false 
positive clusters (i.e. removed clusters attributed to vascular effects [non-neuronal] of 
the stress manipulation) for between-session contrasts of interest. 
1
H fMRS vs. fMRI comparison.  Parameters for the 
1
H fMRS and fMRI letter 2-
back tasks were identical which enabled an exploratory comparison of 
1
H fMRS GLU 
levels and fMRI BOLD response. First, each subject’s 
1
H fMRS voxel was recreated in 
subject space then coregistered to the SPM template brain. Next, the 
1
H fMRS voxel 
was used as a mask for first-level BOLD contrasts (letter 2-back > fix cross rest) at the 
same temporal resolution as 
1
H fMRS (32s; 2-back A and B). Z scores (peak activation) 
and peak cluster extents were extracted for each subject and correlated with GLU 
levels during letter 2-back task performance. fMRI metrics (Z score and cluster extents) 
were compared with 
1
H fMRS GLU levels for 2-back A and B for each task repetition 
(first 
1
H fMRS task block was excluded; practice effects) using bivariate Pearson 
correlations. The analysis space consisted of a correlation matrix with 32 cells (4 fMRI 
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2-back blocks X 8 
1
H fMRS 2-back blocks) for both Z scores and cluster extents for 
each of the placebo and stress sessions. For this exploratory analysis only, the 
statistical threshold was p ≤ .10.  
All self-report, behavioral, physiological and neurochemical data were evaluated 
for missing data, extreme values, and normality (Shapiro-Wilk test of normality; 
skewness and kurtosis statistics > 1.5) (West, Finch, & Curran, 1995). Ordinal and 
continuous variable distributions were normalized with statistical transformations (log10) 
or winsorization (extreme values) prior to outcome analyses. Ordinal or continuous 
variables measured at only one time point were evaluated using one-way ANOVA, 
Pearson bivariate correlations, or linear regression. Ordinal or continuous variables 
collected repeatedly across multiple time points (e.g. physiological, periodic self-report, 
N-back behavioral data, and neurochemistry) were evaluated using rmANOVA. Follow-
up paired t-tests evaluated differences for any significant rmANOVA main effects. 
Sphericity was verified (Mauchly’s test of sphericity) prior to rmANOVA analyses. 
Categorical variables were evaluated using Chi-Square test of independence. FTND 
score was evaluated as a covariate for all outcome variables (only included in analytic 
models when significant). Descriptive statistics are presented as mean ± one standard 
deviation (M ± 1 SD) unless otherwise noted. In figures, error bars represent ± one 
standard error of the mean (SEM) unless otherwise noted. The threshold for statistical 
significance was p ≤ .05. 
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CHAPTER 4 RESULTS 
4.1 
1
H fMRS Pilot Study 
4.1.1 Sample Characteristics 
The modal participant was a 24 year old (± 3.4 yrs; range: 19-30 yrs) Caucasian 
or Asian (50% each) male (56.3%). The sample consisted of cognitively-normal and 
psychiatrically-healthy college-educated participants not currently taking psychoactive 
medications. All participants were right hand dominant.  
4.1.2 Voxel Overlap 
 AVP was used to prescribe each participant’s voxel location (less one subject 
due to experimenter error; manual placement). Voxel placement was highly accurate 
(mean percent geometric overlap with the template voxel = 92.3 ± 4.7%) and reliable 
(mean percent geometric overlap across all participants = 89.9%) across all participants 
(Figure 4.1) (Woodcock et al., 2017). Mean (± one SD) voxel tissue composition was 
36.8 ± 3.8% gray and 60.8 ± 4.5% white matter. Voxel placement was less accurate for 
the one subject without AVP (manual placement: 77.7% vs. AVP: 86.2-96.9%).  
Figure 4.1:  
1
H fMRS Pilot Study Voxel Overlap. Participant voxel placement (N=16) was 
coregistered to template space and orthonormal views depict geometric voxel overlap. 
Percentage of geometric voxel overlap is indicated by color:  white indicates voxel space 
with complete overlap, yellow/red indicate incomplete overlap, across all subjects.  
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4.1.3 Behavioral Data 
Behavioral data 
demonstrated task 
compliance (mean 
correct: 94.8% ± 10.7%; 
mean reaction time: 644 ± 
171ms). rmANOVA 
indicated that task 
performance increased 
across blocks (Time 
effect; F(6,90) = 2.39, p < 
.05, from 88.5% in block 
1 to 96.9% in block 7; 
Figure 4.2). Reaction time 
non-significantly 
decreased across blocks 
(F(6,90) = 1.90, p = .09, 
from 697ms in block 1 to 
638ms in block 7; Figure 
4.3). 
Figure 4.2: Letter 2-back Response Accuracy. Mean 
response accuracy (% correct) is depicted across task 
blocks (± 1 SEM). 
Figure 4.3: Letter 2-back Response Latency. Mean response 
latency (s) is depicted across task blocks (± 1 SEM). 
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4.1.4 LCModel Fit Characteristics 
LCModel fit reliability was evaluated for continuous fixation-cross rest, letter 2-
back A (first 32s of each task block), letter 2-back B (final 32s of each task block), and 
interleaved fixation-cross rests (between 2-back task blocks). Importantly, LCModel fit 
characteristics did not differ as a function of 2-back vs. rest (Time and Task X Time 
Figure 4.4: LCModel Fit of Representative Spectrum. A representative quality 
1
H fMRS 
spectrum (32s temporal resolution; 8 avgs) is depicted. The raw (black line) and 
LCModel fit (red line) signal are displayed above the estimated spectral peaks for GLU 
(red line). At the bottom of the figure, the residual signal (black line; i.e. noise) and 
chemical shift (ppm) are displayed. 
55 
 
 
 
effects examined; ps > .10; see Table 4.1). A representative spectrum and LCModel 
estimation of GLU levels are depicted in Figure 4.4.  
4.1.5 GLU Modulation  
Flashing checkerboard reduced GLU level fluctuation (mean coefficient of 
variation percentage = 4.6%) prior to 2-back (vs. rest) modulation.  
2-back A vs. rest.  GLU levels during 2-back A (first 32s of task performance 
across task blocks) were compared to continuous and interleaved fixation-cross rest 
(Figure 4.5). Overall, GLU 
levels during 2-back A 
were significantly higher 
(3.4%) than continuous 
fixation-cross rest 
(F(1,111) = 6.26, p < .05, 
partial η
2 
= 0.05 [small-to-
moderate effect size]; 
12.07 ± 0.85 vs. 11.75 ± 
1.00, respectively). Overall 
2-back A GLU levels did 
Table 4.1:  LCModel Fit Characteristics. Mean (± 1 SD) LCModel fit characteristics 
are presented by task phase. GLU = glutamate; GLN = glutamine; FWHM = full-
width half-maximum; SNR = signal-to-noise; CRLB = Cramer Rao Lower Bound. 
Figure 4.5: Overall GLU Levels. Mean (± 1 SEM) GLU levels 
for each task phase are depicted. Paired t-test: *p < .05 
 
2.9% higher (p = .07) 
3.4% higher* 
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not differ from 
interleaved fixation-
cross rest (p = .92; 
12.07 ± 0.85 vs. 12.06 
± 1.04, respectively).  
Relative to 
continuous fixation-
cross rest, rmANOVA 
indicated a significant 
Time effect (F(6,90) = 
3.35, p < .01, partial η
2 
= 0.18 [moderate-to-
large effect size]) as 
GLU levels increased 
across task blocks 
(Figure 4.6). Task (2-
back A vs. rest) and 
Time X Task 
interaction effects 
were non-significant 
(ps > .20).  
Relative to 
interleaved fixation-
Figure 4.6 & 4.7:  GLU Levels across Task Blocks. Mean (± 1 
SEM) 2-back GLU levels vs. continuous fixation-cross (upper 
panel) and interleaved fixation-cross (lower panel) are 
depicted across task blocks. 
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cross rest, rmANOVA 
indicated significant Time 
(F(6,90) = 2.78, p < .05, 
partial η
2 
= 0.16 
[moderate-to-large effect 
size]) and Time X Task 
interaction effects 
(F(6,90) = 2.95, p < .05, 
partial η
2 
= 0.16 
[moderate-to-large effect 
size]; Figure 4.7). The 
Task effect was not 
significant (p = .52). The 
Time effect indicated that 
GLU levels increased 
across task blocks. The 
Time X Task interaction 
confirmed that GLU 
levels were significantly 
higher (4.4%) than 
interleaved rest during 
task blocks 2 and 3 
(F(1,31) = 8.49, p < .01, 
Figure 4.8 & 4.9: 2-back A & B GLU Levels vs. Continuous 
Fixation Cross. Mean (± 1 SEM) 2-back A (upper panel) and 
B (lower panel) GLU levels (% relative to continuous fixation 
cross) are depicted across task blocks. Paired t-test: *p < 
.05, **p < .01 
* 
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partial η
2 
= 0.22 
[moderate-to-large effect 
size]; 11.98 ± 0.71 vs. 
11.48 ± 1.01, 
respectively; Figure 4.10), 
and significantly lower 
(4.8%) during task blocks 
4 and 5 (F(1,31) = 12.39, 
p < .001, partial η
2 
= 0.29 
[large effect size]; 11.91 ± 
0.97 vs. 12.49 ± 0.94, 
respectively).    
2-back B vs. rest.  
Overall GLU levels during 
2-back B (final 32s of 
task performance across 
task blocks) were non-
significantly higher (2.9%) 
than continuous fixation-
cross rest (F(1,111) = 
3.28, p = .07, partial η
2 
= 
0.03 [small-to-moderate 
effect size]; 12.00 ± 0.98 
Figure 4.10 & 4.11: 2-back A & B GLU Levels vs. 
Interleaved Fixation Cross. Mean (± 1 SEM) 2-back A (upper 
panel) and B (lower panel) GLU levels (% relative to 
interleaved fixation cross) are depicted across task blocks. 
Paired t-test: *p < .05, **p < .01 
** 
* 
* 
* 
59 
 
 
 
vs. 11.75 ± 1.00, respectively; Figure 4.5).  Overall GLU levels during 2-back B did not 
differ from interleaved fixation-cross rest (p = .61; 12.00 ± 0.98 vs. 12.06 ± 1.04, 
respectively).  
Relative to continuous fixation-cross rest, rmANOVA indicated a non-significant 
Time effect (F(6,165) = 2.08, p = .06; partial η
2 
= 0.12 [moderate-to-large effect size]) as 
GLU levels increased across task blocks (Figure 4.6). Task (2-back B vs. rest) and 
Time X Task interaction effects were non-significant (ps > .20).  
Relative to interleaved fixation-cross rest, rmANOVA indicated significant Time 
(F(6,90) = 3.14, p < .01, partial η
2 
= 0.17 [moderate-to-large effect size]) and Time X 
Task interaction effects (F(6,90) = 3.71, p < .01, partial η
2 
= 0.20 [moderate-to-large 
effect size]; Figure 4.10). The Task effect was not significant (p = .91). The Time effect 
indicated that GLU levels increased across task blocks (Figure 4.7). The Time X Task 
interaction indicated that GLU levels were significantly higher (4.4%) than interleaved 
rest during task blocks 2 and 3 (F(1,31) = 7.28, p < .05, partial η
2 
= 0.19 [moderate-to-
large effect size]; 11.98 ± 0.93 vs. 11.48 ± 1.01, respectively; Figure 4.11), and 
significantly lower (3.6%) during task blocks 4, 5, and 6 (F(1,47) = 8.74, p < .01, partial 
η
2 
= 0.16 [moderate-to-large effect size]; 12.00 ± 0.93 vs. 12.44 ± 1.00, respectively).  
4.1.6 BOLD Effect 
Prior 
1
H fMRS studies found a significant BOLD effect as a function of task vs. 
rest (Mangia et al., 2006; Schaller et al., 2013; Schaller et al., 2014). Increased 
concentration of oxygenated blood in task-active brain regions (i.e. BOLD effect) can 
reduce spectral linewidth (FWHM). Relative to continuous fixation-cross rest, rmANOVA 
revealed FWHM did not significantly differ as a function of 2-back A or B (Task ps > .80; 
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Time X Task interaction ps > .07). Relative to interleaved fixation-cross rest, rmANOVA 
indicated that FWHM did not significantly differ as a function of 2-back A or B (Task ps 
> .10; Time X Task interaction ps > .40).  
4.1.7 Neurochemical Specificity 
 Metabolites other than GLU (Myo-Inositol, GPC+PC, PCr+Cr, and NAA) were 
examined as a function of experimental task. During 2-back A, no metabolites (other 
than GLU) differed as a function of task. However, during 2-back B, rmANOVA 
indicated Time X Task interaction effects for Myo-Inositol and NAA (F(6,90) = 2.57, p < 
.05 and F(6,90) = 2.28, p < .05, respectively). Myo-Inositol and NAA levels were higher 
during 2-back B than interleaved fixation-cross rest in the first few task blocks, but 
converged in later task blocks. GPC+PC and PCr+Cr did not differ significantly as a 
function of task during 2-back A or B (ps > .05). 
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4.2 Dissertation Study 
4.2.1 Sample Characteristics 
The modal participant was 28 (± 
3.9) years old (range: 21-34 years), 
male (85.7%), and African-American 
(71.4%). Participants (N = 21) reported 
smoking 17.2 ± 5.9 cigarettes/day and 
were moderately nicotine dependent 
(FTND = 6.1 ± 2.0). Sample 
characteristics are described in detail in 
Table 4.2.  
4.2.2 Physiological Effects 
 Physiological and periodic self-
report measurements from the first 
time point of each session (11:20am; 
prior to experimental nicotine 
exposure control [paced puff 
procedure]) were excluded from 
analyses for the following reasons. 
Participant data were highly variable 
at the initial time point, which 
suggested external factors influenced 
participant physiology and self-report 
Figure 4.12:  Systolic Blood Pressure. Mean (± 
1 SEM) systolic blood pressure (mmHg) is 
depicted for active (green line) and placebo 
stress sessions (blue line). Approximate 
experimental procedure timing is noted with 
arrows. Paired t-test: *p ≤ .05; **p < .01 
** 
** 
Table 4.2:  Dissertation Sample 
Characteristics.  
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responses. Moreover, several participants reported they did not have access to 
cigarettes in the morning before the start of the experimental session (and were in mild 
nicotine withdrawal). Acclimation to the experimental setting and experimental control 
for recent nicotine exposure established a more stable baseline measurement. 
Therefore, only the final four time points for physiological indices and the periodic self-
report battery were included in outcome analyses.  
 Blood pressure.  As a function of time point and experimental condition (active 
vs. placebo stress), rmANOVA indicated that systolic BP (mmHg) exhibited significant 
Time (F(3,57) = 4.14, p < .01; partial η
2 
= 0.18 [moderate-to-large effect size]), Dose 
(F(1,19) = 10.31, p < .01; partial η
2 
= 0.35 [large effect size]), and Time X Dose 
interaction effects (F(3,57) = 8.33, p < 
.001; partial η
2 
= 0.31 [large effect 
size]; Figure 4.12). YOH+HYD 
significantly increased systolic BP for 
2+ hours throughout the remainder of 
the stress session. At peak 
YOH+HYD effects, systolic BP was 
~11.5 mmHg higher during active vs. 
placebo stress (128.8 mmHg vs. 
117.5 mmHg). FTND was not 
significantly related to systolic BP (ps 
> .20).   
Figure 4.13:  Diastolic Blood Pressure. Mean 
(± 1 SEM) diastolic blood pressure (mmHg) is 
depicted for the active stress (green line) and 
placebo sessions (blue line). The approximate 
timing of each experimental procedure is noted 
with arrows. Paired t-test: *p ≤ .05; **p < .01 
** 
* 
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rmANOVA indicated that diastolic BP (mmHg) exhibited significant Time (F(3,57) 
= 5.88, p < .001; partial η
2 
= 0.24 [large effect size]), Dose (F(1,19) = 6.65, p < .05; 
partial η
2 
= 0.26 [large effect size]), and Time X Dose interaction effects (F(3,57) = 2.98, 
p < .05; partial η
2 
= 0.14 [moderate-to-large effect size]) as a function of time point and 
experimental condition (Figure 4.13). YOH+HYD significantly increased diastolic BP for 
2+ hours throughout the remainder of the stress session. At peak effects, diastolic BP 
was ~7 mmHg higher during active vs. placebo stress (79.6 mmHg vs. 72.5 mmHg). 
FTND was not significantly related to diastolic BP (ps > .25).  
Heart rate.  rmANOVA indicated that HR (bpm) exhibited non-significant Time 
(F(3,57) = 2.58, p = .06; partial η
2 
= 0.12 [moderate-to-large effect size]) and Dose 
effects (p = .42), but there was a 
significant Time X Dose interaction 
(F(3,57) = 3.38, p < .05; partial η
2 
= 
0.15 [moderate-to-large effect size]; 
Figure 4.14). HR decreased 
significantly over time during the 
placebo session (F(3,57) = 3.92, p < 
.01; partial η
2 
= 0.09 [moderate effect 
size]), but not the active stress 
session (p = .55). At peak YOH+HYD 
effects, HR was ~4 bpm faster during 
active vs. placebo stress (77.8 bpm 
Figure 4.14:  Heart Rate. Mean (± 1 SEM) 
heart rate (bpm) is depicted for the active 
stress (green line) and placebo sessions (blue 
line). The approximate timing of each 
experimental procedure is noted with arrows. 
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vs. 73.7 bpm). FTND was not 
significantly related to HR (ps > .35).  
Saliva cortisol.  Due to budget 
restrictions, saliva biomarker data 
(cortisol and α-amylase) were only 
analyzed at three time points 
(baseline, after YOH+HYD dosing but 
prior to the MRI scan, and after the 
puff/money choice task but prior to 
earned nicotine self-administration). 
rmANOVA indicated that saliva 
cortisol (ug/dL; log10-transformed) 
exhibited significant Time (F(2,38) = 
13.59, p < .001; partial η
2 
= 0.42 [very 
large effect size]), Dose (F(1,19) = 29.14, p < .001; partial η
2 
= 0.61 [very large effect 
size]), and Time X Dose interaction effects (F(2,38) = 25.13, p < .001; partial η
2 
= 0.57 
[very large effect size]; Figure 4.15). YOH+HYD significantly increased saliva cortisol 
levels for 2+ hours throughout the remainder of the stress session. At peak YOH+HYD 
effects, saliva cortisol level was ~4x higher during active vs. placebo stress session. 
FTND was not significantly related to saliva cortisol level (ps > .40).  
Saliva α-amylase.  rmANOVA indicated that saliva α-amylase (U/mL) exhibited a 
significant Time effect (F(2,38) = 4.50, p < .05; partial η
2 
= 0.19 [moderate-to-large 
effect size]), but non-significant Dose (p = .57) and Time X Dose interaction effects (p = 
Figure 4.15:  Saliva Cortisol. Mean (± 1 SEM) 
saliva cortisol (ug/dL) is depicted for the active 
stress (green line) and placebo sessions (blue 
line). The approximate timing of each 
experimental procedure is noted with arrows. 
Paired t-test: *p ≤ .05; **p < .01 
** 
** 
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.13; Figure 4.16). Saliva α-amylase 
levels increased significantly over 
time during the active stress session 
(F(2,38) = 5.02, p < .05; partial η
2 
= 
0.21 [moderate-to-large effect size]), 
but not the placebo session (p = .25). 
At peak YOH+HYD effects, saliva α-
amylase level was 28.7% higher 
during active vs. placebo stress 
session. FTND was not significantly 
related to saliva α-amylase level (ps > 
.20).  
4.2.3 Magnitude of Stress 
Manipulation 
 The magnitude of the 
physiological stress response was an important experimental design consideration. If 
the YOH and HYD doses induced physiological responses beyond a naturalistic level, 
the generalizability of study findings might be limited. Thus, to provide context for the 
magnitude of the physiological effects described above, the observed pharmacological 
stress data were qualitatively compared with published studies that used psychosocial 
stress manipulations.  
With regard to saliva cortisol (biomarker of HPA axis response), a meta-analysis 
of psychosocial stress manipulations and saliva cortisol response was examined 
(Dickerson & Kemeny, 2004). A robust psychosocial stress manipulation (public 
Figure 4.16:  Saliva α-Amylase. Mean (± 1 
SEM) saliva α-amylase (U/ml) is depicted for 
the active stress (green line) and placebo 
sessions (blue line). The approximate timing of 
each experimental procedure is noted with 
arrows. 
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speaking + cognitive tasks) used in 23 different studies conducted in the afternoon 
(consistent with the present study; an important consideration because of the diurnal 
rhythm of cortisol) was associated with a large effect on saliva cortisol (Cohen’s d = 
1.09). Similarly, peak saliva cortisol response to YOH+HYD was also a large effect 
(Cohen’s d = 1.61). With regard to cardiovascular biomarkers, a recent study of 102 
cigarette smokers was selected for comparison (Ginty et al., 2014). A similar 
psychosocial stress manipulation (public speaking + cognitive tasks) exhibited large 
effects on systolic BP and HR (Cohen’s d = 1.18 and 1.53, respectively) (Ginty et al., 
2014). In the present study, YOH+HYD was associated with a comparable peak effect 
on systolic BP (Cohen’s d = 1.17; 
range = 0.96-1.37) and smaller 
effect on HR (Cohen’s d = 0.26; 
range = 0.19-0.32). Collectively, 
these qualitative comparisons 
demonstrated the magnitude of 
physiological stress response 
induced by oral pretreatment with 
54mg YOH and 10mg HYD was 
comparable to a robust 
psychosocial stress manipulation.  
4.2.4 Subjective Effects 
Nicotine withdrawal.  Nicotine 
withdrawal symptoms were 
Figure 4.17:  Nicotine Withdrawal. Mean (± 1 
SEM) self-reported nicotine withdrawal symptom 
severity is depicted for the active stress (green 
line) and placebo sessions (blue line). The 
approximate timing of each experimental 
procedure is noted with arrows. 
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measured via self-report (MNWS) 
as part of the periodic self-report 
battery. rmANOVA indicated that 
nicotine withdrawal exhibited a 
significant Time effect (F(3,54) = 
18.15, p < .001; partial η
2 
= 0.50 
[very large effect size]), but non-
significant Dose (p = .83) and Time 
X Dose interaction effects (p = .67; 
Figure 4.17). Nicotine withdrawal 
symptoms increased significantly 
throughout each experimental 
session, but did not differ as a 
function of active vs. placebo 
stress. Mean nicotine withdrawal 
severity was ‘slight’ or ‘mild’ at 
peak levels. FTND was not 
significantly related to nicotine 
withdrawal (ps > .06).  
Appetitive cigarette craving.  
Appetitive craving was measured 
via self-report (QSU) as part of the 
periodic self-report battery. 
Figures 4.18 & 4.19:  Appetitive and Relief-
Motivated Cigarette Craving. Mean (± 1 SEM) self-
reported appetitive (upper panel) and relief-
motivated (lower panel) cigarette craving is 
depicted for the stress (green line) and placebo 
sessions (blue line). The approximate timing of 
each experimental procedure is noted with arrows. 
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rmANOVA indicated that appetitive craving exhibited a significant Time effect (F(3,51) = 
34.02, p < .001; partial η
2 
= 0.67 [very large effect size]), but non-significant Dose (p = 
.62) and Time X Dose interaction effects (p = .12; Figure 4.18). Appetitive cigarette 
craving increased significantly throughout each experimental session, but did not differ 
as a function of active vs. placebo stress. At peak levels, appetitive cigarette craving 
was ‘moderate’ to ‘substantial.’ FTND was not significantly related to appetitive craving 
(ps > .20).  
Relief-motivated cigarette craving.   Relief-motivated craving was measured via 
self-report (QSU) as part of the periodic self-report battery. rmANOVA indicated that 
relief-motivated craving (log10-transformed) exhibited a significant Time effect (F(3,51) = 
25.31, p < .001; partial η
2 
= 0.60 [very large effect size]), but non-significant Dose (p = 
.77) and Time X Dose interaction effects (p = .18; Figure 4.19). Relief-motivated 
cigarette craving increased significantly throughout each experimental session, but did 
not differ as a function of active vs. placebo stress. At peak levels, relief-motivated 
cigarette craving was ‘moderate’ to ‘substantial.’ FTND was not significantly related to 
relief-motivated craving (ps > .30).  
Anxiety.  Anxiety levels were measured via self-report (STAI; state version) as 
part of the periodic self-report battery. rmANOVA indicated that anxiety exhibited a 
significant Time effect (F(3,54) = 8.61, p < .001; partial η
2 
= 0.32 [large effect size]), but 
non-significant Dose (p = .49) and Time X Dose interaction effects (p = .81; Figure 
4.20). Anxiety levels decreased significantly throughout each experimental session, but 
did not differ as a function of active vs. placebo stress. At peak levels (baseline), 
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participants reported they were 
‘somewhat’ anxious. FTND was not 
significantly related to anxiety (ps > 
.15).  
Negative affect.  Negative 
affect was measured via self-report 
(PANAS) as part of the periodic self-
report battery. rmANOVA indicated 
that negative affect exhibited a 
significant Time effect (F(3,54) = 3.81, 
p < .05; partial η
2 
= 0.18 [moderate-to-
large effect size]), but non-significant 
Dose (p = .47) and Time X Dose 
interaction effects (p = .34; Figure 4.21). Negative affect increased significantly 
throughout each experimental session, but did not differ as a function of active vs. 
placebo stress. At peak levels, participants reported ‘very slight’ negative affect. FTND 
was not significantly related to negative affect (ps > .35).  
Figure 4.20:  Anxiety. Mean (± 1 SEM) self-
reported anxiety level is depicted for the active 
stress (green line) and placebo sessions (blue 
line). The approximate timing of each 
experimental procedure is noted with arrows. 
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Positive affect.  Positive 
affect was measured via self-report 
(PANAS) as part of the periodic 
self-report battery. rmANOVA 
indicated that positive affect 
exhibited no significant effects: 
Time (p = .23), Dose (p = .91), or 
Time X Dose interaction (p = .73; 
Figure 4.22). FTND was 
significantly related to positive 
affect:  the FTND X Time 
interaction was significant (F(3,51) 
= 4.31, p < .01; partial η
2 
= 0.20 
[moderate-to-large effect size]). 
Controlling for FTND, positive 
affect decreased  throughout each 
experimental session, but did not 
differ as a function of active vs. 
placebo stress (ps > .20). 
Participants reported ‘moderate’ 
positive affect at baseline (peak 
levels) and between ‘moderate’ Figure 4.21:  Negative Affect (upper panel). 
Figure 4.22:  Positive Affect (lower panel). 
Mean (± 1 SEM) self-reported affect is depicted for 
the active stress (green line) and placebo sessions 
(blue line). The approximate timing of each 
experimental procedure is noted with arrows. 
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and ‘a little’ positive affect at their 
lowest levels.  
4.2.5 Nicotine-seeking and Self-
Administration  
Nicotine-seeking and self-
administration behavior.  Nicotine-
seeking was measured via the 
choice (puffs vs. money) progressive 
ratio task. Three participants were 
excluded from nicotine-seeking 
analyses for the following reasons. 
Task instructions were explained 
incorrectly to the first participant in 
the study (experimenter error). One 
participant reported a significant 
reduction in smoking frequency 
between study enrollment and the 
experimental sessions (below study 
inclusion thresholds; FTND < 4 and 
< 10 cigarettes/day). The third 
participant switched from paper 
cigarettes to e-cigarettes between study enrollment and experimental sessions. Thus, 
nicotine-seeking analyses included 18 participants. The initial rmANOVA indicated that 
Figure 4.23 & 4.24:  Placebo & Stress Puffs vs. 
FTND. Cigarette puffs earned/smoked during the 
placebo (upper panel) and stress (lower panel) 
session are depicted by FTND score.    
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nicotine-seeking did not differ as a 
function of active vs. placebo stress 
(p = .75; 5.3 ± 2.7 vs. 5.6 ± 2.4 puffs, 
respectively). However, FTND was 
significantly related to nicotine-
seeking. FTND was positively 
correlated with nicotine-seeking 
during the placebo (Pearson = .60, p 
< .01; Figure 4.23), but not active 
stress session (Pearson = .11 p = 
.67; Figure 4.24). FTND was 
negatively correlated with the 
nicotine-seeking change score (puffs 
earned during the stress minus 
placebo session; Pearson = -.48, p < 
.05; Figure 4.25). Including FTND in 
the model, rmANOVA indicated 
significant Dose (F(1,16) = 4.93, p < 
.05; partial η
2 
= 0.24 [large effect 
size]) and Dose X FTND interaction 
effects (F(1,16) = 4.83, p < .05; 
partial η
2 
= 0.23 [large effect size]). 
Relative to placebo, nicotine-seeking 
Figure 4.25:  Puffs Delta vs. FTND. Cigarette 
puffs earned/smoked during the placebo minus 
stress session are depicted by FTND score.    
Figure 4.26:  Nicotine-Seeking and Self-
Administration. Mean (± 1 SEM) cigarette 
puffs earned and smoked for more (green 
line) and less (blue line) nicotine dependent 
participants (median split by FTND score) are 
depicted for each experimental session.   
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increased as a function of active stress, controlling for FTND. Moreover, median-split by 
FTND, nicotine-seeking exhibited a significant Dose X FTND interaction (F(1,16) = 4.78, 
p < .05; partial η
2 
= 0.23 [large effect size]) as a function of experimental session 
(Figure 4.26). Relative to placebo, less dependent participants exhibited an increase in 
nicotine-seeking during active stress (~1.5 puffs), while more dependent exhibited a 
decrease in nicotine-seeking (~1.0 puff). 
 Nicotine consumption rate. 
Nicotine consumption rate was 
measured, unbeknownst the participant, 
as mean inter-puff interval (s) during 
nicotine self-administration following the 
nicotine-seeking task. Individuals with 
valid choice data and who earned (and 
smoked) at least two cigarette puffs (n = 
16) were included in analyses. 
rmANOVA indicated that nicotine 
consumption rate (log10-transformed) did 
not differ as a function of active vs. 
placebo stress (p = .60; 27.5 ± 20.8s vs. 
26.4 ± 14.9s, respectively; Figure 4.27). FTND was not significantly related to nicotine 
consumption rate (p > .15).  
Figure 4.27:  Nicotine Consumption Rate. 
Mean (± 1 SEM) inter-puff interval (s) for 
more (green line) and less (blue line) nicotine 
dependent participants (median split by 
FTND score) are depicted for each 
experimental session.   
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4.2.6 Voxel Overlap 
 The voxel used in this study (location, dimensions, and rotation angles) was 
identical to the 
1
H fMRS pilot study. AVP was used to prescribe voxel placement for a 
subset of participants (AVP was under development at the onset of this study) 
(Woodcock et al., 2017). Percentage of voxel overlap (with the template voxel) by voxel 
placement method is described in 
Table 4.3 and illustrated in Figure 
4.28. Voxel overlap improved as AVP 
became functional. Within-subject 
voxel overlap across experimental 
Figure 4.28:  Geometric Voxel Overlap. Participant voxel placement was coregistered to 
template space and orthonormal views depict geometric voxel overlap separately for each 
voxel placement method. Percentage of geometric voxel overlap is indicated by color:  
white indicates voxel space with complete overlap, while yellow/red indicate incomplete 
overlap, across subjects. 
Table 4.3:  Geometric Voxel Overlap. Mean 
percentage (± 1 SD) of geometric voxel overlap 
with the template voxel (i.e. placement 
accuracy) is depicted by voxel placement 
method. 
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sessions (active vs. placebo stress) 
was very good:  87.3 ± 15.1%. 
Voxel tissue composition was 
31.8% gray and 66.0% white 
matter.  
4.2.7 Letter 2-back Behavioral Data   
Behavioral data were 
unintelligible and discarded for 10 
scans (23.8%) due to data 
collection error. Behavioral data 
demonstrated task compliance for 
both the placebo (87.1 ± 13.3% 
correct; 674 ± 233ms response 
latency) and active stress (78.2 ± 
15.1% correct; 715 ± 187ms 
response latency) sessions. As a 
function of experimental session 
and task block, rmANOVA 
indicated that accuracy exhibited a 
significant Time effect (F(4,48) = 
6.61, p < .001; partial η
2 
= 0.36 
[large effect size]; Figure 4.29), 
generally improving across task 
Figure 4.29:  Letter 2-back Response 
Accuracy. 
Figure 4.30:  Letter 2-back Response Latency. 
Mean (± 1 SEM) response accuracy (% correct; 
upper panel) and latency (ms; lower panel) are 
depicted across task blocks separately for the 
active stress (green line) and placebo (blue line) 
sessions. Paired t-test: *p < .05 
* 
* 
76 
 
 
 
blocks during both experimental sessions (Placebo: Block 1 = 77.4 ± 19.2%, Block 5 = 
90.5 ± 14.2%; Stress: Block 1 = 74.5 ± 12.0%, Block 5 = 74.5 ± 19.6%). Response 
accuracy exhibited a significant Dose effect (F(1,12) = 6.35, p < .05; partial η
2 
= 0.35 
[large effect size]), which indicated it was higher during placebo than active stress (87.1 
± 13.3% vs. 78.2 ± 15.1%). Finally, a significant Time X Dose interaction (F(4,48) = 
3.08, p < .05; partial η
2 
= 0.20 [moderate-to-large effect size]) indicated that response 
accuracy improved more across task blocks during the placebo, relative to the active 
stress session.   
rmANOVA indicated that response latency exhibited a significant Time effect 
(F(4,52) = 3.15, p < .05; partial η
2 
= 0.20 [moderate-to-large effect size]), but non-
significant Dose (p = .89) and Time X Dose interaction effects (p = .56; Figure 4.30). 
The significant Time effect indicated response latency generally decreased across task 
blocks during both experimental sessions (Placebo: Block 1 = 739.2 ± 219.8ms, Block 5 
= 655.7 ± 243.1ms; Stress: Block 1 = 788.8 ± 271.4ms, Block 5 = 672.8 ± 150.0ms). 
Table 4.4:  LCModel Fit Characteristics (32s). Mean (± 1 SD) LCModel fit 
characteristics (32s; 8 avgs) are presented by task phase. GLU = glutamate; GLN 
= glutamine; FWHM = full-width half-maximum; SNR = signal-to-noise; CRLB = 
Cramer Rao Lower Bound. 
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FTND was not significantly related to task accuracy or response latency (ps > .10).  
4.2.8 LCModel Fit Characteristics (32s Resolution) 
LCModel fit reliability was evaluated for 2-back A, 2-back B, and interleaved 
fixation-cross rests for both experimental sessions. Four subjects were excluded from 
outcome analyses due to 
relatively poor LCModel fit 
quality (greater than two SDs 
worse SNR and GLU 
CRLB% relative to the group 
mean). Importantly, LCModel 
fit characteristics did not 
differ as a function of 
experimental task (Task and 
Task X Time interaction 
effects examined) during the 
placebo session (Table 4.4; 
upper panel). However, 
during the stress session, 
SNR and FWHM did differ as 
a function of experimental 
task (Table 4.4; lower panel).  
FWHM was lower during 2-
back A relative to interleaved 
Figure 4.31 & 4.32:  Overall GLU Levels. Mean (± 1 SEM) 
GLU levels during the placebo (upper panel) and stress 
(lower panel) session are depicted. 
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rest (Task effect; p < .05). SNR was higher during task (2-back A and B) relative to 
interleaved rest (Task effects; ps ≤ .05).  
4.2.9 Placebo GLU Modulation (32s Resolution) 
The flashing checkerboard 
minimized GLU fluctuation (mean 
coefficient of variation percentage 
= 6.1%) prior to 2-back (vs. rest) 
modulation.  
Placebo 2-back A vs. rest.  
Overall GLU levels during 2-back 
A were significantly higher (2.7%; 
Figure 4.31) than interleaved 
fixation-cross rest (F(1,83) = 8.12, 
p < .01, partial η
2 
= 0.09 
[moderate effect size]; 11.59 ± 
1.05 vs. 11.29 ± 0.93, 
respectively; Figure 4.31). Across 
task blocks, rmANOVA indicated 
a marginal Task effect (F(1,16) = 
4.01, p = .06, partial η
2 
= 0.20 
[moderate-to-large effect size]; 
Figure 4.33), and non-significant 
Time (p = .41) and Time X Task 
Figure 4.33 & 4.34: Placebo 2-back A & B GLU 
Levels (32s). Mean (± 1 SEM) 2-back A (upper 
panel) and B (lower panel) GLU levels (32s; % 
relative to interleaved fixation cross) during the 
placebo session are depicted across task blocks. 
 
** 
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interaction effects (p = .19). 2-back A GLU levels were higher than interleaved fixation-
cross levels (especially in later task blocks).  
Placebo 2-back B vs. rest.  Overall GLU levels during 2-back B did not differ from 
interleaved fixation-cross rest (p 
= .67; 11.25 ± 1.04 vs. 11.29 ± 
0.93, respectively; Figure 4.31). 
Across task blocks, rmANOVA 
indicated no significant effects: 
Time (p = .65), Task (p = .71), 
and Time X Task interaction (p = 
.17; Figure 4.34).  
4.2.10 Stress GLU Modulation 
(32s Resolution) 
The flashing 
checkerboard minimized GLU 
fluctuation (mean coefficient of 
variation percentage = 5.7%) 
prior to 2-back (vs. rest) 
modulation.  
Stress 2-back A vs. rest.  
Overall GLU levels during 2-back 
A were not significantly different 
from interleaved fixation-cross 
Figure 4.35 & 4.36: Stress 2-back A & B GLU 
Levels (32s). Mean (± 1 SEM) 2-back A (upper 
panel) and B (lower panel) GLU levels (32s; % 
relative to interleaved fixation cross) during the 
stress session are depicted across task blocks. 
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rest (p = .58; 11.35 ± 1.03 vs. 11.42 ± 0.98, respectively; Figure 4.32). Across task 
blocks, rmANOVA indicated no significant effects: Time (p = .45), Task (p = .59), and 
Time X Task interaction (p = .18; Figure 4.35).  
Stress 2-back B vs. rest.   Overall GLU levels during 2-back B did not differ from 
interleaved fixation-cross rest (p = .22; 11.27 ± 0.90 vs. 11.42 ± 0.98, respectively; 
Figure 4.32). Across task blocks, rmANOVA indicated no significant effects: Time (p = 
.44), Task (p = .26), and Time X Task interaction (p = .14; Figure 4.36).   
4.2.11 BOLD Effect (32s Resolution) 
Relative to interleaved fixation-cross rest, rmANOVA indicated spectral linewidth 
(FWHM) was significantly more narrow for 2-back A during the active stress (Task 
effect: F(1,16) = 5.30, p < .05; Time X Task interaction effect: p = .99), but not the 
placebo session (ps > .05). rmANOVA indicated no effect for task on FWHM for 2-back 
B for either session (ps > .06).  
4.2.12 Neurochemical Specificity (32s Resolution) 
 During the placebo session, metabolites (PCr+Cr, GPC+PC, Myo-Inositol, and 
NAA) did not significantly differ as a function of task (2-back A and B vs. interleaved 
fixation-cross rest; ps ≥ .09). 
 During the active stress session, Myo-Inositol exhibited significant Task and 
Time X Task interaction effects (F(1,16) = 6.18, p < .05 and F(4,64) = 2.60, p < .05, 
respectively). Interleaved fixation-cross rest Myo-Inositol levels were higher than 2-back 
A levels, but tended to converge in later task blocks. GPC+PC exhibited a significant 
Task effect (F(1,16) = 9.56, p < .01). GPC+PC levels during rest were generally higher 
than 2-back A levels across task blocks. NAA and PCr+Cr did not differ as a function of 
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task (ps > .10). LCModel quantification of NAA levels was not biased by the significant 
BOLD effect (i.e. narrow spectral linewidth did not significantly alter area-under-the-
curve quantification).   
4.2.13 LCModel Fit Characteristics (64s Resolution) 
 As anticipated, 64s temporal resolution (16 avgs) was associated with more 
reliable LCModel fit, relative to 32s (8 avgs) resolution. LCModel fit characteristics 
described in Table 4.5. Importantly, LCModel fit characteristics did not significantly 
differ as a function of task for the placebo session (ps > .08). However, consistent with 
32s resolution, SNR differed as a function of task during the stress session (2-back A > 
rest; p < .01).  
4.2.14 Placebo GLU Modulation (64s Resolution) 
Placebo 2-back A vs. rest.   Across task blocks, rmANOVA indicated a significant 
Time X Task interaction (F(3,48) = 2.80, p = .05, partial η
2 
= 0.15 [moderate-to-large 
effect size]), but non-significant Time (p = .44) and Task effects (p = .59). 2-back A GLU 
Table 4.5:  LCModel Fit Characteristics (64s). Mean (± 1 SD) LCModel fit 
characteristics (64s; 16 avgs) are presented by task phase. GLU = glutamate; GLN = 
glutamine; FWHM = full-width half-maximum; SNR = signal-to-noise; CRLB = Cramer 
Rao Lower Bound. 
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levels were significantly higher than interleaved fixation-cross levels in later task blocks 
(Figure 4.37).  
Placebo 2-back B vs. rest.  Across task blocks, rmANOVA indicated no 
significant effects:  Time (p = .51), Task (p = .19), and Time X Task interaction (p = .30) 
(Figure 4.38).  
** 
Figure 4.37 & 4.38: Placebo 2-back A & B GLU 
Levels (64s). Mean (± 1 SEM) 2-back A (upper 
panel) and B (lower panel) GLU levels (64s; % 
relative to interleaved fixation cross) during the 
placebo session are depicted across task blocks. 
 
Figure 4.39 & 4.40: Stress 2-back A & B GLU 
Levels (64s). Mean (± 1 SEM) 2-back A (upper 
panel) and B (lower panel) GLU levels (64s; % 
relative to interleaved fixation cross) during the 
stress session are depicted across task blocks. 
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4.2.15 Stress GLU Modulation (64s Resolution) 
Stress 2-back A vs. rest.  Across task blocks, rmANOVA indicated no significant 
effects:  Time (p = .90), Task (p = .54), and Time X Task interaction (p = .18) (Figure 
4.39).  
Stress 2-back B vs. rest.  Across task blocks, rmANOVA indicated no significant 
effects:  Time (p = .99), Task (p = .24), and Time X Task interaction (p = .08) (Figure 
4.40).   
4.2.16 BOLD Effect (64s Resolution) 
rmANOVA indicated spectral linewidth (FWHM) did not significantly differ as a 
function of task (2-back vs. rest) for the placebo or stress sessions (ps > .20).  
4.2.17 Neurochemical Specificity (64s Resolution) 
 During the placebo session, NAA exhibited a significant Time X Task interaction 
effect (F(3,48) = 3.24, p < .05), but not a Task effect. NAA levels during interleaved 
fixation-cross rest were higher than 2-back B, but only in later task blocks. No 
significant effect for NAA during 2-back A. Consistent with the 32s temporal resolution 
findings, other metabolites (PCr+Cr, GPC+PC, and Myo-Inositol) did not significantly 
differ as a function of task (2-back A and B vs. interleaved fixation-cross rest; ps ≥ .10).  
 Consistent with findings at 32s temporal resolution, Myo-Inositol and GPC+PC 
differed as a function of task during the active stress session. Myo-Inositol exhibited 
significant Task and Time X Task interaction effects (F(1,17) = 15.92, p < .001 and 
F(3,51) = 2.79, p = .05, respectively). Interleaved fixation-cross rest Myo-Inositol levels 
were higher than 2-back A levels, especially in later task blocks. GPC+PC exhibited 
significant Task effects for 2-back A and B (F(1,17) = 13.02, p < .01; F(1,17) = 4.57, p < 
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.05; respectively). GPC+PC levels during rest were higher than 2-back A and B levels 
across task blocks. NAA and PCr+Cr did not differ as a function of task (ps > .10).  
4.2.18 Cerebrovascular Reactivity   
Second-level contrasts (breath hold > paced breathing) revealed significant 
clusters (voxel-level; p < .05) during both the placebo and active stress sessions (Figure 
4.41). Significant clusters were found throughout the cortex (primarily in gray matter) 
during both sessions. Experimental sessions were contrasted (placebo > stress and 
stress > placebo) to produce CVR difference maps (Figure 4.42). CVR difference maps 
identified clusters that significantly differed (voxel-level; p < .05) as a function of 
vascular reactivity between sessions, and thus, may confound between-session 
contrasts of interest. Therefore, CVR difference maps were subtracted from between-
session contrasts of interest to reduce the likelihood of false positives.  
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Figure 4.41: Cerebrovascular Reactivity Maps. Cerebrovascular reactivity maps 
(voxel-wise p < .05; breath hold > paced breathing) are depicted on contiguous axial 
slices for placebo (upper panel) and active stress (lower panel). Lighter color reflects 
greater cerebrovascular reactivity.  
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Figure 4.42: Cerebrovascular Reactivity Difference Maps. Cerebrovascular reactivity 
difference maps (voxel-wise p < .05) are depicted on contiguous axial slices 
contrasting sessions: placebo > stress (upper panel) and stress > placebo (lower 
panel). Lighter color reflects greater cerebrovascular reactivity.  
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4.2.19 Letter 2-back fMRI Data 
Letter 2-back behavioral data.  Behavioral data demonstrated task compliance 
during the letter 2-back fMRI task. Response accuracy was non-significantly higher 
during placebo, relative to active stress (p = .11; 89.9 ± 13.9% vs. 84.7 ± 14.9%, 
respectively).  
Letter 2-back > fixation-cross rest.  As hypothesized, cluster-level corrected 
images (p < .05) revealed significant bilateral activation in the dlPFC during 2-back task 
performance (> fixation-cross rest) during both experimental sessions (Figure 4.43).  
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 Stress > placebo: letter 2-back > rest.  Contrary to hypotheses, bilateral dlPFC 
clusters survived cluster-level and CVR difference map correction for stress > placebo 
(Figure 4.44). These clusters demonstrated that letter 2-back task performance elicited 
Figure 4.43: Letter 2-back Activation Maps. Cluster-level corrected (p < .05) letter 2-
back (> fixation cross rest) activation maps are depicted on contiguous axial slices 
for the placebo (upper panel) and stress session (lower panel). Lighter color reflects 
more BOLD activation.  
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greater BOLD activation during active stress, relative to placebo. Significant clusters in 
the insula suggest participants processed peripheral signals that may be attributed to 
physiological effects of the stress manipulation (elevated BP, etc.).   
Placebo > stress: letter 2-back > rest.  The converse comparison revealed one 
significant cluster (mPFC; Figure 4.44). These results demonstrated that 2-back 
performance elicited a relatively smaller BOLD response during placebo relative to 
active stress. Participants exhibited non-significantly higher response accuracy, but 
smaller dlPFC BOLD response during placebo, relative to active stress.  
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 Letter 2-back > rest: median-split by FTND.  Exploratory analyses examined the 
BOLD response during letter 2-back by splitting the sample into two groups: median-
split by FTND. These analyses paralleled the nicotine-seeking and self-administration 
Figure 4.44: Letter 2-back Difference Maps. Cluster-level corrected (p < .05) letter 
2-back (> fixation cross rest) difference maps are depicted on contiguous axial 
slices: placebo > stress (upper panel) and stress > placebo (lower panel). Lighter 
color reflects more BOLD activation.  
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data. Less dependent participants exhibited less dlPFC neural engagement (less BOLD 
activation) during 2-back performance in the stress session (relative to placebo; Figure 
4.45). Conversely, more dependent participants engaged their dlPFC more during 2-
back performance in the stress session (relative to placebo).   
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Figure 4.45: Letter 2-back Maps by Nicotine Dependence. Cluster-level corrected 
(p < .05) letter 2-back (> fixation cross rest) difference maps median split by 
FTND score are depicted on contiguous axial slices: less (upper panel) and more 
nicotine dependent (lower panel) stress > placebo. Lighter color reflects more 
BOLD activation.  
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4.2.20 Cued N-back Behavioral 
Data 
fMRI behavioral data:  
smoking vs. neutral cued.  
Accuracy and response latency 
were evaluated across N-back 
levels (0-, 1-, and 2-back) and 
by image type (smoking vs. 
neutral) for both experimental 
sessions.  
Neutral images.  
rmANOVA indicated response 
accuracy decreased as N-back 
task difficulty increased (0-back 
= 94.3 ± 10.9%; 2-back = 64.1 ± 
19.5%) for neutral images 
across experimental sessions 
(N-back effect:  F(2,26) = 31.57, 
p < .001; partial η
2 
= 0.71 [very 
large effect size]; Figure 4.46). 
There was no effect of 
experimental session on neutral 
image response accuracy Figure 4.46 & 4.47: Neutral N-back Response 
Accuracy and Response Latency. Mean (± 1 
SEM) response accuracy (% correct; upper 
panel) and response latency (ms; lower panel) 
for neutral images during the placebo (blue line) 
and active stress session (green line) are 
depicted across N-back levels.  
 
94 
 
 
 
across N-back levels (Dose effect:  
p = .14; N-back X Dose interaction:  
p = .82).  
For neutral images, 
response latency decreased as N-
back difficulty increased (N-back 
effect:  F(2,26) = 13.40, p < .001; 
partial η
2 
= 0.51 [very large effect 
size]; 0-back = 649.3 ± 231.7ms; 2-
back = 449.8 ± 193.8ms; Figure 
4.47). Response latency was not 
differentially affected by 
experimental session across N-
back levels (Dose effect:  p = .73; 
N-back X Dose interaction:  p = 
.69).   
Smoking images.  rmANOVA 
indicated response accuracy non-
significantly decreased as N-back 
difficulty increased (0-back = 95.8 ± 
10.4%; 2-back = 91.1 ± 13.4%) for 
smoking images across both 
experimental sessions (N-back 
Figure 4.48 & 4.49: Smoking N-back Response 
Accuracy and Response Latency. Mean (± 1 
SEM) response accuracy (% correct; upper 
panel) and response latency (ms; lower panel) 
for smoking images during the placebo (blue 
line) and stress session (green line) are 
depicted across N-back levels. Paired t-test: *p 
< .05 
 
* 
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effect:  F(2,26) = 3.08, p = .06; 
partial η
2 
= 0.19 [moderate-to-
large effect size]; Figure 4.48). 
There was no effect of 
experimental session on 
smoking image response 
accuracy across N-back levels 
(Dose effect:  p = .47). However, 
a significant N-back X Dose 
interaction (F(2,26) = 8.24, p < 
.01; partial η
2 
= 0.39 [very large 
effect size]) indicated response 
accuracy decreased more as N-
back difficulty increased during 
the placebo session (relative to 
the stress session).  
For smoking images, 
response latency increased as 
N-back difficulty increased (N-
back effect:  F(2,26) = 3.69, p < 
.05; partial η
2 
= 0.22 [moderate-
to-large effect size]; 0-back = 
556.4 ± 191.4ms; 2-back = 
Figure 4.50 & 4.51: Placebo N-back Response 
Accuracy and Response Latency. Mean (± 1 
SEM) response accuracy (% correct; upper 
panel) and response latency (ms; lower panel) 
during the placebo session are depicted by 
image type (neutral: blue line vs. smoking: green 
line) across N-back levels. Paired t-test: *p < .05 
 
* 
* 
* 
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602.3 ± 231.7ms; Figure 4.49). Response latency was not differentially affected by 
experimental session across N-back levels (Dose effect:  p = .33; N-back X Dose 
interaction:  p = .46).  
Neutral vs. smoking images:  placebo session.  rmANOVA indicated response 
accuracy significantly decreased as N-back difficulty increased (0-back = 99.4 ± 3.2%; 
2-back = 76.8 ± 20.0%) for both image types (N-back effect:  F(2,26) = 22.05, p < .001; 
partial η
2 
= 0.63 [very large effect size]; Figure 4.50). There was no effect of image type 
on response accuracy across N-back levels (Image effect:  p = .38). However, a 
significant N-back X Image interaction (F(2,26) = 10.98, p < .001; partial η
2 
= 0.46 [very 
large effect size]) indicated response accuracy decreased less for smoking images as 
N-back difficulty increased, relative to neutral images.  
rmANOVA indicated response latency non-significantly decreased as N-back 
difficulty increased (N-back effect:  F(2,26) = 2.91, p = .07; partial η
2 
= 0.18 [moderate-
to-large effect size]; 0-back = 580.6 ± 178.8ms; 2-back = 489.9 ± 220.1ms; Figure 
4.51). Response latency did not differ across N-back levels as a function of image type 
(Image effect:  p = .43). However, a significant N-back X Image interaction (F(2,26) = 
6.43, p < .01; partial η
2 
= 0.33 [very large effect size]) indicated response latency 
decreased more for neutral images as N-back difficulty increased, relative to smoking 
images.  
Neutral vs. smoking images:  stress session.  rmANOVA indicated response 
accuracy significantly decreased as N-back difficulty increased (0-back = 91.7 ± 12.9%; 
2-back = 78.2 ± 22.8%) for both image types (N-back effect:  F(2,34) = 16.23, p < .001; 
partial η
2 
= 0.49 [very large effect size]; Figure 4.52). A main effect of image type across 
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N-back levels (F(1,17) = 20.12, p < 
.001; partial η
2 
= 0.54 [very large 
effect size]) indicated that 
participants responded more 
accurately for smoking vs. neutral 
images. In addition, a significant N-
back X Image interaction (F(2,34) = 
17.18, p < .001; partial η
2 
= 0.50 
[very large effect size]) indicated 
that accuracy decreased less for 
smoking images (relative to neutral 
images) as N-back difficulty 
increased.  
rmANOVA indicated 
response latency significantly 
decreased as N-back difficulty 
increased (N-back effect:  F(2,34) 
= 4.39, p < .05; partial η
2 
= 0.21 
[moderate-to-large effect size]; 0-
back = 603.4 ± 202.9ms; 2-back = 
528.0 ± 173.0ms; Figure 4.53). 
Response latency did not differ 
across N-back levels as a function 
Figure 4.52 & 4.53: Stress N-back Response 
Accuracy and Response Latency. Mean (± 1 
SEM) response accuracy (% correct; upper 
panel) and response latency (ms; lower panel) 
during the stress session are depicted by image 
type (neutral: blue line vs. smoking: green line) 
across N-back levels. Paired t-test: *p < .05 
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of image type (Image effect:  p = .94). However, a significant N-back X Image 
interaction (F(2,34) = 11.65, p < .001; partial η
2 
= 0.41 [very large effect size]) indicated 
that response latency decreased more for neutral images as N-back difficulty 
increased, relative to smoking images. 
4.2.21 Cued N-back fMRI Data 
 0-back fMRI activation.  One subject was excluded from all fMRI BOLD activation 
analyses that contrasted image type (smoking vs. neutral) because he switched to e-
cigarettes and reported paper cigarettes were aversive. BOLD activation analyses 
focused on the effect of image type (smoking > neutral and neutral > smoking) across 
N-back levels (0-, 1-, and 2-back; Figure 4.54). During the placebo session, 0-back 
BOLD response was contrasted by image type. Smoking images elicited greater BOLD 
response in the amygdala, mPFC, mOFC, and ventral striatum, relative to neutral 
images. Activation in these regions is often attributed to drug cue salience and/or 
appetitive motivation. Interestingly, a few clusters in the dlPFC were activated during 
smoking > neutral cues. The 0-back is an attentional control task and does not 
substantially engage working memory processes (i.e. dlPFC). Thus, it was plausible 
that dlPFC activation was associated with network interactions with the mOFC and/or 
mPFC.  
 Notably, during the stress session, smoking cues did not elicit the same degree 
of BOLD response in the mPFC, mOFC, and ventral striatum. A few small clusters in 
the striatum and one in mOFC/mPFC survived cluster-level correction. These findings 
were contrary to a priori hypotheses. 
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Figure 4.54: Cued 0-back fMRI Activation Maps. Cluster-level corrected (p < .05) 
activation maps during 0-back (smoking > neutral images) are depicted on 
contiguous axial slices for the placebo (upper panel) and stress session (lower 
panel). Lighter color reflects more BOLD activation.  
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1-back fMRI activation.  During both experimental sessions, smoking > neutral 
images elicited robust activation across the network of interest at the 1-back level 
(Figure 4.55). During placebo, widespread BOLD activation was elicited in the 
amygdala, mOFC, mPFC, ventral and dorsal striatum, dPFC, dlPFC, dACC, and 
superior parietal lobule. During the stress session, clusters were found throughout the 
striatum and PFC, but not in the mOFC or superior parietal lobule. Similar to the 0-back 
findings, smoking images elicited greater BOLD activation in reward network regions 
during placebo, relative to the active stress.  
2-back fMRI activation.  During placebo, subtle BOLD effects were observed in 
the mOFC, mPFC, and striatum for smoking > neutral images (Figure 4.56). During 
stress, BOLD activation was limited to three clusters:  mOFC, dorsal striatum, and 
dorsal PFC. Task difficulty (2-back) may have diminished the salience of the smoking 
images (relative to neutral images). Individuals may have been preoccupied with task 
performance at the expense of image salience. Notably, smoking images were 
associated with higher response accuracy (> neutral images) across experimental 
sessions.  
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Figure 4.55: Cued 1-back fMRI Activation Maps. Cluster-level corrected (p < .05) 
activation maps during 1-back (smoking > neutral images) are depicted on 
contiguous axial slices for the placebo (upper panel) and stress session (lower 
panel). Lighter color reflects more BOLD activation.  
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Overall fMRI activation.  BOLD activation associated with smoking cues (smoking > 
neutral images) across all N-back levels were contrasted by experimental session 
(Figure 4.57). For placebo > stress, robust BOLD activation was observed in the ventral 
Figure 4.56: Cued 2-back fMRI Activation Maps. Cluster-level corrected (p < .05) 
activation maps during 2-back (smoking > neutral images) are depicted on 
contiguous axial slices for the placebo (upper panel) and stress session (lower 
panel). Lighter color reflects more BOLD activation.  
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and dorsal striatum, mPFC, mOFC, dlPFC, dPFC, dACC, and superior parietal lobule. 
Notably, large clusters in the mOFC and mPFC were identified and may be attributed to 
salience of smoking (> neutral) images, independent of task difficulty. For stress > 
placebo, one small cluster was observed (mPFC/dACC). Smoking images elicited a 
more robust BOLD response in the placebo, relative to the stress, session, contrary to a 
priori hypotheses.  
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4.2.22 fMRI vs. 
1
H fMRS 
 Exploratory analyses investigated statistical relationships between 
1
H fMRS GLU 
levels and BOLD fMRI response during the letter 2-back task. Using each subject’s 
1
H 
Figure 4.57: Image Effect Difference Maps. Cluster-level corrected (p < .05) 
difference activation maps across N-back levels (smoking > neutral images) are 
depicted on contiguous axial slices: placebo > stress (upper panel) and stress > 
placebo (lower panel). Lighter color reflects more BOLD activation.  
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fMRS voxel as a mask, Z scores (peak activation) and peak cluster extents were 
extracted from BOLD contrasts (letter 2-back > fixation-cross) at the same temporal 
resolution (32s; 2-back A and B) as 
1
H fMRS analyses. This strategy resulted in two 
correlation matrices: Z scores and cluster extents. Each matrix contained four rows of 
fMRI metrics (2-back A and B X 2 task repetitions) by eight columns of 
1
H fMRS GLU 
levels (first 
1
H fMRS task block was excluded [practice effect]; 2-back A and B X 4 task 
repetitions) for a total of 32 matrix cells. Bivariate Pearson correlations were used to 
examine statistical relationships with a liberal threshold (p ≤ .10). During the placebo 
session, 7 of 32 cells (21.9%) were positively correlated for fMRI Z scores and 5 of 32 
cells (15.6%) were positively correlated for fMRI cluster extents. During the stress 
session, 1 cell (3.1%) was negatively correlated for fMRI Z scores and none were 
correlated for fMRI cluster extents. 
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CHAPTER 5 DISCUSSION 
5.1 
1
H fMRS Pilot Study Discussion 
5.1.1 
1
H fMRS Pilot Study Results Overview 
The goals for the pilot study were three-fold:  1) develop and evaluate an 
automated method for accurate and reliable single voxel placement, 2) develop a 
working memory 
1
H fMRS paradigm, and 3) quantify GLU levels during working memory 
task performance. Our results demonstrated that:  automated voxel placement (AVP) 
method was highly accurate and reliable; the working memory paradigm was feasible; 
LCModel quantification of metabolite levels at 32s temporal resolution (8 avgs) was 
reliable; and left dlPFC GLU levels were modulated during working memory task 
performance. To the best of our knowledge, this was the first study in human subjects 
that demonstrated dlPFC GLU levels were significantly modulated during working 
memory task performance. This study validated a novel biomarker of dlPFC cognitive 
task engagement that is not confounded by vasoactive medications or subject-level 
differences in cardiovascular health (e.g. aging or chronic substance abuse [cigarette 
smoking]). 
Healthy, medication-free, and well-educated right-hand-dominant college 
students (N = 16) narrowly selected for age were recruited to participate in a brief pilot 
study. Participants were instructed to perform two behavioral tasks during continuous in 
vivo single voxel 
1
H MRS spectra acquisition (Figure 3.1). During the first task 
(continuous fixation-cross), participants were instructed to focus their visual gaze on a 
static fixation-cross, relax, and let their thoughts drift. The second task (letter 2-back) 
included two phases. During phase one, participants were instructed to focus their 
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visual gaze on a flashing checkerboard (3Hz), relax, and let their thoughts drift. Pilot 
research in our laboratory demonstrated that flashing checkerboard stabilized GLU 
levels (minimized variance) more effectively than other stabilization paradigms 
(unpublished data). During phase two, participants were instructed to complete a letter 
2-back task with interleaved blocks of fixation-cross rest. The letter 2-back task is a 
well-established working memory paradigm. A meta-analysis of letter 2-back fMRI 
studies demonstrated that task performance was consistently associated with bilateral 
dlPFC BOLD activation (Owen et al., 2005). 
Behavioral data demonstrated that participants were task compliant. Mean letter 
2-back response accuracy was high across task blocks (mean accuracy: 94.8% ± 
10.7%; mean response latency: 644 ± 171ms). Response accuracy significantly 
increased across task blocks (from 88.5% in block 1 to 96.9% in block 7; Figure 4.2).   
5.1.2 Automated Voxel Placement (AVP) 
As part of my graduate training, we developed and evaluated an automated 
voxel placement (AVP) method to address a frequently over-looked source of error 
variance in single-voxel magnetic resonance spectroscopy research studies:  
inconsistent voxel placement. It is well-established that neurochemistry varies by 
anatomical region and voxel tissue composition (gray vs. white matter) (Erecińska & 
Silver, 1990; Pouwels & Frahm, 1998). Therefore, inconsistent voxel placement across 
research subjects (or longitudinally within subjects) increases likelihood of Type I and II 
error. Three Linux- and Matlab-based scripts were developed:  avp_create, 
avp_coregister, and avp_overlap. Avp_create facilitated creation of a library of voxel 
locations in template space prior to subject scanning. At the scanner, avp_coregister 
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automatically coregistered the template voxel to the current research subject based on 
his/her head position in the scanner (T1-weighted image; Figure 3.3). At the end of a 
research study, avp_overlap will extract voxel location information from each subject’s 
.rda file (ASCII file created during MRS spectra acquisition), re-create the voxel in 
subject space, coregister the voxel to template space, and calculate voxel tissue 
composition, geometric voxel overlap with the template voxel (i.e. voxel placement 
accuracy) and geometric voxel overlap across research subjects (i.e. voxel placement 
reliability). AVP was developed and tested for human brain imaging research on a 3T 
Siemens Verio system. However, AVP was programmed to be scanner system-, field 
strength-, anatomy- and subject population-independent.  
AVP was used to prescribe voxels for 15 of the 16 
1
H fMRS pilot study 
participants (AVP not used for one subject; experimenter error). Voxel placement 
accuracy (mean geometric voxel overlap with the template location = 93.2%) and 
reliability (mean geometric voxel overlap across all participants = 89.9%; Figure 4.1) 
were excellent. Mean voxel tissue composition was 36.8 ± 3.8% gray and 60.8 ± 4.5% 
white matter.  
5.1.3 GLU Modulation 
LCModel fit and metabolite quantification was 100% automated. LCModel fit and 
GLU quantification at 32s resolution (8 avgs) was reliable (Table 4.1). Importantly, 
LCModel fit quality did not differ as a function of experimental task. Results from this 
pilot study demonstrated that GLU levels were modulated during working memory task 
performance. Relative to continuous fixation-cross rest, left dlPFC GLU levels were 
significantly higher (3.4%) during the first 32s of letter 2-back task performance (2-back 
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A) across seven task blocks (Figure 4.5). Similarly, the final 32s of letter 2-back task 
performance (2-back B) were elevated (2.9%), but non-significantly higher (p = .07) 
than continuous fixation-cross rest (Figure 4.5). These findings demonstrated, for the 
first time in human subjects, that working memory task performance increased in vivo 
dlPFC GLU levels.  
Relative to interleaved fixation-cross rest, results were more complicated.  2-
back A and B exhibited significant Time X Task interactions relative to interleaved 
fixation-cross rest (Figures 4.7, 4.10, and 4.11). GLU levels were higher during initial 
task blocks, but lower during middle task blocks. These findings indicate that working 
memory task performance was associated with elevated GLU levels, but the effect was 
time-limited. Significant Time effects indicated that GLU levels generally increased 
across task blocks. We speculated that 2-back task performance became routine and 
unchallenging for this well-educated sample. Evidence to support this assertion was 
twofold:  1) response accuracy significantly increased across task blocks (nearly perfect 
response accuracy after the initial task block), and 2) GLU levels significantly increased 
across task blocks. A significant increase in GLU levels across task blocks suggested 
participants engaged their dlPFC during 2-back and during interleaved fixation-cross 
rest – thus, participants were not truly ‘resting.’ As participants demonstrated task 
mastery, their attention may have drifted during the interleaved rest blocks, instead of 
‘resting.’ The dlPFC is involved in numerous cognitive processes – directed attention, 
rumination, and executive control of lower structures – any of which could have 
modulated GLU levels. Future studies will investigate an interleaved 0-back attention 
control task, instead of the interleaved fixation-cross used herein.  
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The 
1
H fMRS signal is a direct measurement of in vivo GLU molecules from all 
sources within the voxel. The 
1
H fMRS signal does not differentiate cell types (pre- vs. 
post-synaptic neurons or glia) or compartments (intracellular vs. extracellular). Results 
presented herein demonstrated that GLU concentration (i.e. total number of GLU 
molecules within the voxel location) was higher during letter 2-back, relative to fixation-
cross rest. We interpret these findings as follows:  task-related cognitive demand (i.e. 
increased neural activity) resulted in increased metabolic activity in the dlPFC, which 
was measured herein as elevated GLU levels. The literature and limitations of the 
approach provided context for interpretation of these data.  
A series of well-controlled studies spanning decades at Yale University 
demonstrated that neuronal spiking frequency increased in the dlPFC during a spatial 
working memory task in non-human primates (Goldman-Rakic, 1995). Using the same 
experimental approach, Arnsten and colleagues demonstrated that spatial working 
memory was associated with persistent excitatory microcircuits (“delay” cells; primarily 
mediated via GLU molecules binding NMDA NR2B receptor subunits) in layer III of the 
cortex (Wang et al., 2013). These microcircuits are thought to maintain memory traces 
during the delay period (time period between the presentation of stimulus and the target 
[i.e. blank screen]) such that the primate can respond accurately (Wang et al., 2013). 
These studies demonstrated that working memory task performance was associated 
with persistent neural activity, mediated via glutamatergic synapses, in the dlPFC. 
However, it is unlikely the signal measured in the present study reflected GLU 
molecules involved in excitatory neurotransmission. Evidence to support this assertion 
was two-fold:  1) low extracellular GLU concentration and 2) synaptic GLU time scale. 
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Intracellular GLU concentration is approximately 10 mM (Erecińska & Silver, 1990), 
whereas extracellular and cerebrospinal GLU concentrations are 0.5-1.0 μM and 1-10 
μM, respectively (Schousboe, Bak, Sickmann, Sonnewald, & Waagepetersen, 2007). 
Thus, the overwhelming majority of the 
1
H fMRS GLU signal was intracellular (~10
3
 
higher concentration than extracellular). Thus, even a 50% increase in synaptic GLU 
concentration would only increase total 
1
H fMRS-measured GLU by ~0.0014%. In 
addition, extracellular GLU molecules are present in the synapse for < 5ms before 
binding transporters, ion-channels, or G-protein coupled receptors. If the first RF pulse 
(in the PRESS sequence) excited a GLU molecule traversing the synapse, it is likely the 
magnetization would be negated when that GLU molecule bound a receptor or 
transporter before digitization of the signal (TE = 23ms). Therefore, although GLU is the 
primary excitatory neurotransmitter and previous work found that working memory is 
mediated via cortical glutamatergic microcircuits in the dlPFC, it is unlikely the signal 
measured herein reflects GLU molecules involved in neurotransmission. Rather, the 
overwhelming majority of signal measured in this study was associated with GLU 
molecules found in pre-synaptic vesicles, circulating as neurochemical intermediates for 
other neurotransmitters (GABA and glutamine), or as an anaplerotic substrate of the 
TCA cycle. Fortunately, interpretation of the present data is informed by prior research, 
which demonstrated GLU concentration scaled with neural activity: increased neural 
activity was associated with increased GLU levels (Mangia et al., 2006; Schaller et al., 
2013; Schaller et al., 2014). Elevated neuronal activity is coupled with elevated glucose 
extraction and metabolism that should result in elevated GLU levels from all sources 
measured via 
1
H fMRS. Extensive 
13
C MRS research demonstrated GLU-glutamine 
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neurotransmission cycling rate was tightly coupled with oxidative metabolism in awake 
and anesthetized rodents (Douglas L Rothman, De Feyter, Graaf, Mason, & Behar, 
2011; D. L. Rothman, De Feyter, Maciejewski, & Behar, 2012). A nearly 1:1 relationship 
indicated that for every molecule of GLU released into the synapse and recycled to the 
presynaptic neuron as glutamine, approximately one molecule of glucose was 
metabolized in the TCA cycle (Douglas L Rothman et al., 2011). In other words, 
elevated spiking activity and excitatory neurotransmission corresponded with elevated 
metabolic activity to support cellular energy demands (e.g. restoration of ion 
concentration gradients and metabolic intermediates). Thus, the GLU signal measured 
in this study likely reflected GLU molecules involved in metabolic events associated with 
excitatory neurotransmission driven by working memory task performance. Our findings 
were consistent with previous 
1
H fMRS studies that demonstrated elevated GLU levels 
(~2-4%) during neural activity (Mangia et al., 2006; Schaller et al., 2013; Schaller et al., 
2014) and a meta-analysis of fMRI studies that found neural activity in the dlPFC was 
consistently elevated during 2-back task performance (Owen et al., 2005).  
5.1.4 Limitations and Alternative Explanations 
This pilot study had a number of important limitations. First, as is the case with 
all single voxel MRS studies, this study was susceptible to partial volume effects. Three 
factors minimized the influence of partial volume effects on these findings. Voxel 
placement reliability was excellent (mean geometric voxel overlap across subjects = 
89.9%) which minimized partial volume effects. Moreover, tissue voxel composition 
variability was low across subjects (gray and white matter coefficient of variation 
percentage was 10.3% and 7.4%, respectively) and included in the calculation of GLU 
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concentration. Finally, outcome analyses were limited to within-subject comparisons 
(i.e. GLU levels contrasted by experimental task). Therefore, it was unlikely partial 
volume effects influenced study findings. Second, we were unable to reliably quantify 
other relevant neurotransmitters (e.g. GABA and glutamine) due to SNR limitations in 
the present study. Future studies could use higher field strengths, lower temporal 
resolution (e.g. more averaging), or other sequences (e.g. MEGA-PRESS) to 
investigate task-related modulation of GABA and glutamine levels.  
There were several alternative explanations for task-related modulation of GLU 
levels in the dlPFC. First, as reported in other 
1
H fMRS studies, there was possibility of 
a BOLD effect (Mangia et al., 2006; Schaller et al., 2013; Schaller et al., 2014). 
Increased neural activity will increase concentration of oxygenated blood (oversupply of 
oxygenated hemoglobin relative to oxygen extraction; BOLD effect) which can influence 
T2* and spectral linewidth. A BOLD effect would result in narrow metabolite peaks 
(FWHM). Inconsistent with prior studies, we found no evidence of a significant BOLD 
effect on FWHM (Task and Time X Task interaction ps > .10). Moreover, LCModel 
should be robust to the influence of spectral linewidth on metabolite level quantification. 
Indeed, during 2-back A, no metabolites differed as a function of experimental task 
other than GLU. Second, GLU’s transverse relaxation (T2*) could have changed as a 
result of task performance. The equation  describes the relationship 
between the initial signal (S0), the measured signal (S), echo time (TE), and transverse 
magnetization (T2). To explain the observed effects (task-related GLU levels increased 
2.9-3.4% relative to continuous fixation-cross rest), transverse relaxation (T2*) would 
need to increase > 30% (GLU T2 = ~200ms at 3T in the dlPFC (Choi et al., 2006)). Prior 
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studies indicated T2* changes alone are unlikely to explain the observed data (Ogawa 
et al., 1992). Third, Type I error is possible. However, evidence against this explanation 
was three-fold: 1) results reported herein were consistent with fMRI, fMRS, and 
electrophysiology literature; 2) the experimental design was carefully selected to 
mitigate Type I error (e.g. use of a stabilization task [flashing checkerboard], two rest 
comparison conditions, cognitively-healthy and unmedicated sample, high task 
compliance, and reliable voxel placement), and 3) moderate effect size (i.e. study was 
not ‘over-powered’). Fourth, LCModel fit quality could have been biased and ‘over-fit’ 
GLU levels during 2-back task performance, relative to rest. This was also unlikely. 
Individual raw spectra were phase- and shift-corrected prior to averaging and LCModel 
fit (using a 100% automated procedure). Moreover, LCModel fit characteristics (FWHM, 
SNR, GLU CRLB% and GLN CRLB%) did not differ as a function of experimental task 
(Table 4.1). Finally, LCModel fit of GLU was reliable (GLU CRLB ~7 ± 1%) across task 
and rest conditions. 
5.1.5 
1
H fMRS Pilot Study Results Summary 
In summary, this pilot study demonstrated that AVP was an accurate and reliable 
method of automated voxel placement, LCModel reliably fit 
1
H fMRS spectra and 
quantified GLU levels at a cognitive task-relevant time scale (32s; 8 avgs), and letter 2-
back task performance modulated GLU levels in the left dlPFC, relative to fixation-cross 
rest. These data validated an in vivo biomarker of cognitive task-related neural 
engagement. To our knowledge, this was the first demonstration of working memory 
task-related modulation of GLU levels in humans. However, to date, similar studies 
using 
1
H fMRS found cognitive task- or sensory stimulation-related GLU modulation in a 
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variety of brain regions, including: dlPFC, hippocampus, occipital lobe, and motor 
cortex. The value of this novel biomarker is twofold:  1) neurochemical specificity and 2) 
neurovascular coupling independence. 
1
H fMRS is a direct in vivo measure of GLU (and 
other metabolites). Neurochemical specificity of this approach provides insight not 
possible using other neuroimaging approaches (e.g. fMRI). While not feasible in the 
present study, future studies at higher field strength could leverage this approach to 
examine task-related modulation of glutamine. It is estimated that ~80% of glutamine 
molecules are directly involved in the GLU-glutamine cycle (i.e. excitatory 
neurotransmission) (Gruetter, Seaquist, & Ugurbil, 2001; Lebon et al., 2002; Mason, 
Petersen, De Graaf, Shulman, & Rothman, 2007; D. L. Rothman et al., 2012; Sibson et 
al., 1997). Second, interpretation of the BOLD fMRI signal (most widely used in vivo 
neuroimaging approach) is complicated by neurovascular coupling. For many research 
questions, neurovascular coupling is not an insurmountable obstacle. However, 
interpretation of BOLD signal from research studies that include older populations, 
compare younger and older subjects, include subjects with cardiovascular confounds 
(e.g. heart disease or chronic substance use), or use vasoactive pharmacological 
challenges (e.g. this dissertation study) can be challenging. 
1
H fMRS is not confounded 
by neurovascular coupling, and thus, presents an alternative approach to BOLD fMRI 
for questions of task-related changes in brain function.  
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5.2 Dissertation Results Discussion 
5.2.1 Dissertation Results Overview 
 The overarching goals for this dissertation project were two-fold:  1) investigate 
the effects of pharmacological stress manipulation on nicotine-seeking and self-
administration, and 2) investigate a plausible neurobiological mechanism by which 
acute stress may potentiate nicotine-seeking and self-administration. Results 
demonstrated that the complex experimental design (within-subject, placebo-controlled, 
double-blind, randomized cross-over design with multi-modal neuroimaging and 
nicotine self-administration outcome variables) was feasible. Oral pretreatment with 
pharmacological agents (YOH 54mg + HYD 10mg) significantly increased biomarkers 
(BP, heart rate, saliva cortisol, and saliva α-amylase) of a physiological stress 
response, relative to placebo (YOH 0mg + HYD 0mg). Experimental stress significantly 
increased nicotine-seeking and self-administration (relative to placebo) among non-
treatment-seeking cigarette smokers (controlling for nicotine dependence level [FTND]). 
Multi-modal neuroimaging demonstrated that acute stress impaired dlPFC function and 
task-related engagement – a plausible neurobiological mechanism of stress-potentiated 
nicotine self-administration. In the remainder of this dissertation, results will be 
interpreted, limitations and alternative explanations discussed, and treatment 
implications described. 
5.2.2 Stress and Relapse 
 As described in the Sections 2.2 and 2.3, ample evidence links experimental 
stress and substance use relapse (or models of relapse). Preclinical studies reliably 
demonstrated that pharmacological agents (e.g. YOH) reinstated drug self-
administration behavior (model of relapse) across drugs of abuse (Ahmed & Koob, 
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1997; Buczek et al., 1999; de Jong et al., 2009; Deroche et al., 1997; Erb et al., 2000; 
Erb et al., 1996; Gass & Olive, 2007; Graf et al., 2013; Mantsch & Katz, 2007; Mantsch 
et al., 2014; Mantsch et al., 2010; Shepard et al., 2004). Clinical treatment studies 
indicated that self-reported stress was among the widely cited precipitants to substance 
use relapse (M. al'Absi, 2006; Heishman, 1999; Hughes, 2009; Hymowitz et al., 1991; 
Matheny & Weatherman, 1998). Further, individuals who reported high stress levels 
during abstinence were more likely to relapse (Brewer et al., 1998; S. Cohen & 
Lichtenstein, 1990). The central question of this dissertation study was simple:  how 
does acute stress influence brain function such that an abstinent individual is more 
likely to relapse? However, it would be unethical to directly test this research question in 
treatment-seeking smokers, who are actively attempting to quit. Rather, an approximate 
ethical approach was used. Nicotine-seeking and self-administration among non-
treatment-seeking individuals was measured during two identical experimental 
sessions:  placebo and active stress.  Broadly, the literature described three 
mechanisms through which acute stress may potentiate nicotine self-administration:  1) 
impair dlPFC function and top-down executive control, 2) intensify aversive internal 
states (e.g. negative affect, anxiety, etc.) that motivate relief via nicotine use, and 3) 
increase appetitive motivation, nicotine salience or craving.  
5.2.3 Dissertation Sample Characteristics 
 Self-reported cigarette smokers were recruited locally via Craigslist 
advertisements. Participants were screened twice for eligibility. Briefly, eligible 
participants were young (21-35 yrs old), daily cigarette smokers (10+/day; FTND ≥ 4), 
not currently using other substances (some marijuana and alcohol use was allowed), 
118 
 
 
 
and without psychiatric, MRI, or cardiovascular contraindications. The modal participant 
was 28 years old, male, and African-American. Participants reported smoking ~17 
(primarily menthol) cigarettes per day, were moderately dependent (FTND ~ 6), and 
averaged 13 years of formal education (Table 4.2). 
5.2.4 Stress Potentiated Nicotine Self-Administration 
 Nicotine-seeking and self-administration behavior was measured via a choice 
progressive ratio task. Participants were able to choose between two options (one puff 
of their preferred brand of cigarette or money [$0.25]) across 11 choice trials, with 
escalating response requirements for each successive unit earned. Participants were 
able to earn any combination of either option, up to a maximum 11 units. Following 
completion of the 30min task, participants smoked the exact number of cigarette puffs 
earned on the choice task and inter-puff interval was timed. In this study, the number of 
puff choices earned (and smoked) defined the extent of nicotine-seeking and self-
administration (i.e. direct measure of appetitive nicotine motivation). In addition, inter-
puff interval was a direct measure of nicotine self-administration rate (i.e. nicotine 
consumption rate). Together, nicotine-seeking and self-administration behaviors reflect 
nicotine motivation, but parsed into appetitive and consumptive phases, respectively.  
Nicotine-seeking and self-administration behavior.  Results from this study 
demonstrated that nicotine-seeking and self-administration during the placebo condition 
were significantly positively correlated with nicotine dependence level (FTND; 
accounted for 36% of the variance). This was not surprising. More heavily nicotine 
dependent participants earned and smoked more cigarette puffs than those who were 
less dependent. In the absence of an experimental manipulation, participants who 
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smoked more outside of the laboratory chose to smoke more during the research study. 
Therefore, FTND score was included as a covariate in outcome analyses. Controlling 
for FTND, active stress significantly increased nicotine-seeking and self-administration 
(i.e. appetitive nicotine motivation), relative to placebo. During the stress session, 
nicotine self-administration was not correlated with nicotine dependence level (FTND 
accounted for 1.1% of the variance). Relative to placebo, less dependent participants 
(median split by FTND) increased, while more dependent participants decreased, their 
nicotine-seeking and self-administration (~1.5 puffs and ~1 puff, respectively) during the 
active stress session. 
 Nicotine consumption rate.  As hypothesized, nicotine consumption rate (mean 
inter-puff interval [s]) did not significantly differ as a function of active vs. placebo 
stress. Limited number of observations and highly variable data across subjects may 
have contributed to this non-significant finding. Nicotine dependence level (FTND) was 
not related to nicotine consumption rate. Interestingly, our data indicate a differential 
effect of acute stress on the appetitive and consumptive phases of nicotine motivation 
which illustrate the specific effects of the stress manipulation. 
 In summary, relative to placebo, oral pretreatment with 54mg YOH and 10mg 
HYD potentiated nicotine-seeking and self-administration, controlling for dependence 
level. These findings were consistent with a priori hypotheses and prior research. 
Further, these data validated this complex experimental model. Future studies can build 
on this approach and evaluate medications that may blunt the effects of stress on 
nicotine-seeking and self-administration. The effectiveness of FDA-indicated 
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medications (e.g. varenicline) for smoking cessation may be enhanced by adjunctive 
stress-blunting medications (e.g. prazosin).  
5.2.5 Subjective and Physiological Effects 
 Physiological effects.  Oral pretreatment with YOH and HYD demonstrated 
significant physiological effects, consistent with a stress response (Section 4.2.2). 
Systolic and diastolic BP and HR exhibited significant Time X Dose interaction effects, 
relative to the placebo session. Peak YOH+HYD effects increased systolic and diastolic 
BP ~12 and ~7 mmHg and heart rate ~4 bpm relative to the placebo session. YOH and 
HYD doses were administered such that physiological effects were apparent at the 
onset of the MRI scan (1pm) and remained elevated throughout experimental 
procedures (2+ hrs). Saliva cortisol levels exhibited a significant Time X Dose 
interaction (biomarker of plasma cortisol levels; HYD administration). Saliva α-amylase 
effects were less obvious and did not exhibit the hypothesized Time X Dose interaction. 
Saliva α-amylase levels increased throughout the stress session (biomarker of plasma 
noradrenaline levels; YOH administration), but not the placebo session. FTND score 
was not related to any physiological effects.  
The magnitude of the YOH+HYD-induced stress response was interpreted in the 
context of other studies. Robust psychosocial stress-induction tasks (public speaking + 
cognitive tasks) resulted in large effects on saliva cortisol, systolic BP, and HR (Section 
4.2.3) (Dickerson & Kemeny, 2004; Ginty et al., 2014). Effect sizes from those studies 
were comparable to those observed in this study. In summary, oral pretreatment with 
YOH 54mg and HYD 10mg elicited a significant physiological stress response that 
lasted 2+ hours (relative to placebo), comparable in magnitude to a robust psychosocial 
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stressor. Physiological effects supported a priori hypotheses (less saliva α-amylase). 
These data provided additional support that YOH+HYD is a valuable experimental 
approach with methodological advantages compared to psychosocial stress-induction 
techniques (reliable physiological stress response, placebo-control, double-blind 
administration, dose-control, and sustained stress response [2+ hr]). Importantly, the 
doses used herein were medically-safe and no adverse events occurred. Yet, despite 
these methodological advantages, few human studies outside Dr. Greenwald’s 
laboratory have investigated their effects in substance use disorders.  
 Subjective effects.  Participants completed a battery of self-reported measures 
periodically throughout each experimental session. The measures assessed general 
internal states (anxiety and positive and negative affect) and nicotine-specific internal 
states (withdrawal symptoms and relief-motivated and appetitive craving).  
Nicotine-specific subjective effects. Self-reported nicotine withdrawal symptoms 
were measured via the Minnesota Nicotine Withdrawal Scale (MNWS). Individuals 
reported a significant increase in nicotine withdrawal across time within each session, 
but withdrawal did not differ as a function of experimental session (active vs. placebo 
stress). This was consistent with a priori hypotheses. Participants reported greater 
nicotine withdrawal severity the longer they were unable to smoke (i.e. positive control), 
but YOH+HYD did not modulate this effect. Similarly, appetitive and relief-motivated 
craving (Brief Questionnaire of Smoking Urges; QSU) scores increased across time 
within each session, but did not differ as a function of active vs. placebo stress. 
Individuals craved cigarettes more the longer they abstained from smoking (i.e. positive 
control of response consistency). We hypothesized that relief-motivated craving, but not 
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appetitive craving, would increase more during the active stress session, relative to 
placebo. In summary, there was no evidence from these subjective effects measures 
that YOH+HYD enhanced nicotine withdrawal symptoms, appetitive craving, or relief-
motivated craving, relative to placebo.  
These findings are relevant for substance use treatment. All three FDA-indicated 
pharmacotherapies for smoking cessation (varenicline, bupropion, and nicotine 
replacement products) target nicotine withdrawal and craving. However, as described in 
Section 1.2, these medications (despite their effective attenuation of nicotine withdrawal 
symptoms and craving) are associated with dismal long-term abstinence rates. Findings 
presented herein indicate that acute stress does not potentiate nicotine-seeking and 
self-administration via enhanced nicotine withdrawal or craving. Therefore, it is unlikely 
that varenicline, bupropion, or nicotine replacement products would successfully 
attenuate the effects of acute stress. Indeed, prior research demonstrated that 
varenicline blocked smoking cue-induced craving, but not stress- plus cue-induced 
craving (Ray et al., 2013). Bupropion increased physiological indices of stress reactivity 
during acute smoking abstinence (Kotlyar et al., 2006). In addition, long term nicotine 
use is associated with elevated circulating stress hormones and dysregulated stress 
reactivity (Kreek & Koob, 1998; Wilkins et al., 1982). In summary, varenicline, 
bupropion, and nicotine replacement products effectively attenuate nicotine withdrawal 
and craving, but do not attenuate (rather, may enhance) an individual’s physiological 
response to stress. Data presented herein suggested that acute stress does not act via 
withdrawal or craving to potentiate nicotine-seeking and self-administration behavior. 
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The effectiveness of FDA-indicated pharmacotherapies for smoking cessation may be 
enhanced by adjunctive medications that blunt an individual’s stress response. 
Alternative explanations.  One alternative explanation is that participants did not 
respond accurately or thoughtfully on these measures. Participant fatigue or disinterest 
is possible as experimental sessions were long and repetitive. However, this is unlikely 
because significant Time effects were found across experimental sessions. Results 
demonstrated that participant withdrawal and craving increased as function of time 
since last cigarette, as hypothesized (i.e. positive control). Moreover, this study was 
powered to detect moderate effect sizes (not likely a statistical power issue).  
General subjective effects.  Self-reported anxiety (STAI; state version) 
decreased throughout each experimental session, but did not differ as a function of 
active vs. placebo stress (Section 4.2.4). While significant, anxiety decreased an 
average of ~5% from baseline levels. We attributed this effect to participant’s becoming 
more comfortable as time elapsed during experimental sessions. Individuals may have 
been slightly apprehensive about participation in a medical research study (especially 
one that involved pharmacological dosing and an MRI scan). Self-reported affect (both 
positive and negative) was measured via the Positive and Negative Affect scale 
(PANAS). Participants reported a significant increase in negative affect throughout each 
experimental session, but no effect of experimental session. Controlling for FTND, 
positive affect decreased throughout each experimental session, but did not differ as a 
function of active vs. placebo stress. FTND was not significantly related to anxiety or 
negative affect. In summary, there is no evidence from this study that YOH+HYD 
intensified aversive internal states, relative to placebo. These findings suggested that 
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acute stress probably does not act via aversive internal states to potentiate nicotine-
seeking and self-administration.  
Alternative explanations.  As described above, this study was not under-powered 
to detect effects. Participant apathy or boredom may have influenced these data 
(possible with any subjective measure). However, participant responding was consistent 
across experimental sessions (conducted at least 48 hrs apart) and within each 
session. Finally, variable distributions approximated normality (or were corrected) at 
each time point prior to statistical analyses. Thus, our observations do not suggest that 
a few apathetic participants skewed these findings. 
5.2.6 Neurochemistry Results 
Voxel placement.  The AVP method was in-development when this project 
launched subject recruitment. AVP was not used during the first six scans (14.3%; 
manual placement), which resulted in poor geometric voxel overlap with the template 
voxel (~62%; Figure 4.28 and Table 4.3). Voxel placement was assisted by AVP (e.g. 
coordinate location was accurate, but rotation angles were incorrect or vice versa) in the 
next 11 scans (~26%), which were associated with moderate accuracy (~75% overlap 
with the template voxel). Finally, AVP prescribed the voxel location and rotation angles 
for the remaining 25 scans (~60%) which had excellent accuracy (96% overlap with the 
template voxel). Across all scans, mean voxel placement accuracy was very good for 
this study (~86% overlap with the template voxel).  
However, it is important to remember that 
1
H fMRS analyses were limited to 
within-subject and within-session comparisons:  GLU levels during 2-back were 
contrasted with rest separately for placebo and active stress. No between-subject or 
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between-session comparisons were analyzed. Therefore, voxel placement variability 
across experimental sessions was more meaningful than voxel placement variability 
across subjects. Mean between-session overlap within each subject (i.e. voxel 
placement consistency across sessions) was very good (87% geometric overlap). To 
provide context, 87% geometric voxel overlap is associated with ~1mm voxel placement 
error during one scan. Mean voxel tissue composition for all scans was approximately 
two-thirds white (~66%) and one-third gray (~32%) matter. In summary, AVP resulted in 
excellent voxel placement accuracy and reliability. Overall, both between-subject and 
between-session voxel overlap accuracy was very good (~86% and ~87%, 
respectively). 
Behavioral data.  Behavioral data demonstrated task compliance for both 
experimental sessions (Section 4.2.7). Response accuracy during the letter 2-back 
increased across task blocks during both experimental sessions (Time effect), but 
accuracy improved more during the placebo session (Time X Dose interaction). On 
average, participants responded significantly more accurately during placebo (~87%) 
than active stress (~78%; Task effect). Response latency decreased across task blocks 
for both sessions (i.e. task proficiency improved with repetition), but did not differ as a 
function of active vs. placebo stress. In summary, response accuracy increased across 
task blocks in both sessions (indicative of practice effects). As hypothesized, 
YOH+HYD impaired 2-back response accuracy (relative to placebo), consistent with 
prior research using a robust psychosocial stressor (Qin et al., 2009). 
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GLU modulation (32s resolution).  LCModel fit and metabolite quantification was 
100% automated. As described above, individual raw spectra were phase- and shift-
corrected prior to averaging and LCModel fit.  
During the placebo session, GLU quantification at 32s resolution (8 avgs) was 
reliable (Table 4.4) and importantly, LCModel fit characteristics did not differ as a 
function of experimental task. GLU levels were significantly higher (2.7%) during 2-back 
A relative to interleaved fixation-cross. Across task blocks, GLU levels were marginally 
higher during 2-back A vs. rest (Task effect: p = .06). 2-back A GLU levels increased 
(relative to rest) in later task blocks. GLU levels during 2-back B did not differ from 
interleaved fixation-cross levels (p = .67). In general, GLU modulation (during 2-back A) 
corresponded with 2-back response accuracy across task blocks (with the exception of 
task block 2). The behavioral data demonstrated that participants performed poorly 
during the first task block, but significantly improved with task repetition. During the first 
task block, poor response accuracy was associated with virtually no GLU modulation 
(i.e. limited dlPFC task engagement). Was poor task performance the cause of, or the 
result of, limited dlPFC task engagement? Unfortunately, the answer is unknowable 
from the present findings. Poor task accuracy and dlPFC engagement in the first task 
block may have resulted from task complexity (resolved in later blocks; i.e. practice 
effects) or the novel and distracting MRI environment (to which, participants 
habituated). From task blocks 3 to 5, GLU modulation was apparent and steadily 
increased which paralleled response accuracy. In summary, letter 2-back task 
performance modulated GLU levels in the left dlPFC during the first 32s (2-back A), but 
the effect was time-limited and not consistently found in the final 32s (2-back B) of task 
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performance. Moreover, GLU modulation generally paralleled response accuracy 
across task blocks. Findings during the placebo session in this study were consistent 
with 
1
H fMRS pilot study results in healthy control subjects.  
During the stress session, GLU levels did not differ as a function of task 
performance (2-back A or B vs. interleaved fixation-cross rest; ps > .10). Moreover, two 
LCModel fit characteristics differed as a function of experimental task (2-back vs. 
interleaved fixation-cross rest):  FWHM and SNR. SNR was higher and FWHM was 
lower (more narrow spectral linewidth) during 2-back > rest. Importantly, these 
differences did not translate into biased LCModel GLU fit uncertainty (GLU and 
glutamine CRLB% did not differ as a function of experimental task). However, we 
cannot rule out the possibility that these biases did not influence or confound GLU 
quantification (Type II error is possible). Therefore a second analysis strategy was 
used:  64s (16 avgs) moving average.  
GLU modulation (64s resolution).  Spectra from the 32s analyses were averaged 
across task blocks:  task block 1 data for 2-back A was averaged with task block 2 data 
for 2-back A, and so on. This strategy was repeated for all task blocks and experimental 
phases (2-back B and rest). This resulted in 4 time points for 2-back A, B, and rest. As 
expected, 64s (16 avgs) resolution was associated with higher SNR and more reliable 
LCModel fit. Relative to 32s resolution, SNR was ~5 points higher and GLU CRLB% 
was at least 1% lower (with less variability). 
During the placebo session, LCModel fit characteristics did not differ as a 
function of experimental task for the placebo session (Table 4.5). A significant Time X 
Task interaction indicated that GLU levels were higher during 2-back A relative to 
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interleaved fixation-cross rest, but only in later task blocks. These results were similar to 
the 32s resolution findings. Again, consistent with 32s resolution GLU findings, 2-back 
B didn’t differ as a function of experimental task. Across four analytic strategies (and 
two samples), findings presented herein repeatedly demonstrated that dlPFC GLU 
levels were modulated during the first 32s of letter 2-back task performance (i.e. 2-back 
A), but the effect was inconsistent and blunted during the final 32s of task performance. 
There are two plausible explanations for these findings:  1) cognitive task switching or 
directed attention modulated dlPFC GLU levels (and that effect was time-limited) or 2) 
working memory performance modulated dlPFC GLU levels temporarily, but new steady 
state levels were not established (i.e. habituation). Unfortunately, there was not 
sufficient temporal resolution to disentangle these explanations. It should be noted that 
this effect was contrary to a priori hypotheses. We hypothesized 2-back performance 
would increase dlPFC GLU levels throughout the entire task block (i.e. establish new 
steady state levels).  
During the stress session, GLU levels were not modulated as a function of 
experimental task (non-significant Task and Time X Task interaction effects). Further, 
GLU levels during 2-back were generally lower than fixation-cross rest. Only one 
LCModel fit characteristic differed as a function of experimental task for the 64s 
resolution (SNR was higher during 2-back A than rest). However, a small difference in 
SNR did not bias the certainty in the LCModel quantification of GLU or glutamine across 
task phases (ps > .19).  
In summary, this second analysis strategy corroborated initial findings at 32s 
resolution and demonstrated, with more reliable LCModel fit, that 2-back performance 
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modulated dlPFC GLU levels (relative to fixation-cross rest) during placebo, but not 
active stress.  
As described in Section 5.1.3 above, the 
1
H fMRS signal is a direct 
measurement of in vivo GLU molecules from all possible sources within the voxel. 
Thus, results during the placebo session demonstrated that the number of GLU 
molecules within the voxel location was higher during letter 2-back A relative to fixation-
cross rest. We interpreted these findings to indicate task-related cognitive demand 
during 2-back increased neural and metabolic activity (and thus, GLU levels) in the left 
dlPFC. These findings were consistent with the electrophysiology, 
1
H fMRS, fMRI BOLD 
literature, and findings in the 
1
H fMRS pilot study.   
 Limitations and alternative explanations.  All of the same limitations from the 
1
H 
fMRS pilot study apply here. First, partial volume effects were possible. However, partial 
volume effects were unlikely because the analysis strategy focused on within-subject 
comparisons (GLU levels during task vs. rest) and voxel tissue composition variability 
was low across experimental sessions (gray and white matter coefficient of variation 
percentage was 10.5% and 7.2%, respectively). Second, AVP was associated with 
accurate and reliable voxel placement. Voxel placement accuracy between-subjects for 
this study was high (~86%). More importantly, within-subject voxel replacement 
reliability (from the first to the second experimental session) was very good (~87%). 
Third, due to SNR limitations, we were unable to reliably quantify other relevant 
neurotransmitters (e.g. GABA and glutamine). Future studies could use higher field 
strengths or different MRS sequences (e.g. MEGA-PRESS) to investigate task-related 
modulation of GABA and glutamine levels.  
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There are several alternative explanations for task-related GLU modulation. First, 
the BOLD effect (i.e. FWHM) was nearly significant during the placebo session (p = .06) 
and was significant during the stress session (p < .05). The BOLD effect may have 
influenced metabolite quantification and T2*. However, LCModel should be immune to 
the influence of linewidth on metabolite level quantification. Indeed, we found that NAA 
levels did not differ as a function of task during either experimental session, which 
suggested the BOLD effect did not bias NAA quantification. During the placebo session, 
no metabolites differed as a function of experimental task other than GLU. However, 
during stress, GPC+PC and Myo-Inositol did differ as a function of experimental task, 
contrary to a priori hypotheses. Second, GLU’s transverse relaxation (T2*) could have 
changed as a result of task performance. However, as described above, transverse 
relaxation alone was unlikely to explain the observed increase in GLU signal during 
placebo (Ogawa et al., 1992). Third, Type I error was possible for the placebo session. 
However, evidence against this explanation was four-fold: 1) results were consistent 
with the pilot study and the literature; 2) the experimental paradigm was designed to 
minimize the possibility of Type I error (e.g. the use of a stabilization task [flashing 
checkerboard], comparison to an interleaved fixation-cross rest condition, and reliable 
voxel placement); 3) observed moderate effect size (i.e. study was not over-powered); 
and 4) LCModel fit characteristics and metabolite levels (other than GLU) didn’t differ as 
a function of experimental task. Fourth, Type II error was possible for the stress 
session. LCModel fit characteristics (FWHM and SNR) significantly differed as a 
function of experimental task during the stress session. However, these differences did 
not influence uncertainty of LCModel GLU fit (GLU and glutamine CRLB% did not differ 
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between 2-back vs. rest; 
1
H MRS glutamine peaks overlap with GLU at 3T). Moreover, 
LCModel fit of GLU was reliable (GLU CRLB <7 ± <1%) across task and rest conditions. 
Further, the FWHM bias (BOLD effect) did not influence the quantification of NAA 
(which didn’t differ as a function of experimental task). Finally, overall GLU levels during 
2-back tended to be lower (not higher) than interleaved fixation-cross levels.  
Neurochemistry results summary.  In summary, our findings indicated that letter 
2-back task performance modulated GLU levels in the left dlPFC (relative to interleaved 
fixation-cross rest) during the placebo, but not the active stress condition (consistent 
with a priori hypotheses). These findings were consistent with the 
1
H fMRS pilot study. 
As described in detail above, we interpreted task-related dlPFC GLU modulation to 
reflect increased neural and metabolic activity associated with excitatory 
neurotransmission driven by working memory task performance. We believe GLU 
modulation is an in vivo biomarker of dlPFC engagement during working memory 
performance. Importantly, 
1
H fMRS GLU levels, as a biomarker, are not confounded by 
neurovascular coupling.  
Extensive research at Yale University 
demonstrated that working memory task 
performance in non-human primates was 
associated with increased neuronal spiking 
frequency in the dlPFC (Goldman-Rakic, 1995). 
As described in Sections 2.4.3 and 2.5.1, 
persistent excitatory microcircuits 
(glutamatergic) in cortical layer III are thought to 
Figure 5.1: Noradrenaline Levels 
and dlPFC Function. The inverted 
‘U’ relationship between 
noradrenaline levels and dlPFC 
function is depicted. 
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maintain working memory traces during the ‘delay’ period (necessary for accurate 
responding) (Wang et al., 2013). Using the same task paradigm and selective 
pharmacological challenges, Arnsten and colleagues demonstrated that working 
memory task performance and dlPFC neural spiking frequency exhibited an inverted 
‘U’-shaped relationship with noradrenaline levels (Figure 5.1) (A. F. Arnsten, 2009). 
Inadequate α2-noradrenergic receptor stimulation (i.e. fatigue) or excessive 
noradrenergic stimulation (i.e. stress) impaired working memory in non-human primates 
(A. F. Arnsten, 2009). Synaptic noradrenaline has the highest binding affinity for α2-
noradrenergic receptors and lower affinity for α1- and β1-noradrenergic receptors (A. F. 
Arnsten, 2009). Thus, in the presence of excessive noradrenaline levels (i.e. stress), 
noradrenaline molecules will ‘spill over’ and bind lower affinity α1- or β1-noradrenergic 
receptors, disrupt persistent excitatory microcircuits that maintain working memory 
traces during the ‘delay’ period, and impair response accuracy (A. F. Arnsten, 2009). 
YOH is a pre-synaptic α2-noradrenegeric antagonist that disinhibits presynaptic 
noradrenergic release. The dose used in this study (oral pretreatment with 54mg of 
YOH) significantly increased two biomarkers of a physiological stress response (BP and 
saliva α-amylase; sympathetic ANS), relative to placebo. It is speculative, but plausible, 
that YOH significantly elevated noradrenergic levels (stimulating lower affinity α1- and/or 
β1-noradrenergic receptors), which disrupted excitatory microcircuits in the dlPFC and 
impaired 2-back task accuracy (shifting individuals to the right side of the downward 
slope on the inverted ‘U’ in Figure 5.1). 
1
H fMRS data support this hypothesis. During 
placebo, noradrenaline levels were ‘normal’ and response accuracy was high. 2-back 
task performance significantly modulated GLU levels indicative of dlPFC engagement 
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(consistent with non-human primate studies) (A. F. Arnsten, 2009). However, during the 
active stress session, YOH+HYD significantly elevated BP and saliva α-amylase, which 
was associated with attenuated GLU modulation (i.e. impaired dlPFC engagement) and 
impaired response accuracy. These data support the hypothesis that acute stress 
potentiates drug-seeking behavior via impaired top-down (specifically dlPFC) executive 
function. Further, the present findings, in combination with the literature, provided 
support that noradrenaline levels may be the culprit. Medications (e.g. prazosin [α1-
adrenoreceptor antagonist] and propranolol [β1- and β2-adrenoreceptor antagonist]) that 
block noradrenergic stimulation of lower affinity α1 and β1 receptors may rescue dlPFC 
function. As described in Section 2.4.3, dlPFC function is associated with a host of 
cognitive processes (e.g. delayed gratification, self-control, decision making, and goal-
directed action) necessary for prolonged abstinence. Acute stress-compromised dlPFC 
function could predispose an individual to habit-directed behavior (i.e. stimulus-
response; cigarette cue induced smoking relapse) or ill-prepared to adequately 
suppress cigarette craving/withdrawal symptoms. Future studies should examine the 
effects of prazosin and/or propranolol on dlPFC function and drug-seeking behavior 
during acute experimental stress challenge.  
The present dlPFC GLU modulation findings were buttressed by the rigorous 
experimental design used:  within-subject, double-blind placebo-controlled, and 
randomized cross-over design. All research subjects completed both experimental 
sessions (which were identical) and typically within 7 days of one another (76% of 
subjects). Further, all outcome analyses examined within-subject comparisons; thus, 
each subject served as his/her own control. 
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5.2.7 BOLD fMRI Results 
Cerebrovascular reactivity (CVR).  In the present study, neurovascular coupling 
was a potential problem due to the use of a pharmacological challenge with known 
vasoconstrictive properties. Thus, the breath-hold challenge task was implemented to 
control for CVR differences. Briefly, participants were instructed (visually) to change 
their breathing throughout the task across three phases:  uncontrolled (‘normal’) 
breathing, paced breathing (3s in and 3s out), and breath hold (11s). Prior research 
demonstrated a robust BOLD response during breath hold (relative to paced breathing) 
(Bright & Murphy, 2013; Lipp et al., 2015; Magon et al., 2009; Murphy et al., 2011; 
Sousa et al., 2014). Significant activation on this task reflected vascular effects (i.e. 
non-neuronal) due to breath hold. As part of our fMRI analysis strategy, all between-
session (placebo vs. active stress) comparisons were CVR-corrected to reduce the 
possibility of false positives due to the vascular effects of YOH+HYD.  
Letter 2-back vs. fixation-cross rest.  Behavioral data demonstrated task 
compliance. Contrary to 
1
H fMRS behavioral data, response accuracy was non-
significantly higher during placebo vs. active stress (p = .11; 90% vs. 85%, 
respectively). Data collection errors resulted in a substantial missing data (24%) for this 
outcome variable and may have resulted in this comparison being under-powered. As 
hypothesized, 2-back performance was associated with robust bilateral PFC activation, 
relative to fixation-cross rest, during both experimental sessions (Figure 4.43; (Owen et 
al., 2005)). However, contrary to a priori hypotheses, between-session comparisons 
(CVR-corrected) revealed significantly more PFC activation during task performance (2-
back > rest) in the stress, relative to placebo, session (Figure 4.44). Even with the CVR-
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correction, we cannot rule out the possibility of YOH confounding these results. YOH 
has robust vasoconstrictive effects that make interpretation of this finding challenging. 
Within-session, task-evoked BOLD responses (i.e. 2-back > rest) are less confounded 
and associated with a more straightforward interpretation.  
Few studies have examined the effect of YOH on task-evoked BOLD responses 
in human subjects. However, a number of studies have investigated the effects of 
caffeine (another vasoconstrictive agent) on BOLD response. Unfortunately, these 
studies provided little clarity for the unexpected BOLD findings in this study. In a well-
controlled study among infrequent caffeine users, visual stimulation and finger-tapping 
tasks evoked attenuated BOLD responses in the visual and motor cortices 
(respectively) during caffeine (250mg oral dose), relative to placebo (Diukova et al., 
2012). Conversely, during visual and motor stimulation tasks, BOLD responses (in 
another study) in visual and motor cortices (respectively) were amplified during 
intravenous caffeine injection (2.5mg/kg), relative to saline (Chen & Parrish, 2009b). 
Further, there was evidence that caffeine altered cerebral blood flow and cerebral 
metabolic rate of oxygen in the visual cortex during visual stimulation, relative to 
placebo (Chen & Parrish, 2009a; Griffeth, Perthen, & Buxton, 2011). Therefore, in 
addition to the conflicting BOLD activation findings in the literature, the neurobiological 
underpinnings of the BOLD signal may be altered by acute administration of a 
vasoconstrictive agent. The present study did not measure other physiological indices 
(e.g. cerebral blood flow, cerebral blood volume, oxygen metabolism) that may have 
provided greater insight into these unexpected BOLD findings.   
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The effects of caffeine on BOLD response in the PFC are more consistent, but 
may be confounded by the cognitive-enhancing effects of caffeine. During an auditory 
oddball task, caffeine was associated with greater task-evoked BOLD response in the 
PFC, relative to placebo (Diukova et al., 2012). Similarly, during working memory task 
performance, caffeine (100mg oral dose) amplified BOLD response in the PFC, relative 
to placebo (Klaassen et al., 2013; Koppelstaetter et al., 2008). These findings were 
consistent with the unexpected results observed herein during the letter 2-back 
paradigm: amplified task-evoked BOLD response in the PFC during YOH+HYD. It is 
possible that task-induced BOLD response exhibited regional differences due to 
heterogeneous vasoconstrictive effects (vessel diameter or vascularization differences 
in the PFC vs. visual/motor cortices). However, caffeine has known cognitive-enhancing 
properties, while YOH+HYD tended to impair task performance, which further 
complicated interpretation. Indeed, auditory oddball task performance was enhanced 
during caffeine, relative to placebo (Diukova et al., 2012). In the working memory 
studies, caffeine mostly did not alter working memory task performance (letter 2-back 
and 3-, 4-, and 5-letter Sternberg accuracy were unaffected; 6-letter Sternberg accuracy 
was impaired), relative to placebo (Klaassen et al., 2013; Koppelstaetter et al., 2008). In 
summary, between-session interpretation of BOLD response data is complicated by the 
vasoconstrictive properties of YOH. Interpretation of task-evoked BOLD within each 
experimental session is more straightforward and provides greater clarity for neural 
activation across brain regions during task performance.   
Letter 2-back exploratory analyses.  Exploratory analyses examined task-
induced activation median split by nicotine dependence level (FTND). These analyses 
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paralleled the significant Dose X FTND interaction effects on nicotine-seeking and self-
administration (Figure 4.45). Less nicotine dependent participants exhibited smaller 
task-evoked BOLD response in the dlPFC in the stress (relative to placebo) session. 
Conversely, more nicotine dependent individuals exhibited larger task-evoked BOLD 
response in the dlPFC. These findings were consistent with the central tenet of this 
research study:  stress potentiated nicotine self-administration via impaired dlPFC task-
engagement.   
fMRI N-back smoking vs. neutral cued.  Accuracy and response latency were 
evaluated across levels of task difficulty (0-, 1-, and 2-back) and by image type 
(smoking vs. neutral) for both experimental sessions. 
Stress effects.  Neutral images were associated with an N-back effect for both 
the placebo and active stress sessions (as task difficulty increased, response accuracy 
decreased; Figure 4.46). Interestingly, a similar effect was found for response latency:  
across both sessions response latency decreased, as task difficulty increased (Figure 
4.47). Smoking images were associated with an N-back X Dose interaction effect:  
response accuracy decreased more as a function of task difficulty during placebo vs. 
active stress. This effect may reflect that acute stress amplified smoking image 
salience, which buoyed response accuracy. Similar to the findings with neutral images, 
response latency decreased as task difficulty increased for smoking images (across 
both experimental sessions).  
Image effects.  During both experimental sessions, significant N-back effects 
demonstrated that response accuracy decreased as task difficulty increased for both 
image types (Figure 4.50 and 4.52). Response accuracy differed as a function of image 
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type during the stress session (smoking > neutral images), but not the placebo session. 
N-back X Image interaction indicated response accuracy decreased more for neutral 
images than smoking images, as task difficulty increased. Response latency (for both 
image types) decreased as task difficulty increased during the stress session, but not 
the placebo session (p = .07; Figures 4.51 and 4.53). During both experimental 
sessions, response latency decreased across N-back levels more for neutral images, 
relative to smoking images. Main effects of image type were non-significant during 
placebo and active stress. 
Activation results.  Following repeated substance use, drug-paired visual cues 
become conditioned stimuli and elicit dopamine release in the nucleus accumbens 
(without substance administration), consistent with anticipatory appetitive craving (N. 
Volkow et al., 2009; N. D. Volkow et al., 2006, 2008). In fMRI studies of visual drug 
cues, BOLD activation was often robust, but patterns varied across studies. 
Consistently activated regions during drug cue exposure fMRI studies were: amygdala, 
mOFC/mPFC, dlPFC, and ventral and dorsal striatum (Chase et al., 2011; Engelmann 
et al., 2012; Kühn & Gallinat, 2011; Wilson et al., 2004). Methodological factors, such 
as treatment status (out-of-treatment individuals show more robust activation), time 
since last cigarette (acute abstinence enhanced cue reactivity), and temporal delay until 
next smoking opportunity (immediate smoking opportunities were associated with more 
robust activation) influence BOLD fMRI results (Jasinska et al., 2014; Wilson et al., 
2005). These factors were considered in the design of the present study. Non-
treatment-seeking smokers, in acute abstinence at the time of fMRI BOLD data 
collection (~2hr since paced puff procedure), were reminded they would have an 
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opportunity to smoke following the MRI scan. fMRI activation analyses focused on the 
effect of image type (smoking > neutral) across N-back levels (0-, 1-, and 2-back) and 
compared the relative task-evoked BOLD response between experimental sessions. 
Across N-back levels, smoking (> neutral) images elicited greater BOLD response in 
‘reward’-associated brain regions during placebo, compared to active stress. These 
findings were contrary to a priori hypotheses. During 0- and 1-back (while response 
accuracy was high and didn’t differ by image type), greater BOLD activation was 
observed in the ventral and dorsal striatum, mPFC, mOFC, and amygdala during 
placebo, relative to stress.  
Activation in the ventral striatum is associated with drug craving, appetitive 
motivation, and encompasses the ‘final common pathway’ of addictive behaviors (Rita Z 
Goldstein & Volkow, 2002; R. Z. Goldstein & Volkow, 2011; Peter W Kalivas & Volkow, 
2005; G. F. Koob & Volkow, 2010; N. Volkow et al., 2009). Amygdala activation is 
associated with the emotional salience of drug cue (Chase et al., 2011; Engelmann et 
al., 2012; Kühn & Gallinat, 2011; Wilson et al., 2004). Activation in the dorsal striatum 
may indicate mental rehearsal of habitual or ‘over-learned’ behaviors (e.g. smoking) (L. 
Schwabe, Joels, et al., 2012; L. Schwabe et al., 2010; L. Schwabe & Wolf, 2011). 
mOFC and mPFC activation may reflect reward appraisal, anticipation, or drug cue 
salience (Chase et al., 2011; Hayashi et al., 2013; Wilson et al., 2004).  
At the 2-back level, response accuracy differed as a function of image type 
(smoking > neutral) and experimental session (stress > placebo). Behavioral proficiency 
differences complicated interpretation of the BOLD activation patterns. Generally, 
activation was diminished during 2-back task performance during both experimental 
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sessions. This was not unexpected; 2-back task performance demanded greater 
attentional focus, which may have minimized the salience of smoking images. Sporadic 
clusters were observed in the amygdala, ventral striatum, mOFC, and vlPFC during the 
placebo session. During stress, three clusters were found: mOFC, dorsal striatum, and 
dorsal PFC. Direct comparisons of experimental sessions (CVR-corrected; stress vs. 
placebo) across all N-back levels revealed robust BOLD activation differences. As 
described above, the vasoconstrictive properties of YOH may confound interpretation of 
direct between-session comparisons, but are presented here for continuity and 
transparency. ‘Reward’-region activation was much greater during placebo, relative to 
active stress. Large clusters were found in the amygdala, ventral and dorsal striatum, 
mOFC, mPFC, dACC, vlPFC, superior parietal lobule, and dlPFC during placebo (> 
stress). These findings may reflect enhanced cue salience and appetitive motivation 
during placebo. Conversely, only one cluster was found in the mOFC for stress (> 
placebo). These neural activation patterns suggest that stress attenuated smoking cue-
evoked BOLD activation, relative to placebo. These findings were contrary to a priori 
hypotheses and inconsistent with subjective effects (nicotine withdrawal and craving) as 
well as, nicotine-seeking and self-administration results. These findings do not support 
the idea that stress potentiated nicotine-seeking and self-administration via amplified 
‘bottom-up’ signaling (e.g. enhanced smoking cue salience or appetitive motivation). 
5.2.8 fMRI vs. 
1
H fMRS 
Exploratory analyses examined the statistical relationship between BOLD fMRI 
response and 
1
H fMRS GLU levels during letter 2-back (> fixation-cross rest). These 
tasks were performed sequentially (
1
H fMRS always preceded fMRI), but task 
parameters were identical. The 
1
H fMRS voxel for each subject was used as a mask for 
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fMRI contrasts, from which Z scores (peak activation) and peak cluster extents were 
extracted, for the initial 32s and final 32s of task performance (2-back A and B, 
respectively). The first fMRS task block was ignored (allow response accuracy to 
stabilize; practice effects). Thus, the analysis space consisted of two bivariate 
correlation matrices (Z score and cluster extents) with 32 cells (four rows of fMRI 
metrics [2-back A and B X 2 task repetitions] by 8 columns of fMRS metrics [2-back A 
and B X 4 task repetitions]) for the placebo and active stress sessions. Seven of 32 
cells (21.9%) were positively correlated for fMRI Z scores and 5 of 32 cells (15.6%) 
were positively correlated for fMRI cluster extents during the placebo session. During 
the stress session, 1 cell (3.1%) was negatively correlated for fMRI Z scores and none 
were correlated for fMRI cluster extents. Thus, letter 2-back task performance was 
associated with moderate statistical coherence within subjects across neuroimaging 
metrics (fMRI BOLD and 
1
H fMRS GLU) during the placebo session, and virtually no 
coherence during the active stress session. These exploratory findings emphasized the 
discrepant effects of stress on neuroimaging biomarkers of dlPFC task-engagement 
(YOH+HYD amplified BOLD activation, but attenuated GLU modulation during letter 2-
back), and highlighted the importance of considering YOH’s vasoconstrictive effects on 
BOLD response.  
5.3 Overall Summary 
 The three primary goals of the 
1
H fMRS pilot study were to:  1) develop and 
evaluate the AVP method for voxel placement, 2) develop a working memory 
1
H fMRS 
paradigm, and 3) quantify dlPFC GLU modulation during working memory task 
performance. Results from the pilot study demonstrated that the AVP method was 
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feasible, reliable, and accurate. This novel method for automated voxel placement is 
publicly available (free-of-charge) for download. AVP was developed to be flexible such 
that it can be used across single voxel neuroimaging studies, regardless of: subject 
population, anatomical region, MRI scanner system, and field strength. Results from the 
1
H fMRS pilot study (N = 16) demonstrated that 2-back task performance modulated 
dlPFC GLU levels relative to continuous and interleaved fixation-cross rest. 2-back A 
GLU levels were ~3% higher than rest. Importantly, LCModel fit characteristics did not 
differ as a function of experimental task and metabolites other than GLU were not 
modulated during 2-back A performance. Results during 2-back B were mixed and 
complicated by significant task-related modulation of Myo-Inositol and NAA. Working 
memory task-related GLU modulation in the dlPFC likely reflected increased metabolic 
activity driven by cognitive task engagement. In summary, the 
1
H fMRS pilot study 
validated a novel in vivo biomarker of dlPFC task-engagement that is not confounded 
by vascular effects.  
 The two primary goals for the dissertation study were to:  1) investigate the 
effects of pharmacological stress manipulation on nicotine-seeking and self-
administration and 2) investigate a neurobiological mechanism through which acute 
stress may potentiate nicotine self-administration. Self-reported cigarette smokers were 
screened for psychiatric, cognitive, MRI and cardiovascular contraindications. 
Participants (N = 21) completed two identical oral-dosing experimental sessions:  active 
(YOH 54mg + HYD 10mg) and placebo stress (YOH 0mg + HYD 0mg). A rigorous 
experimental design was used: within-subject, placebo-controlled, double-blind, and 
randomized cross-over design. Active pharmacological stress increased biomarkers of 
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a physiological stress response (BP, HR, saliva cortisol and α-amylase) throughout 
experimental procedures (2+ hrs), relative to placebo. Active stress (relative to placebo) 
potentiated nicotine-seeking and self-administration (controlling for nicotine 
dependence level [FTND]) on an 11-trial choice progressive ratio task (30min). Stress 
did not alter nicotine consumption rate (inter-puff interval). These findings were 
consistent with a priori hypotheses and validated the experimental model used herein. 
Nicotine withdrawal, cigarette craving, and negative affect increased throughout each 
session (as length of experimental abstinence increased), but were not altered as a 
function of active vs. placebo stress (contrary to a priori hypotheses). Similarly, anxiety 
and positive affect decreased throughout each experimental session, but were not 
differentially affected by active vs. placebo stress. Consistent with the 
1
H fMRS pilot 
study, working memory task performance modulated GLU levels in the left dlPFC during 
the placebo session. GLU levels were 2.7% higher during the first 32s of letter 2-back 
task performance relative to interleaved fixation-cross rest. During the stress session, 
GLU levels did not differ as a function of 2-back performance. Behavioral data 
demonstrated that participants’ responded significantly more accurately during placebo, 
relative to active stress. These results were consistent with a priori hypotheses and 
extensive non-human primate research. During both placebo and active stress, letter 2-
back performance evoked significant bilateral BOLD response. Inconsistent with a priori 
hypotheses, BOLD response in the dlPFC was greater during stress, relative to 
placebo. However, YOH is vasoconstrictive, which may have confounded between-
session BOLD comparisons. Smoking-related and neutral images were yoked with 
letter N-back to investigate smoking cue-evoked BOLD response. Results 
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demonstrated that smoking-related (> neutral) images elicited greater BOLD response 
in ‘reward’-associated brain regions during placebo, relative to active stress. Across N-
back levels, activation was consistently observed in the mOFC, mPFC, ventral striatum, 
amygdala, and PFC during placebo, but not active stress. Activation in ‘reward’-
associated brain regions may reflect the salience of visual smoking cues or cue-elicited 
appetitive motivation.  
Taken together, results from this study suggest that acute experimental stress 
(relative to placebo) elicited a robust physiological stress response, potentiated 
nicotine-seeking and self-administration, impaired dlPFC function, attenuated dlPFC 
task-related engagement, and suppressed ‘reward’ region BOLD response to visual 
smoking cues among non-treatment-seeking cigarette smokers. These findings provide 
empirical support for a plausible neurobiological mechanism. Acute stress may have 
potentiated nicotine-seeking and self-administration via impaired dlPFC function and 
attenuated task-related engagement. It is speculative, but plausible, that excessive 
noradrenergic stimulation mediated the effect of stress on dlPFC function. In summary, 
data presented herein support the theory that acute stress may act via a ‘top-down’ 
mechanism to precipitate substance use relapse. There was no evidence from this 
study that acute stress amplified ‘bottom-up’ signals (withdrawal, craving, aversive 
internal state, or visual smoking cue salience) to increase nicotine-seeking and self-
administration. Future studies will investigate dose-response relationships and 
pharmacological agents (e.g. prazosin and propranolol) that may blunt the effects of 
acute stress on dlPFC function and nicotine-seeking and self-administration.  
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 Nicotine use, especially cigarette smoking, is a significant public health problem. 
Existing pharmacotherapies attenuate nicotine craving and withdrawal symptoms. 
However, the majority of patients relapse within the first year of treatment. Treatment 
studies indicate a commonly cited precipitant to smoking relapse is stress. 
Pharmacotherapies do not attenuate, and may exacerbate, the effects of acute stress. 
Experimental studies (preclinical and clinical) indicate that acute stress potentiates 
drug-seeking behavior across drugs of abuse. Despite a robust literature linking acute 
stress and substance use, neurobiological mechanisms remain poorly understood. A 
more complete understanding of the neurobiological effects of acute stress on brain 
function may facilitate development of novel interventions. Adjunctive stress-blunting 
medications may improve the effectiveness of existing pharmacotherapies. 
 The present study investigated the effects of pharmacological stress-induction 
among cigarette smokers. Non-treatment-seeking cigarette smokers were recruited 
locally and screened for psychiatric, medical, and neuroimaging contraindications. 
Using a double-blind, placebo-controlled within-subject random cross-over design, 
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participants (N = 21) completed two oral-dosing experimental sessions: active 
(yohimbine [YOH] 54mg + hydrocortisone [HYD] 10mg) and placebo (YOH 0mg + HYD 
0mg) stress. Prior research indicated that YOH+HYD is a robust pharmacological 
stress-induction technique that stimulates the Autonomic Nervous System (ANS) and 
Hypothalamic-Pituitary-Adrenal (HPA) axis systems, increases circulating levels of 
noradrenaline and cortisol (two primary stress hormones), and potentiates drug-seeking 
behavior. Throughout each experimental session, subjective and physiological effects 
were measured. In addition, participants completed a 60min magnetic resonance 
imaging (MRI) scan which consisted of three task paradigms: 1) letter 2-back, 2) 
smoking cued letter N-back, and 3) breath-hold challenge. Participants completed a 
working memory paradigm (letter 2-back) during proton functional magnetic resonance 
spectroscopy (
1
H fMRS). Left dorsolateral prefrontal cortex (dlPFC) neurochemistry was 
evaluated during letter 2-back task performance. Next, participants completed a cued 
N-back paradigm that consisted of images (cigarette smoking or neutral) centered 
behind capitalized letters across three levels of N-back task difficulty:  0-, 1-, and 2-
back. Finally, participants were instructed (visually) to control their breathing across 
three phases:  ‘normal’ breathing, paced breathing (3s in/3s out), and breath-hold 
challenge (11s). After the MRI scan, participants completed a choice progressive ratio 
task. Across 11 independent choice trials, participants could earn one cigarette puff 
(preferred brand) or money ($0.25) via behavioral responding. Each successive unit 
earned (puffs or money, independently) was associated with a higher response 
requirement (progressive ratio schedule). At the end of the 30min task, participants 
smoked the exact number of cigarette puffs earned and/or were provided the amount of 
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money earned. Number of puffs earned and smoked was a direct measure of nicotine-
seeking and self-administration behavior (nicotine motivation). Participants were 
compensated for their time. 
 Results indicated that oral pretreatment with YOH+HYD increased biomarkers of 
a physiological stress response:  systolic and diastolic blood pressure, heart rate, saliva 
cortisol and α-amylase (indirect biomarker of noradrenaline levels), relative to placebo. 
YOH+HYD potentiated nicotine-seeking and self-administration behavior (controlling for 
nicotine dependence level), relative to placebo. Appetitive and relief-motivated cigarette 
craving, nicotine withdrawal symptoms, negative affect, and anxiety levels increased 
throughout each session, but did not differ by experimental session (active vs. placebo 
stress). Similarly, positive affect decreased throughout each session, but did not as a 
function of stress. 
1
H fMRS indicated that letter 2-back performance increased left 
dlPFC glutamate (GLU) levels relative to interleaved fixation cross rest (indicative of 
task engagement) during the placebo, but not active stress, session. Further, 
YOH+HYD impaired letter 2-back response accuracy, relative to placebo. Across N-
back levels (0-, 1-, and 2-back), fMRI indicated more robust neural activation across 
‘reward’-associated brain regions in response to smoking images (> neutral images) 
during placebo, relative to active stress. 
Results demonstrated YOH+HYD induced a sustained physiological stress 
response (ANS and HPA axis) and potentiated nicotine-seeking and self-administration. 
YOH+HYD attenuated dlPFC task engagement and impaired response accuracy during 
a well-established working memory task. These findings provide experimental support 
for a plausible neurobiological mechanism through which acute stress may potentiate 
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nicotine self-administration. Acute stress-impaired dlPFC function may potentiate 
nicotine self-administration and, among abstinence-motivated individuals, precipitate 
smoking relapse. Prior research demonstrated dlPFC function is associated with a host 
of cognitive processes (e.g. delayed gratification, self-control, decision making, etc.) 
associated with prolonged smoking abstinence. Future studies are needed to confirm 
this hypothesis, investigate dose-response relationships, and evaluate the efficacy of 
stress-blunting medications in combination with existing pharmacotherapies for smoking 
cessation.  
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